



Pharmaceutical Sciences Faculty Patents

Pharmaceutical Sciences

12-8-2015

High-Activity Mutants of Butyrylcholinesterase for Cocaine Hydrolysis and Method of Generating the Same

Chang-Guo Zhan University of Kentucky, zhan@uky.edu

Hoon Cho University of Kentucky

Hsin-Hsiung Tai University of Kentucky, htai1@uky.edu

Right click to open a feedback form in a new tab to let us know how this document benefits you.

Follow this and additional works at: https://uknowledge.uky.edu/ps_patents Part of the <u>Pharmacy and Pharmaceutical Sciences Commons</u>

Recommended Citation

Zhan, Chang-Guo; Cho, Hoon; and Tai, Hsin-Hsiung, "High-Activity Mutants of Butyrylcholinesterase for Cocaine Hydrolysis and Method of Generating the Same" (2015). *Pharmaceutical Sciences Faculty Patents*. 61. https://uknowledge.uky.edu/ps_patents/61

This Patent is brought to you for free and open access by the Pharmaceutical Sciences at UKnowledge. It has been accepted for inclusion in Pharmaceutical Sciences Faculty Patents by an authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.



US009206403B1

(12) United States Patent

Zhan et al.

(54) HIGH-ACTIVITY MUTANTS OF **BUTYRYLCHOLINESTERASE FOR** COCAINE HYDROLYSIS AND METHOD OF GENERATING THE SAME

- (71) Applicant: University of Kentucky Research Foundation, Lexington, KY (US)
- Inventors: Chang-Guo Zhan, Lexington, KY (US); (72)Hoon Cho, Lexington, KY (US); Hsin-Hsiung Tai, Lexington, KY (US)
- Assignee: University of Kentucky Research (73)Foundation, Lexington, KY (US)
- (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 136 days.
- (21) Appl. No.: 14/163,376
- (22) Filed: Jan. 24, 2014

Related U.S. Application Data

- Division of application No. 13/767,418, filed on Feb. (62) 14, 2013, now Pat. No. 8,835,150, which is a division of application No. 13/449,107, filed on Apr. 17, 2012, now Pat. No. 8,399,644, which is a division of application No. 13/018,641, filed on Feb. 1, 2011, now Pat. No. 8,193,327, which is a division of application No. 12/752,920, filed on Apr. 1, 2010, now Pat. No. 7,919,082, which is a division of application No. 12/192,394, filed on Aug. 15, 2008, now Pat. No. 7,731,957, which is a division of application No. 11/243,111, filed on Oct. 4, 2005, now Pat. No. 7,438,904.
- (51) Int. Cl. C12N 9/16 (2006.01)C12N 9/18
- (2006.01)(52) U.S. Cl.
- CPC C12N 9/18 (2013.01) (58)**Field of Classification Search**
- CPC C12N 9/18; A61K 38/00 USPC 435/196 See application file for complete search history.

(56)**References** Cited

U.S. PATENT DOCUMENTS

7,049,121	B2	5/2006	Watkins et al.
2003/0153062	A1	8/2003	Watkins et al.
2004/4012093		6/2004	Watkins et al.

OTHER PUBLICATIONS

Huang, Xiaoqin et al., Reaction Pathway and Free Energy Profile for Prechemical Reaction Step of Human Butyrylcholinesterase-Catalyzed Hydrolysis of (-)-Cocaine by Combined Targeted Molecular Dynamics and Potential of Mean Force Simulations; J. Phys. Chem., 2010, vol. 114, pp. 13545-13554.

Xue, Liu et al., Design, Preparation, and Characterization of High-Activity Mutants of Human Butyrylcholinesterase Specific for Detoxification of Cocaine, Molecular Pharmacology, 2011, vol. 79, pp. 290-297.

US 9,206,403 B1 (10) **Patent No.:** (45) **Date of Patent:** Dec. 8, 2015

Yang, Wenchao et al., Characterization of a high-activity mutant of human butyrylcholinesterase against (-)-cocaine, Chemico-Biological Interactions, 2010, vol. 187, pp. 148-152.

Yang, Wenchao et al., Free-Energy Perturbation Simulation on Transition States and Redesign of Butyrylcholinesterase, 2009, vol. 96, pp. 1931-1938.

Yang, Wenchao et al., Free Energy Perturbation Simulation on Transition States and High-Activity Mutants of Human Butyrylcholinesterase for (-)-Cocaine Hydrolysis, J. Phys. Chem., 2010, vol. 114, pp. 10889-10896.

Pan, Yongmei et al., Free Energy Perturbation (FEP) Simulation on the Transition States of Cocaine Hydrolysis Catalyzed by Human Butyrylcholinesterase and its Mutants, J. Am. Chem. Soc., 2007, vol. 129, pp. 13537-13543.

Pan, Yongmei et al., Model of Human Butyrylcholinesterase Tetramer by Homology Modeling and Dynamics Simulation, J. Phys. Chem., 2009, vol. 113, pp. 6543-6552.

Zheng, Fang et al., Rational design of an enzyme mutant for anticocaine therapeutics, J. Comput Aided Mol. Des., 2008, vol. 22, pp. 661-671

Zheng, Fang et al., Structure-and-mechanism-based design and discovery of therapeutics for cocaine overdose and addiction, Organic & Biomolecular Chemistry, 2008, vol. 6, pp. 836-843.

Zheng, Fang et al., Design of High-Activity Mutants of Human Butyrylcholinesterase against (-)-Cocaine: Structural and Energetic Factors Affecting the Catalytic Efficiency, Biochemistry, 2010, vol. 49, pp. 9113-9119.

Zheng, Fang et al., Recent progress in protein drug design and discovery with a focus on novel approaches to the development of anticocaine medications, Future Med. Chem, 2009), vol. 1, No. 3, pp. 515-528

Zheng, Fang et al., Enzyme-therapy approaches for the treatment of drug overdose and addition, Future Med. Chem., 2011, vol. 3, No. 1, pp. 9-13.

Zheng, Fang et al., Most Efficient Cocaine Hydrolase Designed by Virtual Screening of Transition States, J. Am. Chem. Soc., 2008, vol. 130, pp. 12148-12155.

(Continued)

Primary Examiner - Tekchand Saidha

(74) Attorney, Agent, or Firm - Stites & Harbison PLLC; Mandy Wilson Decker

(57)ABSTRACT

A novel computational method and generation of mutant butyrylcholinesterase for cocaine hydrolysis is provided. The method includes molecular modeling a possible BChE mutant and conducting molecular dynamics simulations and hybrid quantum mechanical/molecular mechanical calculations thereby providing a screening method of possible BChE mutants by predicting which mutant will lead to a more stable transition state for a rate determining step. Site-directed mutagenesis, protein expression, and protein activity is conducted for mutants determined computationally as being good candidates for possible BChE mutants, i.e., ones predicted to have higher catalytic efficiency as compared with wild-type BChE. In addition, mutants A199S/A328W/ Y332G, A199S/F227A/A328W/Y332G, A199S/S287G/ A328W/Y332G, A199S/F227A/S287G/A328W/Y332G, and A199S/F227A/S287G/A328W/E441D all have enhanced catalytic efficiency for (-)-cocaine compared with wild-type BChE.

6 Claims, 6 Drawing Sheets

(56) **References Cited**

OTHER PUBLICATIONS

Gao, et al.; Modeling effects of oxyanion hole on the ester hydrolyses catalyzed by human cholinesterases; Phys. Chem. B; 2005; 109; pp. 23070-23076.

Gao, et al; Computational design of a human butyrylcholinesterase mutant for accelerating cocaine hydrolysis based on the transition-state simulation; Angew. Chem. Int. Ed.; 2006; 45; pp. 653-657.

Gao, et al; Modeling evolution of hydrogen bonding and stablization of transition states in the process of cocaine hydrolysis catalyzed by human butyrylcholinesterase; Proteins; 2006; 62; pp. 99-110.

Hamza, et al.; Molecular dynamics simulation of cocaine binding with human butyrylcholinesterase and its mutants; J. Phys. Chem. B.; 2005; 109; pp. 4776-4782.

Pan, et al.; Computational redesign of human butyrylcholinesterase for anti-cocaine medication; G. Proc. Natl. Acad. Sci. USA; 2005; 102; pp. 16656-16661.

Zhan, et al.; Fundamental reaction mechanism for cocaine metabolism in human butyrylcholinesterase; J. Am. Chem. Soc.; 2003; 125; pp. 2462-2474.

Zhan, et al.; Catalytic Mechanism and energy barriers for butyrylcholinesterase-catalyzed hydrolysis of cocaine; Biophysical Journal; 2005; 89; 3863-3872.

Xie, et al.; An improved cocaine hydrolase: the A328Y mutant of human butyrylcholinesterase is 4-fold more efficient; Moleculare Pharm; 1999; 55; pp. 83-91.



FIGURE 1

(A) BChE-(-)-cocaine non-prereactive complex

(B) BChE-(-)-cocaine prereactive complex

(C) BChE-(+)-cocaine non-prereactive complex

(D) BChE-(+)-cocaine prereactive complex

FIGURE 2

FIGURE 3

FIGURE 5

FIGURE 6

HIGH-ACTIVITY MUTANTS OF **BUTYRYLCHOLINESTERASE FOR** COCAINE HYDROLYSIS AND METHOD OF GENERATING THE SAME

RELATED APPLICATIONS

This application is a division of and claims benefit to U.S. patent application Ser. No. 13/767,418, filed Feb. 14, 2013 10and now allowed, which is a division of and claims benefit to U.S. patent application Ser. No. 13/449,107, now issued as U.S. Pat. No. 8,399,644, filed Apr. 17, 2012, which is a division of and claims benefit to U.S. patent application Ser. 15 No. 13/018,641, now issued as U.S. Pat. No. 8,193,327, filed Feb. 1, 2011, which is a division of and claims benefit to U.S. patent application Ser. No. 12/752,920, now issued as U.S. Pat. No. 7,919,082, filed Apr. 1, 2010, which is a division of and claims benefit to U.S. patent application Ser. No. 12/192, $_{20}$ 394, now issued as U.S. Pat. No. 7,731,957, filed Aug. 15, 2008, which is a division of and claims benefit to U.S. patent application Ser. No. 11/243,111, now issued as U.S. Pat. No. 7,438,904, filed Oct. 4, 2005. The contents of which are incorporated herein by reference in their entirety. 25

GOVERNMENT INTEREST

Subject matter described herein was made with government support under Grant Number R01DA013930 awarded by the National Institute on Drug Abuse (NIDA) of the National Institutes of Health (NIH). The government has 35 certain rights in the described subject matter.

FIELD OF THE INVENTION

The present invention relates to butyrylcholinesterase variant polypeptides, and in particular, butyrylcholinesterase 45 mutants having amino acid substitutions.

BACKGROUND OF THE INVENTION

Cocaine abuse is a major medical and public health problem that continues to defy treatment. The disastrous medical and social consequences of cocaine addiction, such as violent 55 crime, loss in individual productivity, illness and death, have made the development of an effective pharmacological treatment a high priority. However, cocaine mediates its reinforcing and toxic effects by blocking neurotransmitter reuptake and the classical pharmacodynamic approach has failed to 60 vield small-molecule receptor antagonists due to the difficulties inherent in blocking a blocker. An alternative to receptorbased approaches is to interfere with the delivery of cocaine to its receptors and accelerate its metabolism in the body.

The dominant pathway for cocaine metabolism in primates 65 is butyrylcholinesterase (BChE)-catalyzed hydrolysis at the benzoyl ester group (Scheme 1).

Scheme 1. Schematic representation of BChE-catalyzed hydrolysis at the benzoyl ester group.

Only 5% of the cocaine is deactivated through oxidation by the liver microsomal cytochrome P450 system. Cocaine hydrolysis at benzoyl ester group yields ecgonine methyl ester, whereas the oxidation produces norcocaine. The metabolite ecgonine methyl ester is a biologically inactive metabolite, whereas the metabolite norcocaine is hepatotoxic and a local anesthetic. BChE is synthesized in the liver and widely distributed in the body, including plasma, brain, and lung. Extensive experimental studies in animals and humans demonstrate that enhancement of BChE activity by administration of exogenous enzyme substantially decreases cocaine half-life.

hydrolysis at the benzoyl ester group H₃C. H OCH₃ BChE H_2O O: (-)-cocaine H₃C OH. OCH₃ OH 30 H₃C ,H OCH₂ BChE H_2O 0: 40 (+)-cocaine H_3 OH 50 DCH: OH

2

Scheme 1. Schematic representation of BChE-catalyzed

Enhancement of cocaine metabolism by administration of BChE has been recognized to be a promising pharmacokinetic approach for treatment of cocaine abuse and dependence. However, the catalytic activity of this plasma enzyme is three orders-of-magnitude lower against the naturally occurring (-)-cocaine than that against the biologically inactive (+)-cocaine enantiomer. (+)-cocaine can be cleared from plasma in seconds and prior to partitioning into the central nervous system (CNS), whereas (-)-cocaine has a plasma half-life of approximately 45-90 minutes, long enough for manifestation of the CNS effects which peak in minutes. Hence, BChE mutants with high activity against (-)-cocaine are highly desired for use in humans. Although some BChE mutants with increased catalytic activity over wild-type 15 BChE have previously been generated, there exists a need for mutant BChE with even higher catalytic activity. Thus, prior mutants provide limited enhancement in catalytic activity over wild-type BChE.

Previous studies such as (a) Masson, P.; Legrand, P.; Bar- 20 tels, C. F.; Froment, M-T.; Schopfer, L. M.; Lockridge, O. Biochemistry 1997, 36, 2266 (b) Masson, P.; Xie, W., Froment, M-T.; Levitsky, V.; Fortier, P.-L.; Albaret, C.; Lockridge, O. Biochim. Biophys. Acta 1999, 1433, 281, (c) Xie, 25 W.; Altamirano, C. V.; Bartels, C. F.; Speirs, R. J.; Cashman, J. R.; Lockridge, O. Mol. Pharmacol. 1999, 55, 83, (d) Duysen, E. G.; Bartels, C. F.; Lockridge, O. J. Pharmacol. Exp. Ther. 2002, 302, 751, (e) Nachon, F.; Nicolet, Y.; Viguie, N.; Masson, P.; Fontecilla-Camps, J. C.; Lockridge, O. Eur. J. 30 Biochem. 2002, 269, 630, (f) Zhan, C.-G.; Landry, D. W. J. Phys. Chem. A 2001, 105, 1296; Berkman, C. E.; Underiner, G. E.; Cashman, J. R. Biochem. Pharmcol. 1997, 54, 1261; (g) Sun, H.; Yazal, J. E.; Lockridge, O.; Schopfer, L. M.; 35 Brimijoin, S.; Pang, Y.-P. J. Biol. Chem. 2001, 276, 9330, (h) Sun, H.; Shen, M. L.; Pang, Y. P.; Lockridge, O.; Brimijoin, S. J. Pharmacol. Exp. Ther. 2002, 302, 710, (i) Sun, H.; Pang, Y. P.; Lockridge, O.; Brimijoin, S. Mol. Pharmacol. 2002, 62, 220 (hereinafter "Sun et al"); and (j) Zhan, C.-G.; Zheng, F.; 40 Landry, D. W. J. Am. Chem. Soc. 2003, 125, 2462 (hereinafter "Zhan et al"), herein all incorporated by reference, suggested that, for both (-)-cocaine and (+)-cocaine, the BChE-substrate binding involves two different types of complexes: non-prereactive and prereactive BChE-substrate complexes. Whereas the non-prereactive BChE-cocaine complexes were first reported by Sun et al, Zhan et al were the first reporting the prereactive BChE-cocaine complexes and reaction coordinate calculations, disclosed in Zhan et al.

It was demonstrated that (-)/(+)-cocaine first slides down the substrate-binding gorge to bind to W82 and stands vertically in the gorge between D70 and W82 (non-prereactive complex) and then rotates to a position in the catalytic site within a favorable distance for nucleophilic attack and 55 hydrolysis by S198 (prereactive complex). In the prereactive complex, cocaine lies horizontally at the bottom of the gorge. The main structural difference between the BChE-(-)-cocaine complexes and the corresponding BChE-(+)-cocaine complexes exists in the relative position of the cocaine methyl 60 ester group. Reaction coordinate calculations revealed that the rate-determining step of BChE-catalyzed hydrolysis of (+)-cocaine is the chemical reaction process, whereas for (-)-cocaine the change from the non-prereactive complex to the prereactive complex is rate determining. A further analy- 65 sis of the structural changes from the non-prereactive complex to the prereactive complex reveals specific amino acid

4

residues hindering the structural changes, providing initial clues for the rational design of BChE mutants with improved catalytic activity for (-)-cocaine.

Previous molecular dynamics (MD) simulations of prereactive BChE-cocaine binding were limited to wild-type BChE. Even for the non-prereactive BChE-cocaine complex, only one mutant (A328W/Y332A) BChE binding with (-)cocaine was simulated and its catalytic activity for (-)-cocaine was reported by Sun et al. No MD simulation was performed on any prereactive enzyme-substrate complex for (-)- or (+)-cocaine binding with a mutant BChE. In addition, all previous computational studies of Sun et al and Zhan et al of BChE interacting with cocaine were performed based on a homology model of BChE when three-dimensional (3D) X-ray crystal structure was not available for BChE, as taught by Nicolet, Y.; Lockridge, O.; Masson, P.; Fontecilla-Camps, J.C.; Nachon, F.J. Biol. Chem. 2003, 278, 41141 (hereinafter "Nicolet et al"), recently reported 3D X-ray crystal structures of BChE. As expected, the structure of BChE is similar to a previously published theoretical model of this enzyme and to the structure of acetylcholinesterase.

The main difference between the experimentally determined BChE structure and its model was found at the acyl binding pocket (acyl loop) that is significantly bigger than expected. It is unclear whether the structural difference at the acyl binding pocket significantly affect BChE binding with (-)-cocaine and (+)-cocaine. Although previous MD simulations of cocaine binding with wild-type BChE and the reaction coordinate calculations point to some amino acid residues that might need to be mutated for the purpose of improving the catalytic activity for (-)-cocaine hydrolysis, it remained unknown which exact amino acid mutations will result in a BChE with a higher catalytic activity for (-)cocaine.

Computational studies of wild-type BChE and cocaine from Sun, et al, based on a "homology model," suggest that the rate-determining step for BChE-catalyzed hydrolysis of cocaine is the rotation of the cocaine in the active site of BChE. By decreasing the hindrance of the rotation, the rate of the hydrolysis may be enhanced. Sun, et al describes creating an A328W/Y332A BChE mutant by: (1) replacing Tyr332 with Ala, "to reduce the steric hindrance and the π - π interaction that impede rotation," and (2) replacing Ala328 with Trp "to provide a cation- π interaction to restore substrate affinity lost in disabling the π - π interaction."

Sun et al studied the A328W/Y332A BChE mutant using enzyme assays and kinetics. In vitro studies were conducted using human plasma and in vivo studies were conducted using male Sprague-Dawley rats. The mutant was found to have enhanced catalytic properties. The mutant was further studied using molecular modeling. The three dimensional (3D) structure of A328W/Y332A was generated from the computationally generated 3D model of wild-type BChE and changing the relevant residues using commercially available software. Cocaine was docked to the catalytic gorge of the mutant BChE using other commercially available software. The cocaine-enzyme complex was refined by molecular dynamic simulation. The data generated by the molecular modeling studies were consistent with enzyme assays and kinetic data.

It should be noted that all prior computational techniques (molecular docking and molecular dynamics simulation) used by other researchers are based on an empirical force field which cannot be used to perform any necessary reaction coordinate calculation for the detailed understanding of the complicated catalytic reaction process. As it is well-known, it is particularly challenging to model and simulate the detailed reaction pathway and predict the kinetics of such an enzy-⁵ matic reaction.

U.S. Patent Application Publication Nos. 2004/0121970; 2004/0120939; and 2003/0153062, describe 20+BChE mutants, or "variants," from human and other animals, each having from one to six amino acid alterations and increased ¹⁰ cocaine hydrolysis activity. For example, mutants include F227A/A328W; F227A/S287G/A328W; A119S/S287G/ A328W; A328W/Y332M/S287G/F227A, A199S/F227A/S/ 287G/A328W and A119S/F227A/S287G/A328W/Y332M. ¹⁵ The mutants have varying increases in catalytic activity, up to 100-fold increase relative to wild-type BChE.

There exists a need in the art for determining which proposed mutant BChEs should have ever increasing catalytic activity and for generating those mutants which should have 20 enhanced catalytic activity.

SUMMARY OF THE INVENTION

The present invention includes five novel human BChE mutants that have unexpected increased catalytic efficiency for cocaine hydrolysis. The mutants have various unique amino acid residue substitutions which provide the surprising enhanced catalytic activity. These mutants are (1) A199S/ A328W/Y332G mutant (SEQ ID NO: 2), which has a approximately 65-fold improved catalytic efficiency against (-)-cocaine; (2) A199S/F227A/A328W/Y332G mutant 35 (SEQ ID NO: 8), which has an approximately 148-fold improved catalytic efficiency against (-)-cocaine; (3) A1998/ S287G/A328W/Y332G mutant (SEQ ID NO: 14), which has an approximately 456-fold improved catalytic efficiency against (-)-cocaine; (4) A199S/F227A/S287G/A328W/ 40 Y332G mutant (SEQ ID NO: 20), which has an approximately 1,003-fold improved catalytic efficiency against (-)cocaine; and (5) A199S/F227A/S287G/A328W/E441D mutant (SEQ ID NO: 26), which has an approximately 445fold improved catalytic efficiency against (-)-cocaine.

In addition, the aforementioned mutant amino acid sequences can be truncated without substantially affecting the catalytic activity so that amino acid residues 1-67 and 443-574 can be removed without substantially affecting the catalytic activity of the enzyme. SEQ ID NOS: 4, 10, 16, 22 50 and 28 are the amino acid sequences for residue 68-142 corresponding to mutants 1-5, respectively. In addition, with regard to mutants 1-4, it was found that amino acid residues before 117 and after 438 could be removed without substantially changing the activity of the mutant enzymes, resulting 55 in truncated amino acid sequences having SEQ ID NOS: 6, 12, 18 and 24, respectively. Finally with regard to mutant 5, amino acid residues before 117 and after 441 could be removed without substantially changing its activity resulting in SEQ ID NO: 30.

These aforementioned truncated sequences all of with similar catalytic activity is based on protein structures.

Further, the present invention is directed to a novel and unique pharmaceutical composition which comprises a butyrylcholinesterase variant, namely mutants 1-5, along 65 with a suitable pharmaceutical carrier. The pharmaceutical composition can be administered to an individual in an effec-

tive amount to lower the patient's cocaine blood concentration and in particular (–)-cocaine blood concentration.

In addition, the present invention is directed to a novel and unique method for developing mutants which have enhanced catalytic efficiency. The generation method includes both a computational portion and an experimental portion. With regard to the computational portion, a variety of state of the art computational techniques including molecular modeling, molecular dynamics (MD) simulations and hybrid quantum mechanical/molecular mechanical (OM/MM) calculations, provide a virtual screening of possible BChE mutants. This virtual screening predicts which mutation will lead to a more stable transition state for a rate-determining step compared to the corresponding separated reactants, i.e., free cocaine and free enzyme. The more stable the transition state, the lower the energy barrier, and the higher the catalytic efficiency. Following the computational portion, an experimental test is then conducted on the possible mutants of the computation portion. The experimental test includes site-directed mutagenesis, protein expression, and enzyme activity assay. The experimental tests are conducted on mutants which are predicted to have a high catalytic efficiency against (-)-cocaine than the wild-type BChE and/or other known BChE mutants against (-)-cocaine. Thus, the present method identifies or predicts mutants having high catalytic activity for cocaine hydrolysis by performing molecular modeling and MD simulations on the transition state structures of possible mutants of BChE. This method is an improvement over traditional random-search approaches, which, given the complex catalytic mechanism of cocaine hydrolysis, makes it difficult to improve the catalytic activity of BChE for cocaine hydrolysis.

The present invention in one form, concerns a butyrylcholinesterase variant peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, and 30.

The present invention in another form thereof concerns a nucleic acid molecule comprising a nucleic acid sequence which encodes a butyrylcholinesterase variant peptide, the nucleic acid sequence selected from the group consisting of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, and 29.

The present invention in another form thereof concerns a pharmaceutical composition comprising a butyrylcholinest-45 erase variant polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, and 30; and a suitable pharmaceutical carrier.

The present invention in another form thereof concerns a method for treating a cocaine-induced condition comprising administering to an individual an effective amount of butyryl-cholinesterase variant peptide having an amino acid sequence selected from the group consisting of SEQ ID NOS. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, and 30, to lower blood cocaine concentration.

The present invention is another form thereof concerns a method for treating a cocaine induced condition comprising administering to an individual an effective amount of a pharmaceutical composition comprising a butyrylcholinesterase variant having an amino acid sequence selected from the group consisting of SEQ ID NOS. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, and 30, and suitable pharmaceutical carrier of claim **3** to an individual in an effective amount to lower blood cocaine concentration.

The present invention in yet another form thereof concerns a method for generating butyrylcholinesterase mutants. The method includes generating an initial structure of the transi-

45

55

tion state structure for the rate-determining step of the cocaine hydrolysis catalyzed by a possible butyrylcholinesterase mutant. A sufficiently long time molecular dynamics simulation is performed on the transition state structure in water to have a stable molecular dynamics trajectory. The molecular dynamics trajectory is analyzed and the hydrogen bonding energies are estimated between the carboxyl oxygen of the (-)-cocaine benzyl ester and the oxyanion hole of the possible butyrylcholinesterase mutant. If the overall hydro-10gen binding energy between the carboxyl oxygen of the (-)cocaine benzyl ester and the possible butyrylcholinesterase mutant, in the transition state, is stronger than the overall hydrogen binding energy between the carboxyl oxygen of the 15(-)-cocaine benzyl ester and the wild-type butyrylcholinesterase, optionally, hybrid quantum mechanical/molecular mechanical (QM/MM) geometry optimization is performed to refine the molecular dynamics-simulated structure, the hydrogen binding energies are calculated and the energy bar- $^{\ 20}$ rier is evaluated. Finally, the butyrylcholinesterase mutant is generated.

In various alternative embodiments, the generating an initial structure of the transition state structure is based on reaction coordinate calculations for the wild-type butyrylcholinesterase. The generating butyrylcholinesterase mutant includes performing site-directed mutagenesis on a nucleic acid sequence which includes wild-type butyrylcholinesterase to generate the mutant butyrylcholinesterase nucleic acid sequence. Using the mutant butyrylcholinesterase nucleic acid sequence, the protein encoded by the mutant nucleic acid sequences is expressed to produce mutant butyrylcholinesterase and catalytic activity assay is performed on the mutant butyrylcholinesterase.

The hybrid quantum mechanical/molecular mechanical geometry optimization may include calculating the hydrogen binding energies and evaluating the energy barriers only if the overall hydrogen binding energy between the carboxyl oxygen of the (–)-cocaine benzyl ester and the possible butyryl-cholinesterase mutant, in the transition state, is stronger than known butyrylcholinesterase mutants against (–)-cocaine.

In yet another alternative further embodiment, the method for generating butyrylcholinesterase mutants further includes determining the rate-limiting step in the hydrolysis of (–)cocaine by the possible butyrylcholinesterase mutant by conducting molecular dynamics simulations and quantum mechanical/molecular mechanical calculations relating to the transition states for other reaction steps between (–)-cocaine by the possible butyrylcholinesterase mutant and calculating respective energy barriers, thereby establishing which of the reaction steps is the rate-determining one.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 are plots of distances in the MD simulation (–)cocaine binding with A328W/Y332G BChE versus the simulation time, along with root-mean-square deviation (RMSD) ₆₀ in the enzyme-substrate complexes where FIG. 1A represents the non-prereactive enzyme-substrate complexes; and FIG. 1B represents the prereactive enzyme-substrate complexes in accordance with the present invention.

FIG. **2** shows the binding of structures of the simulated ₆₅ non-prereactive and prereactive complexes of wild-type BChE binding with two entomers of cocaine in which FIG.

8

2A depicts BChE (-)-cocaine non-prereactive complex; FIG. 2B depicts BChE (-)-cocaine prereactive complex, FIG. 2C depicts BChE (+)-cocaine non-prereactive complex; and FIG. 2D depicts BChE (+)-cocaine prereactive complex.

FIG. **3**A shows the (-)-cocaine rotation in the BChE active site for the non-prereactive complex to the prereactive complex hindered by some residues at positions Y332, A328, and F329 residues in the non-prereactive complexes which are significantly different from the corresponding positions in the prereactive complex; and FIG. **3**B shows the (+)-cocaine rotation in the BChE active site where none of the aforementioned residues hinders the (+)-cocaine rotation in the BChE active site from the non-prereactive complex to the prereactive complex in accordance with the present invention.

FIG. 4A depicts the (–)-cocaine rotation in the active site of A328W/Y332A; FIG. 4B depicts the (–)-cocaine rotation in the active site of A328W/Y332G BChE from the non-preactive complex to the prereactive complex; and FIG. 4C depicts the (–)-cocaine rotation in the active site of wild-type BChE.

FIG. **5**A is a plot of the key internuclear distances (in A) versus the time in the simulated TS1 structure for (–)-cocaine hydrolysis catalyzed by A328W/Y332A; and FIG. **5**B for A199S/A328W/Y332G BChE.

FIG. **6** is a plot of key internuclear distances (in A) versus the time in the simulated TS1 structure for (–)-cocaine hydrolysis catalyzed by A199S/S287G/A328W/Y332G 30 BChE.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention has two major improvements over the prior art. The first is the presently discovered BChE mutants, mutant 1, A199S/A328W/Y332G; mutant 2, A199S/F227A/A328W/Y332G; mutant 3, A199S/S287G/ A328W/Y332G; mutant 4, A199S/F227A/S287G/A328W/ Y332G; and mutant 5, A199S/F227A/S287G/A328W/ E441D each have a significantly higher catalytic efficiency. The second improvement is concerning the mutant designing or discovering process.

The BChE mutants 1-5 have full length amino acid sequences, SEQ ID NOS: 2, 8, 14, 20, and 26, respectively, which are encoded by nucleic acid sequences having SEQ ID NOS: 1, 7, 13, 19, and 25, respectively. Table 1 summarizes the catalytic efficiency against (–)-cocaine for the five mutants.

In addition to the full length BChE mutants, the respective amino acid sequence can be truncated without substantially affecting the respective catalytic activity. With all mutants, residues 1-67 and 443-574 can be removed without substantially affecting the catalytic activity of the respective mutant BChE. Further, with regard to mutant 1-4, amino acids 1-116 and 439-574 can be omitted without substantially affecting its respective catalytic activity. With regard to mutant 5, amino acid residues 1-116 and 442-574 can be omitted without substantially affecting its catalytic activity. Table 1 also provides a summary of amino acid SEQ ID NOS and corresponding nucleic acid SEQ ID NOS for the aforementioned truncated mutant BChE sequences.

-	ΓΔ R	ΙF	1

Mutant	Amino Acid Substi-	Nucleic Acid SEQ	Amino Acid SEQ ID	Partially Truncated Nucleic Acid Sequence Corresponding To Amino Acid Pescidues 68 442	SEQ ID NO. for Amino Acid Residues	SEQ ID NO Corresponding To Amino Acid Residues 117 438/441*	SEQ ID NO. for Amino Acid Residues	Catalytic Efficiency Against
Number	tutting	ID NO.	no.	Residues 08-442	08-442	11/-450/441	11/-438/441	(=)-cocanic
1	A199S/	1	2	3	4	5	6	65-fold
	A328W/							
2	¥332G	7	0	0	10	11	10	148 fold
2	A1995/ E227A/	/	0	9	10	11	12	148-1010
	A328W/							
	Y332G							
3	A1998/	13	14	15	16	17	18	456-fold
	S287G/							
	A328W/							
4	Y332G	10	20	21	22	22	24	1 002 6 11
4	A1998/	19	20	21	22	22	24	1,003-101d
	S287G/							
	A328W/							
	Y332G							
5	A199S/	25	26	27	28	29	30	445-fold
	F227A/							
	S287G/							
	A328W/							
	E441D							

(*Amino acid residues 117-438 for mutants 1-4 and residues 117-441 for mutant 5.)

The BChE variant polypeptide, e.g., SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, and 30 can be formulated in a pharmaceutical composition along with a suitable pharmaceutical carrier known to one skilled in the art.

The present BChE variant polypeptides can be used in treating a cocaine-induced condition by administering to an individual, an effective amount of one of the BChE variant polypeptides, i.e., SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, and 30, to lower blood cocaine concentration. The BChE variant polypeptide may be administered in the form of a pharmaceutical composition in which the BChE 40 variant is included with a suitable pharmaceutical carrier. Treatment of a cocaine induced condition using one of the aforementioned BChE variant polypeptides can be done in accordance with Zhan et al., page 2463.

The preferred dose for administration of a butyrylcho- 45 linesterase or peptide composition in accordance with the present invention is that amount which will be effective in lowering (-)-cocaine concentration in a patient's bloodstream, and one would readily recognize that this amount will vary greatly depending on the nature of cocaine consumed, 50 e.g., injected or inhaled, and the condition of a patient. An "effective amount" of butyrylcholinesterase mutant or pharmaceutical agent to be used in accordance with the invention is intended to mean a nontoxic but sufficient amount of the agent, such that the desired prophylactic or therapeutic effect 55 is produced. Thus, the exact amount of the enzyme or a particular agent that is required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the condition being treated, the particular carrier or adjuvant being used and its mode of 60 administration, and the like. Similarly, the dosing regimen should also be adjusted to suit the individual to whom the composition is administered and will once again vary with age, weight, metabolism, etc. of the individual. Accordingly, the "effective amount" of any particular butyrylcholinest- 65 erase composition will vary based on the particular circumstances, and an appropriate effective amount may be deter-

mined in each case of application by one of ordinary skill in the art using only routine experimentation.

A unique method was used to determine potential BChE mutants with projected increased catalytic activity for the hydrolysis of cocaine. The method provides a unique approach which first models the potential BChE mutant interaction with cocaine followed by generating the BChE mutant if the predicted model indicates that the BChE variant should have enhanced catalytic activity. The method includes generating an initial structure of the transition state structure for the rate-determining step for the cocaine hydrolysis catalyzed by a possible BChE mutant. A sufficiently long time molecular dynamics simulation is performed on the transition state structure in water to have a stable molecular dynamics trajectory. The molecular dynamics trajectory is analyzed and the hydrogen binding energies are estimated between the carboxyl oxygen of the (-)-cocaine benzoyl ester and the oxyanion hole of the possible BChE mutant. If the overall hydrogen binding energy between the carboxyl oxygen of the (-)cocaine benzoyl ester and the possible BChE mutant, in the transition state, is stronger than the overall hydrogen binding energy between the carboxyl oxygen of the (-)-cocaine benzoyl ester and the wild-type BChE, hybrid quantum mechanical/molecular mechanical (QM/MM) geometry optimization is performed to refine the molecular dynamics-simulated structure, the hydrogen binding energies are calculated and the energy barrier is evaluated. The QM/MM calculations make the computational predictions more reliable. Finally, the BChE mutant is generated.

With regard to the molecular dynamics (MD) simulations and quantum mechanical/molecular mechanical (QM/MM) calculations, the first chemical reaction step of (–)-cocaine hydrolysis catalyzed by butyrylcholinesterase (BChE) mutants and, when needed, other reaction steps are modeled and calculated using molecular dynamics simulations and QM/MM calculations. Following this modeling, mutant BChE's are created using site-directed mutagenesis followed by protein expression. The aforementioned five mutants were identified by computational analysis and generated by site-

25

directed mutagenesis which have significantly enhanced (-)cocaine hydrolysis catalytic efficiency compared with wildtype BChE

In the present method computational analysis in the form of molecular modeling of a potential BChE mutant and MD simulations and QM/MM calculations provide virtual screening of possible BChE mutants which have predicted enhanced catalytic activity for (-)-cocaine. For example, the MD simulations and QM/MM calculations predict which mutation will lead to a more stable transition state for the rate determining 10 step compared to the corresponding separated reagents, i.e., free cocaine and free possible mutant BChE, where the more stable transition state leads to a lower energy barrier and higher predicted catalytic efficiency. Only after the computational analysis predicts enhanced catalytic efficiency, is sitedirected mutagenesis conducted on wild-type BChE nucleic acid sequence to generate a mutant nucleic acid sequence which is then used to express a mutant BChE protein. The mutant BChE protein is then used in catalytic assays to determine the catalytic efficiency against (-)-cocaine.

The use of predictive, computational modeling of the present method for identifying mutant BChE candidates and the resulting mutant BChE are novel and unexpected over prior conventional methods which will now be readily apparent to one of ordinary skill in the art.

Using the present method, most discovered new mutants include a specific mutation (Y332G) on residue #332. No prior BChE mutant having the Y332G mutation had ever been reported previously; only mutations Y332A and Y332M on residue #332 had been tested previously by other researchers. 30 Prior to the present invention, there was no reason to expect that a mutant including Y332G mutation should be better than the corresponding mutant including Y332A mutation or Y332M. Thus, the present mutants with a Y332G mutation which have enhanced catalytic activity represent a surprising 35 and unexpected result over prior BChE mutants.

A Y332G mutant (single mutation) was first tested and found that the Y332G mutant had a slightly low (or approximately equal) catalytic efficiency than the wild-type. So, only an appropriate combination of different mutations on differ- 40 ent residues could make the enzyme more active. As seen below, the prior art did not reveal that any of the particular combinations tested was expected to have an improved catalytic efficiency. The present method is based on the present unique, extensive computational modeling and simulations of 45 the detailed catalytic mechanism for both the wild-type BChE and the mutants.

The primary improvement of the present method over the prior art is that high-performance computational modeling and simulations of the detailed catalytic mechanism are per- 50 formed, which includes modeling how cocaine binds with BChE and the subsequent structural transformation and chemical reaction process. The prior art only considered the cocaine binding with the enzyme (BChE) and was unable to examine the detailed catalytic reaction process after the 55 BChE-cocaine binding. When molecular modeling was limited to studying the BChE-cocaine binding, one could only design a mutation to improve the BChE-cocaine binding without knowing whether the mutation will also speedup the subsequent chemical reaction process or not.

To overcome the obstacles of prior challenges to using computational techniques such as molecular docking and molecular dynamics simulation previously used by others which were based on an empirical force field which cannot be used to perform necessary reaction coordinate calculations for the catalytic reaction process, a variety of state-of-the-art computational techniques of homology modeling, molecular

docking, molecular dynamics, quantum mechanics (QM), and hybrid quantum mechanics/molecular mechanics (QM/ MM) were used for the rational design of the BChE mutants. The combined use of these computational techniques, including QM and QM/MM, led to the study of the detailed reaction coordinate of the BChE-catalyzed hydrolysis of cocaine which, for the first time, provided the detailed structures of all transition states and intermediates existing in the reaction process and the corresponding energetics. These extensive computational modeling and simulation studies provided for the rational design of possible BChE mutants that not only can improve the BChE-cocaine binding, but also can speedup the subsequent chemical reaction process. As a result, one can now quickly discover the BChE mutants with the significantly improved catalytic efficiency.

In addition, to the differences mentioned above, the present molecular modeling of the BChE-cocaine binding also differs from the prior modeling. The molecular modeling in the prior art considered only one binding mode for each BChE-cocaine system, without modeling the possible cocaine rotation in the BChE active site after the binding. The present method considers two different binding modes for each BChE-cocaine system and the structural transformation between them: nonprereactive and prereactive BChE-cocaine complexes. The present modeling provides more detailed information about the BChE-cocaine binding and the subsequent structural transformation.

The present method includes molecular dynamics simulations performed on the cocaine binding with both the wildtype BChE and the mutants whereas prior molecular dynamics simulations were only performed on the cocaine binding with the wild-type BChE. As is shown below in the following experiments, the computational prediction could be completely wrong without directly modeling and simulating cocaine binding with the proposed mutants.

The present invention will now be discussed with regard to the following non-limiting examples in the form of experiments which are provided to enhance understanding of the present invention but in no way limit its scope or applicability.

Experiment 1

Computational Study of Cocaine Binding with Wild-Type and Mutant BChE's for A328W/Y332G, A328W/Y332A, and A328W/Y332A/Y419S

A detailed computational study of cocaine binding with wild-type and mutant BChE's starting from the available X-ray crystal structure of wild-type BChE was performed. The simulated mutants include A328W/Y332G, A328W/ Y332A, and A328W/Y332A/Y419S, as simple geometric consideration of the binding site suggests that these mutations could be important for changing the (-)-cocaine rotation from the non-prereactive complex to the prereactive complex. Wet experimental tests were conducted on the catalytic activity of these mutants for (-)-cocaine in order to verify the computational predictions. All of the obtained results clearly demonstrate that molecular modeling and MD simulations of cocaine binding with BChE mutants provide a reliable computational approach to the rational design of high-activity mutants of BChE for the (-)-cocaine hydrolysis.

3D Model of BChE.

60

65

The initial coordinates of human BChE used in the computational studies came from the X-ray crystal structure deposited in the Protein Data Bank (pdb code: 1P0P). The missing residues (D2, D3, E255, D378, D379, N455, L530, E531, and M532) in the X-ray crystal structure were built

using the automated homology modeling tool Modeler disclosed by Sali, A.; Blundell, T. L. *J. Mol. Biol.* 1990, 212 403, and Sali, A.; Blundell, T. L. *J. Mol. Biol.* 1993, 234, 779, herein incorporated by reference, and InsightII software (Accelrys, Inc.) with the default parameters.

Molecular Docking.

Molecular docking was performed for each non-prereactive protein-ligand binding complex. The binding site was defined as a sphere with an approximately 15 Å radius around the active site residue S198. The amino acid residues included 10 in the binding site model are not contiguous in the protein. Cocaine, considered as a ligand, was initially positioned at 17 Å in front of S198 of the binding site. Each BChE-cocaine binding complex was energy-minimized by using the steepest descent algorithm first until the maximum energy derivative 15 is smaller than 4 kcal/mol/Å and then the conjugated gradient algorithm until the maximum energy derivative is smaller than 0.001 kcal/mol/Å. The energy minimization was followed by a 300 ps molecular dynamics (MD) simulation at T=298 K with a time step of 1 fs. During the energy minimi- 20zation and MD simulation, only cocaine and the residues of BChE included in the binding site were allowed to move, while the remaining part of the protein was fixed. The energyminimization and MD simulation for these processes were performed by using the Amber force field implemented in the 25 Discover_3/InsightII calculation engine, disclosed by Cornell, W. D.; Cieplak, P.; Bayly, C. I.; Gould, I. R.; Merz, Jr., K. M.; Ferguson, D. M.; Spellmeyer, D. C.; Fox, T.; Caldwell, J. W.; Kollman, P. A. J. Am. Chem. Soc. 1995, 117, 5179. The non-bonded cut-off method and the dielectric constant were 30 set up to group based (12 Å cut-off distance) and distance dependent, respectively ($\in =4r$) in accordance with Harvey, S. C. Proteins 1989, 5, 78-92, herein incorporated by reference.

Molecular Dynamic Simulation in Water.

The initial coordinates used in the MD simulation of the 35 non-prereactive complexes were determined by using the molecular docking procedure described above, whereas the initial coordinates used in the MD simulation of the prereactive complexes were obtained from superimposing backbone of the X-ray crystal structure to that of the previously dis- 40 closed simulated prereactive complex of Zhan et al between cocaine and a homology model of wild-type BChE. Each BChE-cocaine binding complex was neutralized by adding two chloride counterions and was solvated in a rectangular box of TIP3P water molecules with a minimum solute-wall 45 distance of 10 Å. The general procedure for carrying out the MD simulations in water is similar to that used in our previously reported other computational studies such as those in Zhan et al and (a) Zhan, C.-G.; Norberto de Souza, O.; Rittenhouse, R.; Ornstein, R. L. J. Am. Chem. Soc. 1999, 121, 50 7279, (b) Koca, J.; Zhan, C.-G.; Rittenhouse, R.; Ornstein, R. L. J. Am. Chem. Soc. 2001, 123, 817, (c) Koca, J.; Zhan, C.-G.; Rittenhouse, R. C.; Ornstein, R. L. J. Comput. Chem. 2003, 24, 368, herein all incorporated by reference. These simulations were performed by using the Sander module of 55 Amber7 program as taught by Case, D. A.; Pearlman, D. A.; Caldwell, J. W.; Cheatham III, T. E.; Wang, J.; Ross, W. S.; Simmerling, C. L.; Darden, T. A.; Merz, K. M.; Stanton, R. V.; Cheng, A. L.; Vincent, J. J.; Crowley, M.; Tsui, V.; Gohlke, H.; Radmer, R. J.; Duan, Y.; Pitera, J.; Massova, I.; Seibel, G. L.; 60 Singh, U.C.; Weiner, P.K.; Kollman, P.A. (2002), AMBER 7, University of California, San Francisco, herein incorporated by reference. The solvated system was optimized prior to the MD simulation. First, the protein-ligand was frozen and the solvent molecules with counterions were allowed to move 65 during a 5000-step minimization with the conjugate gradient algorithm and a 5 ps MD run at T=300 K. After full relaxation

14

and the entire solvated system was energy-minimized, the system was slowly heated from T=10 K to T=300 K in 30 ps before the production MD simulation for 500 ps. The full minimization and equilibration procedure was repeated for each mutant. The MD simulations were performed with a periodic boundary condition in the NPT ensemble at T=300 K with Berendsen temperature coupling and constant pressure (P=1 atm) with isotropic molecule-based scaling disclosed in Berendsen, H. C.; Postma, J. P. M.; van Gunsteren, W. F.; DiNola, A.; Haak, J. R. J. Comp. Phys. 1984, 81, 3684, herein incorporated by reference. The SHAKE algorithm of Ryckaert, J. P.; Ciccotti, G.; Berendsen, H. C. J. Comp. Phys. 1977, 23, 327 (herein incorporated by reference) was applied to fix all covalent bonds containing a hydrogen atom, a time step of 2 fs was used, and the non-bond pair list was updated every 10 steps. The pressure was adjusted by isotropic position scaling. The particle mesh Ewald (PME) method of Essmann, U.; Perera, L.; Berkowitz, M. L.; Darden, T. A.; Lee, H., Pedersen; L. G. J. Chem. Phys. 1995, 98, 10089, herein incorporated by reference, was used to treat long-range electrostatic interactions. A residue-based cutoff of 10 Å was applied to the noncovalent interactions. During the 500 ps production MD simulation, the coordinates of the simulated complex were saved every 1 ps.

Molecular docking and MD simulation procedures described above were performed to study cocaine binding with wild-type BChE and three mutants, i.e., A328W/Y332A, A328W/Y332A/Y419S, and A328W/Y332G. For each protein system (wild-type or mutant BChE), the protein binding with cocaine was considered in both the non-prereactive and prereactive enzyme-substrate complexes.

Most of the MD simulations in water were performed on a supercomputer, Superdome (shared-memory, with 4 nodes and 256 processors), at the Center for Computational Sciences, University of Kentucky. The other computations were carried out on SGI Fuel workstations and a 34-processors IBM x335 Linux cluster.

Experimental Procedure.

Site-directed mutagenesis of human BChE cDNA was performed by the QuikChange method of Braman, J.; Papworth, C.; Greener, A. Methods Mol. Biol. 1996, 57, 5731, herein incorporated by reference. Mutations were generated from wild-type human BChE in a pRc/CMV expression plasmid in accordance with Xie, W.; Altamirano, C. V.; Bartels, C. F.; Speirs, R. J.; Cashman, J. R.; Lockridge, O. Mol. Pharmacol. 1999, 55, 83, all herein incorporated by reference, kindly provided by Dr. Lockridge at University of Nebraska Medical Center. Using plasmid DNA as template and primers with specific base-pair alterations, mutations were made by polymerase chain reaction with Pfu DNA polymerase, for replication fidelity. The PCR product was treated with Dpn I endonuclease to digest the parental DNA template. Modified plasmid DNA was transformed into Escherichia coli, amplified, and purified. The DNA sequences of the mutants were confirmed by DNA sequencing. BChE mutants were expressed in human embryonic kidney cell line 293T/17. Cells were grown to 80-90% confluence in 6-well dishes and then transfected by Lipofectamine 2000 complexes of 4 µg plasmid DNA per each well. Cells were incubated at 37° C. in a CO₂ incubator for 24 hours and cells were moved to 60-mm culture vessel and cultured for four more days. The culture medium [10% fetal bovine serum in Dulbecco's modified Eagle's medium (DMEM)] was harvested for a BChE activity assay. To measure cocaine and benzoic acid, the product of cocaine hydrolysis by BChE, we used sensitive radiometric assays based on toluene extraction of [3H]cocaine labeled on its benzene ring were used in accordance with Masson, P.; Xie, W., Froment, M-T.; Levitsky, V.; Fortier, P.-L.; Albaret, C.; Lockridge, O. Biochim. Biophys. Acta 1999, 1433, 281, herein incorporated by reference. In brief, to initiate reactions, 100 nCi of [³H]cocaine was mixed with 100 µl of culture medium. Reactions proceeded at 37° C. for varying times. Reactions were stopped by adding 300 µl of 0.02 M HCl, which neutralized the liberated benzoic acid while ensuring a positive charge on the residual cocaine. [³H]benzoic acid was extracted by 1 ml of toluene and measured by scintillation counting. Finally, the measured time-dependent radiometric data were fitted to the kinetic equation so that the catalytic efficiency (k_{cat}/K_M) was determined.

Depicted in FIG. 1 are plots of some important distances in the MD-simulated (-)-cocaine binding with A328W/Y332G BChE versus the simulation time, along with root-meansquare deviation (RMSD) of the coordinates of backbone atoms in the simulated structure from those in the X-ray 15 crystal structure. MD trajectories for other complexes were similar to these two in FIG. 1, although the simulated average distances are different. Summarized in Table 2 are the average values of some important geometric parameters in the simulated complexes. 20

^a Refers to (-)-cocaine binding with wild-type human BChE or (-)-cocaine binding with a mutant BChE, unless indicated otherwise.

^b Refers to (+)-cocaine binding with wild-type human 25 BChE

c<D1>non and <D1> represent the average distances between the S198 O^{γ} atom and the carbonyl carbon of the cocaine benzovl ester in the simulated non-prereactive and prereactive BChE-cocaine complexes, respectively. <D2>, <D3>, <D4> refer to the average values of the simulated distances from the carbonyl oxygen of the cocaine benzoyl ester to the NH hydrogen atoms of G116, G117, and A199 residues, respectively. <0> is the average value of the dihedral angle formed by the S198 O^{γ} atom and the plane of the 35 carboxylate group of the cocaine benzoyl ester. See Scheme 2.

^d The root-mean-square deviation (RMSD) of the coordinates of backbone atoms in the simulated structure from those in the X-ray crystal structure of BChE. "nonpre" and "pre" 40 refer to the non-prereactive and prereactive BChE-cocaine complexes, respectively.

TABLE 2

BChE- cocaine		Ave: geon	RMS	45					
binding ^a	$<\!\mathrm{D1}\!>_{non}$	<d1></d1>	<d2></d2>	<d3></d3>	<d4></d4>	< 0>	nonpre	pre	
wild-type	5.60	3.27	5.77	2.71	3.37	67	1.14	1.27	
wild-type	7.64	3.69	2.88	2.30	2.83	61	1.15	1.13	50
with (+)- cocaine ^b									
A328W/	7.11	3.87	3.30	2.14	3.01	51	1.58	1.65	
Y332A									
A328W/	7.06	3.96	2.28	2.52	2.42	60	1.20	1.35	
Y332G									55
A328W/	5.18	5.84	5.64	4.56	6.97	164	2.66	2.62	00
Y332A/									
Y419S									

^aRefers to (-)-cocaine binding with wild-type human BChE or (-)-cocaine binding with a mutant BChE, unless indicated otherwise. ^bRefers to (+)-cocaine binding with wild-type human BChE.

60

65

FIG. 2 shows the binding structures of the simulated nonprereactive and prereactive complexes of wild-type BChE binding with the two enantiomers of cocaine. In the nonprereactive complexes with (-)- and (+)-cocaine, the methyl ester group of cocaine is positioned at the top of the H438 backbone, while the cocaine benzoyl ester moiety is quasiparallel to the C-O^Y side chain of S198 with a dihedral angle Θ of -8° and 140° , respectively.

Scheme 2. Hydrolysis of (-)-cocaine and (+)-cocaine.

Here, Θ refers to the dihedral angle formed by S198 O^{γ} and the plane of carboxylate group of the cocaine benzoyl ester as shown in the structure diagram below.

The simulated internuclear distances between the carbonyl oxygen of cocaine benzoyl ester group and the NH hydrogen of G116, G117, and A199 are comparable for the two enantiomers. The simulated average distances between the carbonyl carbon of the benzoyl ester and S198 O^{γ} are 5.60 Å and 45 5.18 Å for (-)- and (+)-cocaine, respectively. Comparing the simulated protein backbone structures to the X-ray crystal structure of Nicolet et al. one can see from FIG. 1 that the RMSD values are all smaller than 1.3 Å for the whole protein structures.

The MD simulations of the prereactive complexes reveal that wild-type BChE binding with (-)-cocaine is essentially the same as the binding with (+)-cocaine in the binding site, except for the different positions of methyl ester group of the substrates. The simulated average distances between the carbonyl carbon of the benzoyl ester and S198 O^{γ} are 3.27 and 3.69 Å for (-)-cocaine and (+)-cocaine, respectively. Moreover, the (+)-cocaine is stabilized more effectively by the formation of strong hydrogen bonds with the backbone NH of residues G116, G117, and A199 as summarized above in Table 2. The cocaine benzoyl ester moiety is positioned quasiperpendicular to S198 C— O^{γ} with a dihedral angle Θ of ~67° and $\sim 61^{\circ}$ for (-)- and (+)-cocaine, respectively.

A comparison was made between the currently simulated structures of the BChE-cocaine binding with those simulated previously by using a homology model of BChE and it was noted that two major differences between the two sets of structures. By using the X-ray crystal structure in accordance

^c<D1>_{non} and <D1> represent the average distances between the S198 O^y atom and the ΔD_{appr}^{2} and ΔD_{appr}^{2} represent the average distances between the S198 O atom and the carbonyl action of the cocaine benzoyl ester in the simulated non-prereactive and prereactive BChE-cocaine complexes, respectively. ΔD_{2} , ΔD_{4} refer to the average values of the simulated distances from the carbonyl oxygen of the cocaine benzoyl ester to the NH hydrogen atoms of G116, G117, and A199 residues, respectively. $\langle \Phi \rangle$ is the average value of the dihedral angle formed by the S198 O' atom and the plane of the carboxylate group of the cocaine benzoyl estrem Res. See Scheme 2. "The root-mean-square deviation (RMSD) of the coordinates of backbone atoms in the simulated simultance from those in the X-ray crystal structure of BChE "nonzer" and "mer"

simulated structure from those in the X-ray crystal structure of BChE. "nonpre" and "pre' refer to the non-prereactive and prereactive BChE-cocaine complexes, respectively.

with Nicolet et al, the acyl loop is positioned on the top of the cocaine benzoyl ester moiety of the cocaine, whereas the acyl loop is far from the cocaine benzoyl ester moiety in the structure simulated starting from the homology model of Zhan et al. The RMSD of the coordinates of backbone atoms in the previously simulated prereactive BChE-(-)-cocaine complex from those in the X-ray crystal structure of BChE is ~2.0 Å for the entire protein and ~3.0 Å for the acyl loop. The RMSD value became ~2.4 Å for the entire protein and ~3.3 Å for the acyl loop, when the X-ray crystal structure was replaced by the MD-simulated prereactive BChE-(-)-cocaine complex starting from the X-ray crystal structure. Despite these structural differences, the benzoyl ester group of the ligand is still close to the key residues (S197, G116, and G117) in the BChE binding site. Some significant differences are associated with the distances between the S198 O^{γ} atom and the carbonyl carbon of the cocaine benzoyl ester in nonprereactive complexes. The average values of this distance in $_{20}$ the non-prereactive complexes were ~9.5 and ~8.5 Å for (-)and (+)-cocaine, respectively, when a homology model was used. Using the X-ray crystal structure to conduct the analysis, corresponding average values became ~5.6 and ~5.2 Å, respectively. Therefore, both (-)- and (+)-cocaine became ²⁵ closer to the binding site when the homology model was replaced by the X-ray crystal structure. However, no significant changes of the binding in the prereactive complexes were observed when the used homology model was replaced by the X-ray crystal structure. The average values of the simulated distance between the S198 O^{γ} atom and the carbonyl carbon of the cocaine benzoyl ester in the prereactive complexes are always close to ~3.5 Å for both (-)- and (+)-cocaine no matter whether the X-ray crystal structure or homology model of 35 BChE was used as the starting structure. The similar computational results obtained from the use of the X-ray crystal structure and homology model of BChE provides evidence that the fundamental structural and mechanistic insights obtained from the previous computational studies of Zhan et al are reliable, despite the previous simulations were performed by using the homology model when the X-ray crystal structure was not available.

Further, the simulated structures of the non-prereactive 45 BChE-cocaine complexes were superimposed with the corresponding prereactive complexes. As shown in FIG. **3**, the (–)-cocaine rotation in the BChE active site from the nonprereactive complex to the prereactive complex is hindered by some residues as the positions of Y332, A328, and F329 residues in the non-prereactive complex are significantly different from the corresponding positions in the prereactive complex, whereas none of these residues hinders the (+)cocaine rotation in the BChE active site from the non-prereactive complex to the prereactive complex because these residues stay in nearly the same positions in the two BChE-(+)cocaine complexes.

(-)-Cocaine Binding with BChE Mutants.

Now that the (-)-cocaine rotation from the non-prereactive ⁶⁰ complex to the prereactive complex has been known to be the rate-determining step of the BChE-catalyzed hydrolysis of (-)-cocaine as shown by Zhan et al, useful BChE mutants should be designed to specifically accelerate the change from the non-prereactive BChE-(-)-cocaine complex to the prereactive complex. The question is whether MD simulation can

be performed to help design BChE mutants that have higher catalytic activity for (–)-cocaine hydrolysis.

In the simulated non-prereactive complex, the average distance between the carbonyl carbon of cocaine benzoyl ester and S198 O^{γ} is 7.6 Å for A328W/Y332A BChE and 7.1 Å for A328W/Y332G BChE, as seen in Table 2 above. In the simulated prereactive complex, the average values of this important internuclear distance become 3.87 and 3.96 Å for A328W/Y332A and A328W/Y332G BChE's, respectively. Compared to the simulated wild-type BChE-(-)-cocaine prereactive complex, the average distances between the carbonyl carbon of the cocaine benzoyl ester and S198 O^{γ} in the prereactive complex of (-)-cocaine with A328W/Y332A and A328W/Y332G BChE's are all slightly longer, whereas the average distances between the carbonyl oxygen of the cocaine benzoyl ester and the NH of G116, G117, and A199 residues are all shorter. This provides evidence that (-)-cocaine more strongly bind with A328W/Y332A and A328W/ Y332G BChE's in the prereactive complexes. More importantly, the (-)-cocaine rotation in the active site of A328W/ Y332A and A328W/Y332G BChE's from the nonprereactive complex to the prereactive complex did not cause considerable changes of the positions of A332 (or G332), W328, and F329 residues as seen in FIG. 4, compared to the (-)-cocaine rotation in the active site of wild-type BChE. These results provide evidence that A328W/Y332A and A328W/Y332G BChE's should be associated with lower energy barriers than the wild-type for the (-)-cocaine rotation from the non-prereactive complex to the prereactive complex. Further, (-)-cocaine binding with A328W/Y332G BChE is very similar to the binding with A328W/Y332A BChE, but the position change of F329 residue caused by the (-)-cocaine rotation was significant only in A328W/Y332A BChE, thus suggesting that the energy barrier for the (-)-cocaine rotation in A328W/Y332G BChE should be slightly lower than that in A328W/Y332A BChE.

Concerning (-)-cocaine binding with A328W/Y332A/ Y419S BChE, Y419 stays deep inside the protein and does not directly contact with the cocaine molecule. The Y419S mutation was tested because it was initially expected that this mutation would further increase the free space of the active site pocket so that the (-)-cocaine rotation could be easier. However, as seen in Table 2 above, the average distance between the carbonyl carbon of cocaine benzoyl ester and S198 O^Y atom in the simulated prereactive complex was as long as 5.84 Å. The average distances between the carbonyl oxygen of the cocaine benzoyl ester and the NH hydrolysis atoms of G116, G117, and A199 residues are between 4.56 and 6.97 Å; no any hydrogen bond between them. In addition to the internuclear distances, another interesting geometric parameter is the dihedral angle, 0, formed by S198 O^{γ} and the plane of the carboxylate group of the cocaine benzoyl ester. As seen in Table 2, the Θ values in the prereactive complexes of cocaine with wild-type BChE and all of the BChE mutants other than A328W/Y332A/Y419S BChE all slightly deviate from the ideal value of 90° for the nucleophilic attack of S198 O^{γ} at the carbonyl carbon of cocaine. The 0 value in the prereactive complex of (-)-cocaine with A328W/Y332A/ Y419S BChE is 164°, which is considerably different from the ideal value of 900.

Catalytic Activity.

The aforementioned discussion provides evidence that the energy barriers for the (-)-cocaine rotation in A328W/ Y332A and A328W/Y332G BChE's from the non-prereactive complex to the prereactive complex, the rate-determining step for the BChE-catalyzed hydrolysis of (-)-cocaine, should be lower than that in the wild-type BChE. Thus, the MD simulations predict that both A328W/Y332A and A328W/Y332G BChE's should have a higher catalytic activ- 10 ity than the wild-type BChE for (-)-cocaine hydrolysis. Further, the MD simulations also suggest that the energy barrier for the (-)-cocaine rotation in A328W/Y332G BChE should be slightly lower than that in A328W/Y332A BChE and, therefore, the catalytic activity of A328W/Y332G BChE for the (-)-cocaine hydrolysis should be slightly higher than the activity of A328W/Y332A BChE. In addition, the MD simulations predict that A328W/Y332A/Y419S BChE should have no catalytic activity, or have a considerably lower cata- 20 lytic activity than the wild-type, for (-)-cocaine hydrolysis because (-)-cocaine binds with the mutant BChE in a way that is not suitable for the catalysis.

The catalytic efficiency (k_{cat}/K_M) of A328W/Y332A BChE for (–)-cocaine hydrolysis was reported to be $8.56 \times 10^{6-25}$ M min⁻¹, which is 9.39 times of the k_{cat}/K_M value (9.11×10⁵ M min⁻¹) of the wild-type BChE. To examine these theoretical predictions of the relative activity for A328W/Y332G and A328W/Y332A/Y419S BChE's, a A328W/Y332A, A328W/ Y332G, and A328W/Y332A/Y419S BChE was produced through site-directed mutagenesis. To minimize the possible systematic experimental errors of the kinetic data, kinetic studies were performed with all of three mutants under the same condition and compared the catalytic efficiency of the 35 A328W/Y332G and A328W/Y332A/Y419S to that of the A328W/Y332A for (-)-cocaine hydrolysis at benzoyl ester group. Based on the kinetic analysis of the measured timedependent radiometric data, the ratio of the k_{cat}/K_M value of A328W/Y332G BChE to the k_{cat}/K_M value of A328W/ Y332A BChE for the (-)-cocaine hydrolysis was determined to be ~2.08, or A328W/Y332G BChE has a k_{cat}/K_M value of ~ 1.78×10^7 M min⁻¹ for the (-)-cocaine hydrolysis. The radiometric data show no significant catalytic activity for A328W/ 45 Y332A/Y419S BChE. These experimental data are consistent with the theoretical predictions based on the MD simulations.

Conclusion.

Molecular modeling, molecular docking, and molecular dynamics (MD) simulations were performed to study cocaine binding with human butyrylcholinesterase (BChE) and its mutants, based on a recently reported X-ray crystal structure of human BChE. The MD simulations of cocaine binding 55 with wild-type BChE led to average BChE-cocaine binding structures similar to those obtained recently from the MD simulations based on a homology model of BChE, despite the significant difference found at the acyl binding pocket. This confirms the fundamental structural and mechanistic insights obtained from the prior computational studies of Zhan et al based on a homology model of BChE, e.g., the rate-determining step for BChE-catalyzed hydrolysis of biologically active (-)-cocaine is the (-)-cocaine rotation in the BChE active site from the non-prereactive BChE-(-)-cocaine complex to the prereactive complex.

20

The MD simulations further reveal that the (-)-cocaine rotation in the active site of wild-type BChE from the nonprereactive complex to the prereactive complex is hindered by some residues such that the positions of Y332, A328, and F329 residues in the non-prereactive complex are significantly different from those in the prereactive complex. Compared to (-)-cocaine binding with wild-type BChE, (-)-cocaine more strongly bind with A328W/Y332A and A328W/ Y332G BChE's in the prereactive complexes. More importantly, the (-)-cocaine rotation in the active site of A328W/Y332A and A328W/Y332G BChE's from the nonprereactive complex to the prereactive complex did not cause considerable changes of the positions of A332 or G332, W328, and F329 residues. These results provide evidence that A328W/Y332A and A328W/Y332G BChE's are associated with lower energy barriers than wild-type BChE for the (-)cocaine rotation from the non-prereactive complex to the prereactive complex. Further, (-)-cocaine binding with A328W/Y332G BChE is very similar to the binding with A328W/Y332A BChE, but the position change of F329 residue caused by the (-)-cocaine rotation was significant only in A328W/Y332A BChE, thus suggesting that the energy barrier for (-)-cocaine rotation in A328W/Y332G BChE should be slightly lower than that in A328W/Y332A BChE. It has also been demonstrated that (-)-cocaine binds with A328W/ Y332A/Y419S BChE in a way that is not suitable for the catalysis.

Based on the computational results, both A328W/Y332A and A328W/Y332G BChE's have catalytic activity for (–)cocaine hydrolysis higher than that of wild-type BChE and the activity of A328W/Y332G BChE should be slightly higher than that of A328W/Y332A BChE, whereas A328W/ Y332A/Y419S BChE is expected to lose the catalytic activity. The computational predictions are completely consistent with the experimental kinetic data, providing evidence that the used computational protocol, including molecular modeling, molecular docking, and MD simulations, is reliable in prediction of the catalytic activity of BChE mutants for (–)cocaine hydrolysis.

Experiment 2

MD Simulations and Quantum Mechanical/Molecular Mechanical (QM/MM) Calculations Relating to A199S/A328W/Y332G Mutant (Mutant 1) (SEQ ID NO: 1)

Generally speaking, for rational design of a mutant enzyme with a higher catalytic activity for a given substrate, one needs to design a mutation that can accelerate the rate-determining step of the entire catalytic reaction process while the other steps are not slowed down by the mutation. Reported computational modeling and experimental data indicated that the formation of the prereactive BChE-(–)-cocaine complex (ES) is the rate-determining step of (–)-cocaine hydrolysis catalyzed by wild-type BChE as disclosed by Sun et al, Zhan et al and Hamza, A.; Cho, H.; Tai, H.-H.; Zhan, C.-G. J. Phys. Chem. B 2005, 109, 4776, herein incorporated by reference, whereas the rate-determining step of the corresponding (+)cocaine hydrolysis is the chemical reaction process consisting of four individual reaction steps disclosed by Zhan et al and shown in Scheme 3 and Scheme 4 below. $\underline{Scheme \ 3. \ Schematic \ representation \ of \ BChE-catalyzed \ hydrolysis \ of \ (-)-cocaine.}$

Scheme 3. Schematic representation of BChE-catalyzed hydrolysis of (-)-cocaine. Only QM-treated high-layer part of the reaction system in the QM/MM calculations are drawn. Notation [H] refers to a non-hydrogen atom in the MMtreated low-layer part of the protein and the cut covalent bond 65 with this atom is saturated by a hydrogen atom. The dash lines in the transition state structures represent the transition bonds.

This mechanistic understanding is consistent with the experimental observation of Sun et al, that the catalytic rate constant of wild-type BChE against (+)-cocaine is pH-dependent, whereas that of the same enzyme against (-)-cocaine is independent of the pH. The pH-dependence of the rate constant for (+)-cocaine hydrolysis is clearly associated with the protonation of H438 residue in the catalytic triad (S198,

H438, and E325). For the first and third steps of the reaction process, when H438 is protonated, the catalytic triad cannot function and, therefore, the enzyme becomes inactive. The lower the pH of the reaction solution is, the higher the concentration of the protonated H438 is, and the lower the concentration of the active enzyme is. Hence, the rate constant was found to decrease with decreasing the pH of the reaction solution for the enzymatic hydrolysis of (+)-cocaine.

Based on the above mechanistic understanding, the efforts 10for rational design of the BChE mutants reported in literature have been focused on how to improve the ES formation process. Indeed, several BChE mutants, including A328W, A328W/Y332A, A328W/Y332G, and F227A/S287G/ A328W/Y332M, have been found to have a significantly higher catalytic efficiency (k_{cat}/K_M) against (-)-cocaine; these mutants of BChE have an approximate 9 to 34-fold improved catalytic efficiency against (-)-cocaine. Experimental observation also indicated that the catalytic rate con- $_{20}$ stant of A328W/Y332A BChE is pH-dependent for both (-)and (+)-cocaine. The pH-dependence reveals that for both (-)- and (+)-cocaine, the rate-determining step of the hydrolysis catalyzed by A328W/Y332A BChE should be either the first or the third step of the reaction process. Further, 25if the third step were rate determining, then the catalytic efficiency of the A328W/Y332A mutant against (-)-cocaine should be as high as that of the same mutant against (+)cocaine because the (-)- and (+)-cocaine hydrolyses share the same third and fourth steps (see Scheme 3). However, it has also been observed that the A328W/Y332A mutant only has a ~9-fold improved catalytic efficiency against (-)-cocaine, whereas the A328W/Y332A mutation does not change the high catalytic activity against (+)-cocaine. This analysis of 35 the experimental and computational data available in literature clearly shows that the rate-determining step of (-)-cocaine hydrolysis catalyzed by the A328W/Y332A mutant should be the first step of the chemical reaction process. Further, recently reported computational modeling also suggests that the formation of the prereactive BChE-(-)-cocaine complex (ES) is hindered mainly by the bulky side chain of Y332 residue in wild-type BChE, but the hindering can be removed by the Y332A or Y332G mutation. Therefore, start- 45 ing from the A328W/Y332A or A328W/Y332G mutant, the truly rational design of further mutation(s) to improve the catalytic efficiency of BChE against (-)-cocaine should aim to decrease the energy barrier for the first reaction step without significantly affecting the ES formation and other chemical reaction steps.

The following rational design of a high-activity mutant of BChE against (–)-cocaine is based on detailed computational modeling of the transition state for the rate-determining step 55 (i.e., the first step of the chemical reaction process). Molecular dynamics (MD) simulations and hybrid quantum mechanical/molecular mechanical (QM/MM) calculations were performed to model the protein environmental effects on the stabilization of the transition-state structure for BChE-catalyzed hydrolysis of (–)-cocaine. The simulated and calculated results indicate that the transition-state structure can be stabilized better by the protein environment in A199S/A328W/Y332G mutant of BChE than that in the wild-type. 65 The computational modeling led to a prediction of the higher catalytic efficiency for the A199S/A328W/Y332G mutant

against (-)-cocaine. The prediction has been confirmed by wet experimental tests showing that the A199S/A328W/ Y332G mutant has a significantly improved catalytic efficiency against (-)-cocaine. All of the obtained results clearly demonstrate that directly modeling the transition-state structure provides a reliable computational approach to the rational design of a high-activity mutant of BChE against (-)cocaine.

MD Simulations.

It should be stressed that a critical issue exists with regard to any MD simulation on a transition state. In principle, MD simulation using a classical force field (molecular mechanics) can only simulate a stable structure corresponding to a local minimum on the potential energy surface, whereas a transition state during a reaction process is always associated with a first-order saddle point on the potential energy surface. Hence, MD simulation using a classical force field cannot directly simulate a transition state without any restraint on the geometry of the transition state. Nevertheless, if one can technically remove the freedom of imaginary vibration in the transition state structure, then the number of vibrational freedoms (normal vibration modes) for a nonlinear molecule will decrease from 3N-6. The transition state structure is associated with a local minimum on the potential energy surface within a subspace of the reduced vibrational freedoms, although it is associated with a first-order saddle point on the potential energy surface with all of the 3N-6 vibrational freedoms. Theoretically, the vibrational freedom associated with the imaginary vibrational frequency in the transition state structure can be removed by appropriately freezing the reaction coordinate. The reaction coordinate corresponding to the imaginary vibration of the transition state is generally characterized by a combination of some key geometric parameters. These key geometric parameters are bond lengths of the forming and breaking covalent bonds for BChE-catalyzed hydrolysis of cocaine, as seen in Scheme 3. Thus, one just needs to maintain the bond lengths of the forming and breaking covalent bonds during the MD simulation on a transition state. Technically, one can maintain the bond lengths of the forming and breaking covalent bonds by simply fixing all atoms within the reaction center, by using some constraints on the forming and breaking covalent bonds, or by redefining the forming and breaking covalent bonds. It should be pointed out that the only purpose of performing such type of MD simulation on a transition state is to examine the dynamic change of the protein environment surrounding the reaction center and the interaction between the reaction center and the protein environment. For this study, of interest is the simulated structures, as the total energies calculated in this way are meaningless.

The initial BChE structures used in the MD simulations were prepared based on the previous MD simulation in accordance with Hamza et al on the prereactive ES complex for wild-type BChE with (–)-cocaine in water by using Amber7 program package. The previous MD simulations on the prereactive BChE-(–)-cocaine complex (ES) started from the X-ray crystal structure of Nicolet et al deposited in the Protein Data Bank (pdb code: 1P0P). The present MD simulation on the transition state for the first step (TS1) was performed in such a way that bond lengths of the partially formed and partially broken covalent bonds in the transition state were all constrained to be the same as those obtained from our previous ab initio reaction coordinate calculations on the model reaction system of wild-type BChE in accordance with Zhan et al. The partially formed and partially broken covalent bonds in the transition state will be called "transition" bonds below, for convenience. A sufficiently long MD simulation with the transition bonds constrained should lead to a reasonable protein environment stabilizing the reaction center in the transition-state structure simulated. Further, the simulated TS1 structure for wild-type BChE with (–)-cocaine was used to build the initial structures of TS1 for the examined BChE mutants with (–)-cocaine; only the side chains of mutated residues needed to be changed.

The partial atomic charges for the non-standard residue atoms, including cocaine atoms, in the TS1 structures were calculated by using the RESP protocol implemented in the Antechamber module of the Amber7 package following electrostatic potential (ESP) calculations at ab initio HF/6-31G* 20 level using Gaussian03 program known in the art. The geometries used in the ESP calculations came from those obtained from the previous ab initio reaction coordinate calculations of Zhan et al, but the functional groups representing the oxyanion hole were removed. Thus, residues G116, G117, and ²⁵ A199 were the standard residues as supplied by Amber7 in the MD simulations. The general procedure for carrying out the MD simulations in water is essentially the same as that used in our previously reported other computational studies including Zhan et al, Hamza et al and (a) Zhan, C.-G.; Norberto de Souza, O.; Rittenhouse, R.; Ornstein, R. L. J. Am. Chem. Soc. 1999, 121, 7279, (b) Koca, J.; Zhan, C.-G.; Rittenhouse, R.; Ornstein, R. L. J. Am. Chem. Soc. 2001, 123, 817, (c) Koca, J.; Zhan, C.-G.; Rittenhouse, R. C.; Ornstein, 35 R. L. JComput. Chem. 2003, 24, 368, (d) Hamza, A.; Cho, H.; Tai, H.-H.; Zhan, C.-G. Bioorg. Med. Chem. 2005, 13, 4544, herein all incorporated by reference. Each aforementioned starting TS1 structure was neutralized by adding chloride counterions and was solvated in a rectangular box of TIP3P water molecules with a minimum solute-wall distance of 10 Å as described by Jorgensen, W. L.; Chandrasekhar, J.; Madura, J.; Klein, M. L. J. Chem. Phys. 1983, 79, 926, herein incorporated by reference. The total numbers of atoms in the sol- 45 vated protein structures for the MD simulations are nearly 70,000, although the total number of atoms of BChE and (-)-cocaine is only 8417 (for the wild-type BChE). All of the MD simulations were performed by using the Sander module of Amber7 package. The solvated systems were carefully equilibrated and fully energy minimized. These systems were gradually heated from T=10 K to T=298.15 K in 30 ps before running the MD simulation at T=298.15 K for 1 ns or longer, making sure that a stable MD trajectory was obtained for each 55 of the simulated TS1 structures. The time step used for the MD simulations was 2 fs. Periodic boundary conditions in the NPT ensemble at T=298.15 K with Berendsen temperature coupling and P=1 atm with isotropic molecule-based scaling were applied. The SHAKE algorithm was used to fix all covalent bonds containing hydrogen atoms. The non-bonded pair list was updated every 10 steps. The particle mesh Ewald (PME) method in accordance with Essmann, U.; Perera, L.; Berkowitz, M. L.; Darden, T. A.; Lee, H., Pedersen, L. G. J. 65 Chem. Phys. 1995, 98, 10089, herein incorporated by reference, was used to treat long-range electrostatic interactions. A

residue-based cutoff of 10 Å was utilized to the non-covalent interactions. The coordinates of the simulated systems were collected every 1 ps during the production MD stages.

QM/MM Calculations.

For each TS1 structure examined, after the MD simulation was completed and a stable MD trajectory was obtained, all of the collected snapshots of the simulated structure, excluding those before the trajectory was stabilized, were averaged and further energy-minimized. The energy-minimized average structure (with the transition bonds constrained) was used as an initial geometry to carry out a further geometry optimization by using the ONIOM approach of Dapprich, S.; Komaromi, I.; Byun, K. S.; Morokuma, K.; Frisch, M. J. J. Mol. Struct. (Theochem) 1999, 461, 1-21, herein incorporated by reference, implemented in the Gaussian03 program of Frisch, M. J. et al Gaussian 03, Revision A. 1, Gaussian, Inc., Pittsburgh, Pa., 2003, herein incorporated by reference. Two layers were defined in the present ONIOM calculation: the high layer, as depicted in Scheme 3 above, was calculated quantum mechanically at the ab initio HF/3-21G level, whereas the low layer was calculated molecular mechanically by using the Amber force field as used in our MD simulation and energy minimization with the Amber7 program. The ONIOM calculations at the HF/3-21G: Amber level in this study are a type of QM/MM calculations of Vreven, T.; Morokuma, K. J. Chem. Phys. 2000, 113, 2969-2975 and Frisch, M.; Vreven, T.; Schlegel, H. B.; Morokuma, K. J. Comput. Chem. 2003, 24, 760-769, herein both incorporated by reference. Previous reaction coordinate calculations with an active site model of wild-type BChE demonstrate that the HF/3-21G level is adequate for the geometry optimization of this enzymatic reaction system shown by Zhan et al, although the final energy calculations for calculating the energy barriers must be carried out at a higher level. As depicted in Scheme 3, for all of these QM/MM calculations, the same part of the enzyme was included in the QM-treated high layer. So, the QM-treated high layer included (-)-cocaine, key functional groups from the catalytic triad (S198, H438, and E325), and the three residues, i.e., G116, G117, and A199 (or S199 for a particular mutant, see Scheme 4), of the possible oxyanion hole, whereas the entire enzyme structure of BChE was included in the MM-treated low layer. A language computer program was developed to automatically generate the input files for the ONIOM calculations following the MD simulations and subsequent energy minimizations in order to make sure that the atom types used for all low-layer atoms are the same as what were used in the Amber7. During the TS1 geometry optimization using the two-layer ONIOM, the length of a key transition C-O bond was fixed which dominates the reaction coordinate; all of the other transition bond lengths were relaxed. The C and O atoms in the key transition C--O bond are the carbonyl carbon of (-)-cocaine benzoyl ester and the O^{γ} atom of S198, respectively, according to the previous reaction coordinate calculations with an active site model of wild-type BChE of Zhan et al.

Most of the MD simulations and QM/MM calculations were performed in parallel on an HP supercomputer (Superdome, with 256 shared-memory processors) at the Center for Computational Sciences, University of Kentucky. Some of the computations were carried out on a 34-processors IBM x335 Linux cluster and SGI Fuel workstations.

Scheme 4. Schematic representation of the first reaction step for (–)-cocaine hydrolysis catalyzed by a BChE mutant with an A199S mutation.

Experimental Materials.

Cloned pfu DNA polymerase and Dpn I endonuclease were obtained from Stratagene (La Jolla, Calif.). ³H-(-)-cocaine (50 Ci/mmol) was purchased from PerkinElmer Life Sciences (Boston, Mass.). The expression plasmid pRc/CMV was a gift from Dr. O. Lockridge, University of Nebraska Medical Center (Omaha, Nebr.). All oligonucleotides were synthesized by the Integrated DNA Technologies, Inc. The QIAprep Spin Plasmid Miniprep Kit and Qiagen plasmid purification kit and QIAquick PCR purification kit were 35 obtained from Qiagen (Santa Clarita, Calif.). Human embryonic kidney 293T/17 cells were from ATCC (Manassas, Va.). Dulbecco's modified Eagle's medium (DMEM) was purchased from Fisher Scientific (Fairlawn, N.J.). Oligonucleotide primers were synthesized by the Integrated DNA Tech- 40 nologies and Analysis Facility of the University of Kentucky. 3,3',5,5'-Tetramethylbenzidine (TMB) was obtained from Sigma (Saint Louis, Mo.). Anti-butyrylcholinesterase (mouse monoclonal antibody, Product #HAH002-01) was purchased from AntibodyShop (Gentofte, Denmark) and Goat anti- 45 mouse IgG HRP conjugate from Zymed (San Francisco, Calif.).

Site-Directed Mutagenesis, Protein Expression, and BChE Activity Assay.

Site-directed mutagenesis of human BChE cDNA was per- 50 formed by using the QuikChange method of Braman et al. Mutations were generated from wild-type human BChE in a pRc/CMV expression plasmid in accordance with (a) Masson, P.; Legrand, P.; Bartels, C. F.; Froment, M.-T.; Schopfer, L. M.; Lockridge, O. Biochemistry 1997, 36, 2266, (b) Mas- 55 son, P.; Xie, W., Froment, M-T.; Levitsky, V.; Fortier, P.-L.; Albaret, C.; Lockridge, O. Biochim. Biophys. Acta 1999, 1433, 281, (c) Xie, W.; Altamirano, C. V.; Bartels, C. F.; Speirs, R. J.; Cashman, J. R.; Lockridge, O. Mol. Pharmacol. 1999, 55, 83, (d) Duysen, E. G.; Bartels, C. F.; Lockridge, O. 60 J. Pharmacol. Exp. Ther. 2002, 302, 751, (e) Nachon, F.; Nicolet, Y.; Viguie, N.; Masson, P.; Fontecilla-Camps, J. C. Lockridge, O. Eur. J. Biochem. 2002, 269, 630, herein all incorporated by reference. Using plasmid DNA as template and primers with specific base-pair alterations, mutations 65 were made by polymerase chain reaction with Pfu DNA polymerase, for replication fidelity. The PCR product was treated

with Dpn I endonuclease to digest the parental DNA template. Modified plasmid DNA was transformed into Escherichia coli, amplified, and purified. The DNA sequences of the mutants were confirmed by DNA sequencing. BChE mutants were expressed in human embryonic kidney cell line 293T/ 17. Cells were grown to 80-90% confluence in 6-well dishes and then transfected by Lipofectamine 2000 complexes of 4 µg plasmid DNA per each well. Cells were incubated at 37° C. in a CO₂ incubator for 24 hours and cells were moved to 60-mm culture vessel and cultured for four more days. The culture medium [10% fetal bovine serum in Dulbecco's modified Eagle's medium (DMEM)] was harvested for a BChE activity assay. To measure (-)-cocaine and benzoic acid, the product of (-)-cocaine hydrolysis catalyzed by BChE, sensitive radiometric assays were used based on toluene extraction of $[^{3}H]$ -(-)-cocaine labeled on its benzene ring in accordance with Sun et al. In brief, to initiate the enzymatic reaction, 100 nCi of [³H]-(-)-cocaine was mixed with 100 µl of culture medium. The enzymatic reactions proceeded at room temperature (25° C.) for varying time. The reactions were stopped by adding 300 µl of 0.02 M HCl, which neutralized the liberated benzoic acid while ensuring a positive charge on the residual (-)-cocaine. [³H]benzoic acid was extracted by 1 ml of toluene and measured by scintillation counting. Finally, the measured time-dependent radiometric data were fitted to the kinetic equation so that the catalytic efficiency (k_{cat}/K_{M}) was determined along with the use of an enzyme-linked immunosorbent assay (ELISA) described below.

Enzyme-Linked Immunosorbent Assay (ELISA).

The ELISA buffers used in the present study are the same as those described in the literature such as (a) Brock, A.; Mortensen, V.; Loft, A. G. R.; Nergaard-Pedersen, B. *J. Clin. Chem. Clin. Biochem.* 1990, 28, 221-224, (b) Khattab, A. D.; Walker, C. H.; Johnston, G.; Siddiqui, M. K. Saphier, P. W. *Environmental Toxicology and Chemistry* 1994, 13, 1661-1667, herein both incorporated by reference. The coating buffer was 0.1 M sodium carbonate/bicarbonate buffer, pH 9.5. The diluent buffer (EIA buffer) was potassium phosphate monobasic/potassium phosphate monohydrate buffer, pH 7.5, containing 0.9% sodium chloride and 0.1% bovine serum albumin. The washing buffer (PBS-T) was 0.01 M potassium phosphate monobasic/potassium phosphate monohydrate buffer, pH 7.5, containing 0.05% (v/v) Tween-20. All the assays were performed in triplicate. Each well of an ELISA microtiter plate was filled with 100 µl of the mixture buffer consisting of 20 µl culture medium and 80 µl coating buffer. The plate was covered and incubated overnight at 4° C. to allow the antigen to bind to the plate. The solutions were then removed and the wells were washed four times with PBS-T. 5 The washed wells were filled with 200 µl diluent buffer and kept shaking for 1.5 h at room temperature (25° C.). After washing with PBS-T for four times, the wells were filled with 100 µl antibody (1:8000) and were incubated for 1.5 h, followed by washing for four times. Then, the wells were filled 10 with 100 µl goat anti-mouse IgG HRP conjugate complex diluted to a final 1:3000 dilution, and were incubated at room temperature for 1.5 h, followed by washing for four times. The enzyme reactions were started by addition of 100 µl substrate (TMB) solution. The reactions were stopped after 15 15 min by the addition of 100 µl of 2 M sulfuric acid, and the absorbance was read at 460 nm using a Bio-Rad ELISA plate reader.

Hydrogen Bonding Revealed by the MD Simulations.

In accordance with one aspect of the present invention, 20 namely the generation of high-activity mutants of BChE against (-)-cocaine, the present invention includes predicting some possible mutations that can lower the energy of the transition state for the first chemical reaction step (TS1) and, therefore, lower the energy barrier for this critical reaction 25 step. Apparently, a mutant associated with the stronger hydrogen bonding between the carbonyl oxygen of (-)-cocaine benzoyl ester and the oxyanion hole of the BChE mutant in the TS1 structure may potentially have a more stable TS1 structure and, therefore, a higher catalytic activity for (-)- 30 cocaine hydrolysis. Hence, the hydrogen bonding with the oxyanion hole in the TS1 structure is a crucial factor affecting the transition state stabilization and the catalytic activity. The possible effects of some mutations on the hydrogen bonding were examined by performing MD simulations and QM/MM 35 calculations on the TS1 structures for (–)-cocaine hydrolysis catalyzed by the wild-type and various mutants BChE's.

The MD simulation in water was performed for 1 ns or longer to make sure a stable MD trajectory was obtained for each simulated TS1 structure with the wild-type or mutant 40 BChE. The MD trajectories actually became stable quickly, so were the H . . . O distances involved in the potential hydrogen bonds between the carbonyl oxygen of (-)-cocaine and the oxyanion hole of BChE.

Depicted in FIG. 5 are plots of four important H . . . O 45 distances in the MD-simulated TS1 structure versus the simulation time for (-)-cocaine hydrolysis catalyzed by A328W/ Y332A or A199S/A328W/Y332G BChE, along with the root-mean-square deviation (RMSD) of the simulated positions of backbone atoms from those in the corresponding 50 initial structure. Traces D1, D2, and D3 refer to the distances between the carbonyl oxygen of (-)-cocaine and the NH hydrogen of G116, G117, and S199, respectively. Trace D4 is the internuclear distance between the carbonyl oxygen of (-)-cocaine and the hydroxyl hydrogen of the S199 side chain 55 which exists only in A199S/A328W/Y332G BChE. RMSD represents the root-mean-square deviation (in A) of the simulated positions of the protein backbone atoms from those in the initial structure. The H . . . O distances in the simulated TS1 structures corresponding to the wild-type BChE and the 60 two mutants are summarized in Table 3. The H . . . O distances between the carbonyl oxygen of (-)-cocaine and the peptidic NH hydrogen atoms of G116, G117, and A199 (or S199) of BChE are denoted by D1, D2, and D3, respectively, in Table 2 and FIG. 1. D4 in Table 3 and FIG. 5 refers to the H . . . O distance between the carbonyl oxygen of (-)-cocaine and the hydroxyl hydrogen of S199 side chain in the simulated TS1

structure corresponding to the A199S/A328W/Y332G mutant, mutant (1) (SEQ ID NO: 2).

Table 3. Summary of the MD-simulated and QM/MMoptimized key distances (in A) and the calculated total hydrogen-bonding energies (HBE, in kcal/mol) between the oxyanion hole and the carbonyl oxygen of (-)-cocaine benzoyl ester in the first transition state (TS1).

Transition				Total			
State		Method	D1	D2	D3	D4	HBE^b
TS1 for (-)-cocaine hydrolysis catalyzed by wild- type BChE TS1 for (-)-cocaine hydrolysis	MD MD	Average Maximum Minimum Fluctuation QM/MM Average Maximum Minimum Eluctuation	4.59 5.73 3.35 0.35 4.10 3.62 4.35 2.92	2.91 4.14 1.97 0.35 2.21 2.35 3.37 1.78 0.27	1.92 2.35 1.61 0.12 2.05 1.95 3.02 1.61		-5.5 (-4.6) -4.2 -6.2 (-4.9)
by A328W/ Y332A mutant TS1 for (-)-cocaine hydrolysis catalyzed by A199S/ A328W/	MD	Average Maximum Minimum Fluctuation QM/MM	5.30 6.08 4.57 0.22 4.83	2.21 3.06 1.71 0.20 2.09	1.94 2.47 1.66 0.13 1.91	-3.3 2.15 3.27 1.56 0.29 2.59	-9.7 (-7.4) -7.46

^aD1, D2, and D3 represent the internuclear distances between the carbonyl oxygen of cocaine benzoyl ester and the NH hydrogen of residues#116 (i.e., G116), #117 (i.e., G117), and #119 (i.e., A199 or S199) of BChE, respectively. D4 is the internuclear distance between the carbonyl oxygen of cocaine benzoyl ester and the hydroxyl hydrogen of S199 side chain in the A199S/A328W/Y332G mutant. The total HBE value under MD is the arge of the HBE values calculated by using the instantaneous distances in all of the snapshots. The value in the parenthesis is the total HBE value calculated by using the MD-simulated average distances. The total HBE value under QM/MM was evaluated by using the QM/MM-optimized distances.

As seen in Table 3, the simulated H . . . O distance D1 is always too long for the peptidic NH of G116 to form a N-H... O hydrogen bond with the carbonyl oxygen of (-)-cocaine. In the simulated TS1 structure corresponding to wild-type BChE, the carbonyl oxygen of (-)-cocaine formed a firm N—H . . . O hydrogen bond with the peptidic NH hydrogen atom of A199 residue; the simulated H . . . O distance was 1.61 to 2.35 Å, with an average value of 1.92 Å. Meanwhile, the carbonyl oxygen of (-)-cocaine also had a partial N-H . . . O hydrogen bond with the peptidic NH hydrogen atom of G117 residue; the simulated H . . . O distance was 1.97 to 4.14 Å (the average value: 2.91 Å). In the simulated TS1 structure corresponding to the A328W/Y332A mutant, the simulated average H . . . O distances with the peptidic NH hydrogen of G117 and A199 are 2.35 and 1.95 Å, respectively. These distances suggest a slightly weaker N-H . . . O hydrogen bond with A199, but a stronger N—H...O hydrogen bond with G117, in the simulated TS1 structure corresponding to the A328W/Y332A mutant. The overall strength of the hydrogen bonding between the carbonyl oxygen of (-)-cocaine and the oxyanion hole of the enzyme is not expected to change considerably when wildtype BChE is replaced by the A328W/Y332A mutant.

However, the story for the simulated TS1 structure associated with the A199S/A328W/Y332G mutant was remarkably different. As one can see from Scheme 4, FIG. 5, and Table 3, when residue #199 becomes a serine (i.e., S199), the hydroxyl group on the side chain of S199 can also hydrogenbond to the carbonyl oxygen of (-)-cocaine to form an O-H . . . O hydrogen bond, in addition to the two N-H...O hydrogen bonds with the peptidic NH of G117 and S199. The simulated average H . . . O distances with the peptidic NH hydrogen of G117, peptidic NH hydrogen of S199, and hydroxyl hydrogen of S199 are 2.21, 1.94, and 2.15 Å, respectively. Due to the additional O—H . . . O hydrogen bond, the overall strength of the hydrogen bonding with the modified oxyanion hole of A199S/A328W/Y332G 5 BChE should be significantly stronger than that of the wild-type and A328W/Y332A BChE's.

To better represent the overall strength of hydrogen bonding between the carbonyl oxygen of (-)-cocaine and the oxyanion hole in a MD-simulated TS1 structure, the hydrogen 10 bonding energy (HBE) associated with each simulated H... O distance was estimated by using the empirical HBE equation implemented in AutoDock 3.0 program suite in accordance with (a) Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew. R. K.; Olson, A. J. J. Comput. Chem. 1998, 19, 1639-1662, and based on the general HBE equation, HBE(r) $\approx 5 \in r_0^{12}/r^{12}-6 \in r_0^{10}/r^{10}$, in which r is the H . . . O distance in the considered hydrogen bond and r_0 is the minimum value of the H...O distance for which the HBE equation can be used. For the calculation, $r_0=1.52$ Å, 20 because it is the shortest H . . . O distance found in all of our MD simulations. The \in value was determined by using the condition that HBE(r)=-5.0 kcal/mol when r=1.90 Å, herein incorporated by reference. Specifically, for each hydrogen bond with the carbonyl oxygen of (-)-cocaine, a HBE value 25 can be evaluated with each snapshot of the MD-simulated structure. The final HBE of the MD-simulated hydrogen bond is considered to be the average HBE value of all snapshots taken from the stable MD trajectory. The estimated total HBE value for the hydrogen bonds between the carbonyl oxygen of 30 (-)-cocaine and the oxyanion hole in each simulated TS1 structure is given in Table 3.

The HBE for each hydrogen bond was estimated by using the MD-simulated average H . . . O distance. As seen in Table 3, the total hydrogen-bonding energies (i.e., -4.6, -4.9, and 35 -7.4 kcal/mol for the wild-type, A328W/Y332A, and A1998/ A328W/Y332G BChE's, respectively) estimated in this way are systematically higher (i.e., less negative) than the corresponding total hydrogen-bonding energies (i.e., -5.5, -6.2, and -9.7 kcal/mol) estimated in the aforementioned way. 40 However, the two sets of total HBE values are qualitatively consistent in terms of the relative hydrogen-bonding strengths in the three simulated TS1 structures. In particular, the two sets of total HBE values consistently reveal that the overall strength of the hydrogen bonding between the carbo- 45 nyl oxygen of (-)-cocaine and the oxyanion hole in the simulated TS1 structure for A199S/A328W/Y332G BChE is significantly higher than that for the wild-type and A328W/ Y332A BChE's.

Hydrogen Bonding Based on the QM/MM Calculations. The above conclusion obtained from the MD simulations was further examined by carrying out QM/MM calculations. Although this enzymatic reaction system is too large to calculate the QM/MM force constant matrix required in the automated search for a first-order saddle point corresponding 55 to TS1, a partial geometry optimization was performed by fixing the length of the transition C-O bond between the carbonyl carbon of (–)-cocaine and the O^{γ} atom of S198 in the QM/MM calculation. This transition C-O bond length dominates the reaction coordinate, according to the previous 60 first-principle reaction coordinate calculations, in accordance with Zhan et al, with an active model of wild-type BChE. In the partial geometry optimization, the transition C-O bond length was fixed at that in the TS1 geometry optimized previously by performing the first-principle reaction coordinate 65 calculation with an active site model of wild-type BChE. This partially optimized geometry should be close to the precisely

defined TS1 geometry associated with a first-order saddle point on the potential energy surface, particularly for the hydrogen bonding between the carbonyl oxygen of (–)-co-caine and the oxyanion hole of BChE.

The QM/MM results summarized in Table 3 demonstrate two hydrogen bonds in each of the QM/MM-optimized TS1 structures. Specifically, D2=2.21 Å and D3=2.05 Å in the optimized TS1 structure for wild-type BChE; D2=2.05 Å and D3=2.47 Å in the optimized TS1 structure for the A328W/ Y332A mutant; D2=2.09 Å, D3=1.91 Å, and D4=2.59 Å in the optimized TS1 structure for the A199S/A328W/Y332G mutant. Although the QM/MM-optimized individual H . . . O distances and the estimated HBE values are different from the corresponding values for individual hydrogen bonds, the relative total HBE values (i.e., -4.2, -3.3, and -7.46 kcal/mol for the wild-type, A328W/Y332A, and A199S/A328W/Y332G BChE's, respectively) estimated from these optimized distances are qualitatively consistent with the corresponding total HBE values (i.e., -4.6, -4.9, and -7.4 kcal/mol) estimated from the MD-simulated average H . . . O distances.

It should be pointed out that the absolute HBE values estimated in this study are not expected to be accurate, as different computational approaches led different HBE values. Nevertheless, for the purpose of our computational design of a high-activity mutant of BChE, one only needs to know the relative strength of the hydrogen bonding based on the estimated relative total HBE values of different mutants. The three sets of total HBE values (Table 3) estimated from the MD-simulated and QM/MM-optimized H . . . O distances all consistently demonstrate: (1) the overall strength of hydrogen bonding between the carbonyl oxygen of (-)-cocaine and the oxyanion hole in the TS1 structure for (-)-cocaine hydrolysis catalyzed by A328W/Y332A BChE should be close to that in the TS1 structure for (-)-cocaine hydrolysis catalyzed by wild-type BChE; (2) the overall hydrogen bonding between the carbonyl oxygen of (-)-cocaine and the oxyanion hole in the TS1 structure for (-)-cocaine hydrolysis catalyzed by A199S/A328W/Y332G BChE should be significantly stronger than that in the TS1 structure for (-)-cocaine hydrolysis catalyzed by A328W/Y332A BChE.

Catalytic Activity.

The computational results discussed above suggest that the transition state for the first chemical reaction step (TS1) of (-)-cocaine hydrolysis catalyzed by the A199S/A328W/ Y332G mutant should be significantly more stable than that by the A328W/Y332A mutant, due to the significant increase of the overall hydrogen bonding between the carbonyl oxygen of (-)-cocaine and the oxyanion hole of the enzyme in the TS1 structure. The aforementioned analysis of the literature, 50 namely Sun et al and Hamza et al, also indicate that the first chemical reaction step associated with TS1 should be the rate-determining step of (-)-cocaine hydrolysis catalyzed by a BChE mutant including Y332A or Y332G mutation, although the formation of the prereactive enzyme-substrate complex (ES) is the rate-determining step for (-)-cocaine hydrolysis catalyzed by wild-type BChE. This provides evidence of a clear correlation between the TS1 stabilization and the catalytic activity of A328W/Y332A and A1998/A328W/ Y332G BChE's for (-)-cocaine hydrolysis: the more stable the TS1 structure, the lower the energy barrier, and the higher the catalytic activity. Thus, both the MD simulations and QM/MM calculations predict that A199S/A328W/Y332G BChE should have a higher catalytic activity than A328W/ Y332A BChE for (-)-cocaine hydrolysis.

The catalytic efficiency (k_{cat}/K_M) of A328W/Y332A BChE for (–)-cocaine hydrolysis was reported by Sun et al to be ~8.6×10⁶ M min⁻¹, which is ~9.4 times of the k_{cat}/K_M

value (~9.1×10⁵ M min⁻¹) of wild-type BChE. To examine the theoretical prediction of the higher catalytic activity for A199S/A328W/Y332G BChE, A328W/Y332A and A199S/ A328W/Y332G mutants of BChE were produced through site-directed mutagenesis. To minimize the possible system-5 atic experimental errors of the kinetic data, kinetic studies were performed with the two mutants and wild-type BChE under the same condition and compared the catalytic efficiency of A328W/Y332A and A199S/A328W/Y332G 10BChE's to that of the wild-type for (-)-cocaine hydrolysis at benzoyl ester group. Based on the kinetic analysis of the measured time-dependent radiometric data and the ELISA data, the ratio of the k_{cat}/K_M value of A328W/Y332A BChE to the k_{cat}/K_M value of wild-type BChE for (-)-cocaine hydrolysis was determined to be ~8.6. The determined catalytic efficiency ratio of ~8.6 is in good agreement with the ratio of ~9.4 determined by Sun et al. Further, by using the same experimental protocol, the ratio of the k_{car}/K_{M} value of A199S/A328W/Y332G BChE to the k_{cat}/K_M value of 20 A328W/Y332A BChE for (-)-cocaine hydrolysis was determined to be ~7.2. These data indicate that the ratio of the $k_{\it cat}/K_{\it M}$ value of A199S/A328W/Y332G BChE to the $k_{\it cat}/$ K_M value of wild-type BChE for (-)-cocaine hydrolysis should be ~7.2×8.6=~62 or ~7.2×9.4=~68. Thus, A1998/ A328W/Y332G BChE has a ~(65±6)-fold improved catalytic efficiency against (-)-cocaine compared to the wild-type, or A199S/A328W/Y332G BChE has a k_{cat}/K_M value of ~(5.9±0.5)×10⁷ M min⁻¹ for (–)-cocaine hydrolysis.

Very recently reported F227A/S287G/A328W/Y332M 30 BChE (i.e., AME-359, k_{ca}/K_{M} =3.1×10⁷ M min⁻¹) has a ~34fold improved catalytic efficiency for (–)-cocaine hydrolysis. AME-359 has the highest catalytic efficiency against (–)cocaine within all of the BChE mutants reported in literature prior to the present study. The catalytic efficiency for our 35 A199S/A328W/Y332G BChE is about two times of that for AME-359 against (–)-cocaine.

Conclusion.

Molecular dynamics (MD) simulations and hybrid quantum mechanical/molecular mechanical (QM/MM) calcula- 40 tions on the transition state for the first chemical reaction step (TS1) of (-)-cocaine hydrolysis catalyzed by butyrylcholinesterase (BChE) mutants lead to a better understanding of the effects of protein environment on the transition state stabilization. All of the computational results consistently dem- 45 onstrate that the overall hydrogen bonding between the carbonvl oxygen of (-)-cocaine benzovl ester and the oxyanion hole of BChE in the TS1 structure for (-)-cocaine hydrolysis catalyzed by A199S/A328W/Y332G BChE should be significantly stronger than that in the TS1 structure for (-)-cocaine 50 hydrolysis catalyzed by the wild-type and A328W/Y332A BChE's. Thus, both the MD simulations and QM/MM calculations predict that A199S/A328W/Y332G BChE should have a lower energy barrier for the chemical reaction process and, therefore, a higher catalytic efficiency (k_{cat}/K_M) for (-)- 55 cocaine hydrolysis; A328W/Y332A BChE has been known to have a ~9-fold improved catalytic efficiency for (-)-cocaine hydrolysis. The theoretical prediction has been confirmed by wet experimental tests showing a \sim (65±6)-fold improved catalytic efficiency for A199S/A328W/Y332G 60 BChE against (-)-cocaine compared to the wild-type BChE. The k_{cat}/K_M value determined for A199S/A328W/Y332G BChE is about two times of the k_{cat}/K_M value for F227A/ S287G/A328W/Y332M BChE (i.e., AME-359, which has the highest catalytic efficiency within all BChE mutants 65 reported prior to the present study) against (-)-cocaine. The encouraging outcome of this study suggests that the transi-

tion-state modeling is a promising approach for rational design of high-activity mutants of BChE as a therapeutic treatment of cocaine abuse.

Experiment 3

MD Simulation and Generation of Mutant A199S/S287G/A328W/Y332G BChE (Mutant 3) (SEQ ID NO: 14)

The following simulation and mutant generation relate to A199S/S287G/A328W/Y332G (mutant 3) as a rational design of a high-activity mutant of BChE against (-)-cocaine based on detailed computational modeling of the transition state for the rate-determining step (i.e., the first step of the chemical reaction process). Molecular dynamics (MD) simulations were performed to model the protein environmental effects on the stabilization of the transition-state structure for BChE-catalyzed hydrolysis of (-)-cocaine as described above for mutant A199S/A328W/Y332G (mutant 1). The simulated results indicate that the transition-state structure can be stabilized much better by the protein environment in A199S/S287G/A328W/Y332G BChE than that in wild-type BChE and in other BChE mutants examined. The computational modeling led to a prediction of the higher catalytic efficiency for the A199S/S287G/A328W/Y332G mutant against (-)-cocaine. The prediction has been confirmed by wet experimental tests showing that the A199S/S287G/ A328W/Y332G mutant has a remarkably improved catalytic efficiency against (-)-cocaine. All of the obtained results clearly demonstrate that directly modeling the transition-state structure provides a reliable computational approach to the rational design of a high-activity mutant of BChE against (-)-cocaine.

MD Simulations.

As with the A199S/A328W/Y332G mutant, when performing any MD simulation on a transition state, in principle, MD simulation using a classical force field (molecular mechanics) can only simulate a stable structure corresponding to a local minimum on the potential energy surface, whereas a transition state during a reaction process is always associated with a first-order saddle point on the potential energy surface.

The initial BChE structures used in the MD simulations were prepared based on our previous MD simulation as above with the prior mutant and the prereactive BChE-(–)-cocaine complex (ES) started from the X-ray crystal structure deposited in the Protein Data Bank (pdb code: 1P0P).

The general procedure for carrying out the MD simulations in water is essentially the same as that used in the computational studies for mutant A199S/A328W/Y332G (mutant 1). Site-directed mutagenesis of human BChE cDNA was performed as described before.

The MD simulation in water was performed as described above, on this mutant. Depicted in FIG. 6 are plots of four important H... O distances in the MD-simulated TS1 structure versus the simulation time for (-)-cocaine hydrolysis catalyzed by A199S/S287G/A328W/Y332G BChE, along with the root-mean-square deviation (RMSD) of the simulated positions of backbone atoms from those in the corresponding initial structure. Traces D1, D2, and D3 refer to the distances between the carbonyl oxygen of (-)-cocaine and the NH hydrogen of G116, G117, and S199, respectively. Trace D4 is the internuclear distance between the carbonyl oxygen of (-)-cocaine and the hydroxyl hydrogen of the S199 side chain in A199S/S287G/A328W/Y332G BChE (mutant 3). RMSD represents the root-mean-square deviation (in A) of the simulated positions of the protein backbone atoms from those in the initial structure.

4∩

The H . . . O distances in the simulated TS1 structures for wild-type BChE and its three mutants are summarized in Table 4. The H . . . O distances between the carbonyl oxygen of (-)-cocaine and the peptidic NH hydrogen atoms of G116, G117, and A199 (or S199) of BChE are denoted by D1, D2, 5 and D3, respectively, in Table 4 and FIG. 6. D4 in Table 4 and FIG. 6 refers to the H . . . O distance between the carbonyl oxygen of (-)-cocaine and the hydroxyl hydrogen of S199 side chain in the simulated TS1 structure corresponding to the A199S/S287G/A328W/Y332G mutant. 10

Table 4. Summary of the MD-simulated key distances (in A) and the calculated total hydrogen-bonding energies (HBE, in kcal/mol) between the oxyanion hole and the carbonyl oxygen of(-)-cocaine benzoyl ester in the first transition state (TS1).

	Distance ^a												
Transition State		D1	D2	D3	D4	HBE^{b}	20						
TS1 structure for (-)-cocaine	Average	4.59	2.91	1.92		-5.5 (-4.6)	20						
hydrolysis catalyzed	Maximum	5.73	4.14	2.35		· · · ·							
by wild-type	Minimum	3.35	1.97	1.61									
	Fluctuation	0.35	0.35	0.12									
TS1 structure for (-)-cocaine	Average	3.62	2.35	1.95		-6.2 (-4.9)	25						
hydrolysis catalyzed	Maximum	4.35	3.37	3.02									
by	Minimum	2.92	1.78	1.61									
	Fluctuation	0.23	0.27	0.17									
TS1 structure for (-)-cocaine	Average	3.60	2.25	1.97		-6.4 (-5.0)	30						
hydrolysis catalyzed	Maximum	4.24	3.17	2.76		· /	50						
by A328W/Y332G	Minimum	2.89	1.77	1.62									
mutant of BChE	Fluctuation	0.23	0.24	0.17									
TS1 structure for (-)-cocaine	Average	4.39	2.60	2.01	1.76	-14.0 (-12.0)							
hydrolysis catalyzed	Maximum	5.72	4.42	2.68	2.50	· · · · ·							
by A1998/S287G/	Minimum	2.87	1.76	1.62	1.48		35						
Å328W/Y332G	Fluctuation	0.48	0.36	0.17	0.12								

^aD1, D2, and D3 represent the internuclear distances between the carbonyl oxygen of cocaine benzoyl ester and the NH hydrogen of residues #116 (i.e., G116), #117 (i.e., G117), and #119 (i.e., A199 or S199) of BChE, respectively. D4 is the internuclear distance between the carbonyl oxygen of cocaine benzoyl ester and the hydroxyl hydrogen of S199 side chain in the A1995/A328W/Y332G mutant. ^bThe total HBE value under MD is the average of the HBE values calculated by using the instantaneous distances in all of the snapshots. The value in the parenthesis is the total HBE value under OMOM output of the total HBE value under OMOM with the total HBE value under OMOM we are under the Unit of the output of the snapshots. The value in the parenthesis is the total HBE value under OMOM we are under the Unit of the OMOM output of the snapshot.

QM/MM was evaluated by using the QM/MM-optimized distances

42

As seen in Table 4, the simulated H . . . O distance D1 is always too long for the peptidic NH of G116 to form a N-H . . . O hydrogen bond with the carbonyl oxygen of (-)-cocaine in all of the simulated TS1 structures. In the simulated TS1 structure for wild-type BChE, the carbonyl oxygen of (-)-cocaine formed a firm N-H... O hydrogen bond with the peptidic NH hydrogen atom of A199 residue; the simulated H . . . O distance (D2) was 1.61 to 2.35 Å, with an average D2 value of 1.92 Å. Meanwhile, the carbonyl oxygen of (-)-cocaine also had a partial N-H... O hydrogen bond with the peptidic NH hydrogen atom of G117 residue; the simulated H . . . O distance (D3) was 1.97 to 4.14 Å (the average D3 value: 2.91 Å). The average D2 and D3 values became 2.35 and 1.95 Å, respectively, in the simulated TS1 structure for the A328W/Y332A mutant. These distances suggest a slightly weaker N-H . . . O hydrogen bond with A199, but a stronger N—H... O hydrogen bond with G117, in the simulated TS1 structure for the A328W/Y332A mutant that the corresponding N-H... O hydrogen bonds for the wild-type. The average D2 and D3 values (2.25 and 1.97 Å, respectively) in the simulated TS1 structure for the A328W/ Y332G mutant are close to the corresponding distances for the A328W/Y332A mutant. The overall strength of the hydrogen bonding between the carbonyl oxygen of (-)-cocaine and the oxyanion hole of the enzyme is not expected to change considerably when wild-type BChE is replaced by the A328W/Y332A or A328W/Y332G mutant.

However, the story for the simulated TS1 structure for the A199S/S287G/A328W/Y332G mutant was remarkably different. As one can see from Scheme 5, FIG. 6, and Table 4, when residue #199 becomes a serine (i.e., S199), the hydroxyl group on the side chain of S199 can also hydrogenbond to the carbonyl oxygen of (-)-cocaine to form an O-H . . . O hydrogen bond, in addition to the two $N{-\!\!\!-\!\!\!-\!\!\!-\!\!\!H}$. . . O hydrogen bonds with the peptidic NH of G117 and S199. The simulated average H . . . O distances with the peptidic NH hydrogen of G117, peptidic NH hydrogen of S199, and hydroxyl hydrogen of S199 are 2.60, 2.01, and 1.76 Å, respectively. Due to the additional O-H . . . O hydrogen bond, the overall strength of the hydrogen bonding with the modified oxyanion hole of A199S/S287G/A328W/ Y332G BChE should be significantly stronger than that of wild-type, A328W/Y332A, and A328W/Y332G BChE's.

Scheme 5. Schematic representation of the transition-state structure for first reaction step for (-)-cocaine hydrolysis catalyzed by a BChE mutant with an A199S mutation.

To better represent the overall strength of hydrogen bonding between the carbonyl oxygen of (-)-cocaine and the oxyanion hole in a MD-simulated TS1 structure, the hydrogen bonding energy (HBE) associated with each simulated -5 H... O distance was estimated by using the empirical HBE equation implemented in AutoDock 3.0 program suite of (a) Masson, P.; Legrand, P.; Bartels, C. F.; Froment, M.-T.; Schopfer, L. M.; Lockridge, O. Biochemistry 1997, 36, 2266, (b) Masson, P.; Xie, W., Froment, M-T.; Levitsky, V.; Fortier, P.-L.; Albaret, C.; Lockridge, O. Biochim. Biophys. Acta 1999, 1433, 281, (c) Xie, W.; Altamirano, C. V.; Bartels, C. F.; Speirs, R. J.; Cashman, J. R.; Lockridge, O. Mol. Pharmacol. 1999, 55, 83, (d) Duysen, E. G.; Bartels, C. F.; Lockridge, O. J. Pharmacol. Exp. Ther. 2002, 302, 751, (e) Nachon, F.; 15 Nicolet, Y.; Viguie, N.; Masson, P.; Fontecilla-Camps, J. C.; Lockridge, O. Eur. J. Biochem. 2002, 269, 630, herein all incorporated by reference. Specifically, for each hydrogen bond with the carbonyl oxygen of (-)-cocaine, a HBE value can be evaluated with each snapshot of the MD-simulated 20 structure. The final HBE of the MD-simulated hydrogen bond is considered to be the average HBE value of all snapshots taken from the stable MD trajectory. The estimated total HBE value for the hydrogen bonds between the carbonyl oxygen of (-)-cocaine and the oxyanion hole in each simulated TS1 25 structure is also listed in Table 4.

The HBE for each hydrogen bond was estimated by using the MD-simulated average H . . . O distance. As seen in Table 4, the total hydrogen-bonding energies (i.e., -4.6, -4.9, -5.0, and -12.0 kcal/mol for the wild-type, A328W/Y332A, 30 A199S/S287G/A328W/Y332G A328W/Y332G, and BChE's, respectively) estimated in this way are systematically higher (i.e., less negative) than the corresponding total hydrogen-bonding energies (i.e., -5.5, -6.2, -6.4, and -14.0 kcal/mol) estimated in the aforementioned way. However, the 35 two sets of total HBE values are qualitatively consistent with each other in terms of the relative hydrogen-bonding strengths in the three simulated TS1 structures. In particular, the two sets of total HBE values consistently reveal that the overall strength of the hydrogen bonding between the carbo- 40 nyl oxygen of (-)-cocaine and the oxyanion hole in the simulated TS1 structure for A199S/S287G/A328W/Y332G BChE is significantly higher than that for wild-type, A328W/ Y332A, and A328W/Y332G BChE's.

Catalytic Activity.

The computational results discussed above provides evidence that the transition state for the first chemical reaction step (TS1) of (-)-cocaine hydrolysis catalyzed by the A199S/ S287G/A328W/Y332G mutant should be significantly more stable than that by the A328W/Y332A or A328W/Y332G 50 mutant, due to the significant increase of the overall hydrogen bonding between the carbonyl oxygen of (-)-cocaine and the oxyanion hole of the enzyme in the TS1 structure. The aforementioned analysis of the literature of Sun et al and Hamza et al also indicates that the first chemical reaction step associ- 55 ated with TS1 should be the rate-determining step of (-)cocaine hydrolysis catalyzed by a BChE mutant including Y332A or Y332G mutation, although the formation of the prereactive enzyme-substrate complex (ES) is the rate-determining step for (-)-cocaine hydrolysis catalyzed by wild- 60 type BChE. This suggests a clear correlation between the TS1 stabilization and the catalytic activity of A328W/Y332A, A1998/S287G/A328W/Y332G A328W/Y332G, and BChE's for (-)-cocaine hydrolysis: the more stable the TS1 structure, the lower the energy barrier, and the higher the 65 catalytic activity. Thus, the MD simulations predict that A199S/S287G/A328W/Y332G BChE should have a higher

catalytic activity than A328W/Y332A or A328W/Y332G BChE for (-)-cocaine hydrolysis.

The catalytic efficiency (k_{cat}/K_M) of A328W/Y332A BChE for (–)-cocaine hydrolysis was reported to be $\sim 8.6 \times 10^{\circ}$ M min⁻¹, which is ~9.4 times of the k_{cat}/K_M value (~9.1×10⁵ M min⁻¹) of wild-type BChE for (-)-cocaine hydrolysis. The catalytic efficiency of A328W/Y332G BChE was found to be slightly higher than that of A328W/Y332A BChE for (-)cocaine hydrolysis. To examine the theoretical prediction of the higher catalytic activity for A199S/S287G/A328W/ Y332G BChE, the A328W/Y332A and A199S/S287G/ A328W/Y332G mutants of BChE were produced as previously discussed through site-directed mutagenesis. To minimize the possible systematic experimental errors of the kinetic data, kinetic studies were performed with the two mutants and wild-type BChE under the same condition and compared the catalytic efficiency of A328W/Y332A and A199S/S287G/A328W/Y332G BChE's to that of the wildtype for (-)-cocaine hydrolysis at benzoyl ester group. Based on the kinetic analysis of the measured time-dependent radiometric data and the ELISA data, the ratio of the k_{car}/K_{M} value of A328W/Y332A BChE to the k_{cat}/K_M value of wild-type BChE for (-)-cocaine hydrolysis was determined to be ~8.6. The determined catalytic efficiency ratio of ~8.6 is in good agreement with the ratio of ~9.4 determined by Sun et al. Further, by using the same experimental protocol, the ratio of the k_{cat}/K_M value of A199S/S287G/A328W/Y332G BChE to the k_{cat}/K_M value of A328W/Y332A BChE for (-)-cocaine hydrolysis was determined to be ~50.6. These data indicate that the ratio of the k_{cat}/K_M value of A199S/S287G/A328W/ Y332G BChE to the k_{cat}/K_M value of wild-type BChE for (-)-cocaine hydrolysis should be \sim 50.6×8.6= \sim 435 or \sim 50.6× 9.4=~476. Thus, A199S/S287G/A328W/Y332G BChE has a ~(456±41)-fold improved catalytic efficiency against (-)-cocaine compared to the wild-type, or A199S/S287G/A328W/ Y332G BChE has a k_{cat}/K_M value of \sim (4.15±0.37)×10⁸ M min⁻¹ for (-)-cocaine hydrolysis. The catalytic efficiency of A199S/S287G/A328W/Y332G BChE against (-)-cocaine is much higher than that of AME-359 (i.e., F227A/S287G/ A328W/Y332M BChE, $k_{cat}/K_{M}=3.1\times10^{7}$ M min, whose catalytic efficiency against (-)-cocaine is the highest within all of the previously reported BChE mutants) which has a ~34-fold improved catalytic efficiency against (-)-cocaine compared to wild-type BChE.

By using the designed A199S/S287G/A328W/Y332G BChE as an exogenous enzyme in human, when the concentration of this mutant is kept the same as that of the wild-type BChE in plasma, the half-life time of (–)-cocaine in plasma should be reduced from the ~45-90 min to only ~6-12 seconds, considerably shorter than the time required for cocaine crossing the blood-brain barrier to reach CNS. Hence, the outcome of this study could eventually result in a valuable, efficient anti-cocaine medication.

Conclusion.

45

The transition-state simulations demonstrate that the overall hydrogen bonding between the carbonyl oxygen of (–)cocaine benzoyl ester and the oxyanion hole of BChE in the TS1 structure for (–)-cocaine hydrolysis catalyzed by A199S/ S287G/A328W/Y332G BChE should be significantly stronger than that in the TS1 structure for (–)-cocaine hydrolysis catalyzed by the wild-type BChE and other BChE mutants simulated. Thus, the MD simulations predict that A199S/ S287G/A328W/Y332G BChE should have a significantly lower energy barrier for the chemical reaction process and, therefore, a significantly higher catalytic efficiency (k_{car}/K_M) for (–)-cocaine hydrolysis. The theoretical prediction has been confirmed by wet experimental tests showing a ~(456±41)-fold improved catalytic efficiency for A199S/ S287G/A328W/Y332G BChE against (–)-cocaine compared to the wild-type BChE. The k_{cat}/K_M value determined for A199S/S287G/A328W/Y332G BChE is much higher than the k_{cat}/K_M value for AME-359 (i.e., F227A/S287G/A328W/ S232M BChE, whose catalytic efficiency against (–)-cocaine is the highest within all of the BChE mutants reported previously in literature) which has a ~34-fold improved catalytic efficiency against (–)-cocaine compared to the wild-type

BChE. The outcome of this study provides evidence that the transition-state simulation is a novel and unique approach for rational enzyme redesign and drug discovery.

Although the invention has been described in detail with respect to preferred embodiments thereof, it will be apparent that the invention is capable of numerous modifications and variations, apparent to those skilled in the art, without departing from the spirit and scope of the invention.

<160> NUMBER OF SEQ ID NOS: 30

<210> SEQ 3 <211> LENG <212> TYPE <213> ORGAI <220> FEAT <223> OTHER	ID NO 1 TH: 1722 : DNA NISM: Artif: JRE: R INFORMATIC	icial DN: 14-1 mut	ant A1995/2	4328W/Y332G	of Human	
buty	rylcholinest	erase (BChB	Ξ)			
<400> SEQUI	ENCE: 1					
gaagatgaca	tcataattgc	aacaaagaat	ggaaaagtca	gagggatgaa	cttgacagtt	60
tttggtggca	cggtaacagc	ctttcttgga	attccctatg	cacagccacc	tcttggtaga	120
cttcgattca	aaaagccaca	gtctctgacc	aagtggtctg	atatttggaa	tgccacaaaa	180
tatgcaaatt	cttgctgtca	gaacatagat	caaagttttc	caggcttcca	tggatcagag	240
atgtggaacc	caaacactga	cctcagtgaa	gactgtttat	atctaaatgt	atggattcca	300
gcacctaaac	caaaaaatgc	cactgtattg	atatggattt	atggtggtgg	ttttcaaact	360
ggaacatcat	ctttacatgt	ttatgatggc	aagtttctgg	ctcgggttga	aagagttatt	420
gtagtgtcaa	tgaactatag	ggtgggtgcc	ctaggattct	tagetttgee	aggaaatcct	480
gaggetecag	ggaacatggg	tttatttgat	caacagttgg	ctcttcagtg	ggttcaaaaa	540
aatatagcag	cctttggtgg	aaatcctaaa	agtgtaactc	tctttggaga	aagttccgga	600
gcagcttcag	ttagcctgca	tttgctttct	cctggaagcc	attcattgtt	caccagagcc	660
attctgcaaa	gtggttcctt	taatgctcct	tgggcggtaa	catctcttta	tgaagctagg	720
aacagaacgt	tgaacttagc	taaattgact	ggttgctcta	gagagaatga	gactgaaata	780
atcaagtgtc	ttagaaataa	agatccccaa	gaaattette	tgaatgaagc	atttgttgtc	840
ccctatggga	ctcctttgtc	agtaaacttt	ggtccgaccg	tggatggtga	ttttctcact	900
gacatgccag	acatattact	tgaacttgga	caatttaaaa	aaacccagat	tttggtgggt	960
gttaataaag	atgaagggac	atggttttta	gtcggtggtg	ctcctggctt	cagcaaagat	1020
aacaatagta	tcataactag	aaaagaattt	caggaaggtt	taaaaatatt	ttttccagga	1080
gtgagtgagt	ttggaaagga	atccatcctt	tttcattaca	cagactgggt	agatgatcag	1140
agacctgaaa	actaccgtga	ggccttgggt	gatgttgttg	gggattataa	tttcatatgc	1200
cctgccttgg	agttcaccaa	gaagttctca	gaatggggaa	ataatgcctt	tttctactat	1260
tttgaacacc	gatcctccaa	acttccgtgg	ccagaatgga	tgggagtgat	gcatggctat	1320
gaaattgaat	ttgtctttgg	tttacctctg	gaaagaagag	ataattacac	aaaagccgag	1380
gaaattttga	gtagatccat	agtgaaacgg	tgggcaaatt	ttgcaaaata	tgggaatcca	1440
aatgagactc	agaacaatag	cacaagctgg	cctgtcttca	aaagcactga	acaaaaatat	1500
ctaaccttga	atacagagtc	aacaagaata	atgacgaaac	tacgtgctca	acaatgtcga	1560
ttctggacat	cattttttcc	aaaagtcttg	gaaatgacag	gaaatattga	tgaagcagaa	1620

SEQUENCE LISTING

-continued

tgggagtgga aagcaggatt ccatcgctgg aacaattaca tgatggactg gaaaaatcaa 1680												
tttaacgatt acactagcaa gaaagaaagt tgtgtgggtc tc 1722												
<pre><210> SEQ ID NO 2 <211> LENGTH: 574 <212> TYPE: PRT <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: 14-1 mutant (A199S/A328W/Y332G) amino acid sequence modified BChE</pre>												
<400> SEQUENCE: 2												
Glu Asp Asp Ile Ile Ala Thr Lys Asn Gly Lys Val Arg Gly Met 1 5 10 15												
Asn Leu Thr Val Phe Gly Gly Thr Val Thr Ala Phe Leu Gly Ile Pro 20 25 30												
Tyr Ala Gln Pro Pro Leu Gly Arg Leu Arg Phe Lys Lys Pro Gln Ser 35 40 45												
Leu Thr Lys Trp Ser Asp Ile Trp Asn Ala Thr Lys Tyr Ala Asn Ser 50 55 60												
Cys Cys Gln Asn Ile Asp Gln Ser Phe Pro Gly Phe His Gly Ser Glu 65 70 75 80												
Met Trp Asn Pro Asn Thr Asp Leu Ser Glu Asp Cys Leu Tyr Leu Asn 85 90 95												
Val Trp Ile Pro Ala Pro Lys Pro Lys Asn Ala Thr Val Leu Ile Trp 100 105 110												
Ile Tyr Gly Gly Gly Phe Gln Thr Gly Thr Ser Ser Leu His Val Tyr 115 120 125												
Asp Gly Lys Phe Leu Ala Arg Val Glu Arg Val Ile Val Val Ser Met 130 135 140												
Asn Tyr Arg Val Gly Ala Leu Gly Phe Leu Ala Leu Pro Gly Asn Pro 145 150 155 160												
Glu Ala Pro Gly Asn Met Gly Leu Phe Asp Gln Gln Leu Ala Leu Gln 165 170 175												
Trp Val Gln Lys Asn Ile Ala Ala Phe Gly Gly Asn Pro Lys Ser Val 180 185 190												
Thr Leu Phe Gly Glu Ser Ser Gly Ala Ala Ser Val Ser Leu His Leu 195 200 205												
Leu Ser Pro Gly Ser His Ser Leu Phe Thr Arg Ala Ile Leu Gln Ser 210 215 220												
Gly Ser Phe Asn Ala Pro Trp Ala Val Thr Ser Leu Tyr Glu Ala Arg 225 230 235 240												
Asn Arg Thr Leu Asn Leu Ala Lys Leu Thr Gly Cys Ser Arg Glu Asn 245 250 255												
Glu Thr Glu Ile Ile Lys Cys Leu Arg Asn Lys Asp Pro Gln Glu Ile 260 265 270												
Leu Leu Asn Glu Ala Phe Val Val Pro Tyr Gly Thr Pro Leu Ser Val 275 280 285												
Asn Phe Gly Pro Thr Val Asp Gly Asp Phe Leu Thr Asp Met Pro Asp 290 295 300												
Ile Leu Glu Leu Gly Gln Phe Lys Lys Thr Gln Ile Leu Val Gly 305 310 315 320												
Val Asn Lys Asp Glu Gly Thr Trp Phe Leu Val Gly Gly Ala Pro Gly 325 330 335												
Phe Ser Lys Asp Asn Asn Ser Ile Ile Thr Arg Lys Glu Phe Gln Glu												

continued

												COII		ucu		
			340					345					350			
ly	Leu	Lys 355	Ile	Phe	Phe	Pro	Gly 360	Val	Ser	Glu	Phe	Gly 365	Lys	Glu	Ser	
lle	Leu 370	Phe	His	Tyr	Thr	Asp 375	Trp	Val	Asp	Asp	Gln 380	Arg	Pro	Glu	Asn	
Fyr 385	Arg	Glu	Ala	Leu	Gly 390	Asp	Val	Val	Gly	Asp 395	Tyr	Asn	Phe	Ile	Cys 400	
Pro	Ala	Leu	Glu	Phe 405	Thr	Lys	Lys	Phe	Ser 410	Glu	Trp	Gly	Asn	Asn 415	Ala	
Phe	Phe	Tyr	Tyr 420	Phe	Glu	His	Arg	Ser 425	Ser	ГÀа	Leu	Pro	Trp 430	Pro	Glu	
Γrp	Met	Gly 435	Val	Met	His	Gly	Tyr 440	Glu	Ile	Glu	Phe	Val 445	Phe	Gly	Leu	
Pro	Leu 450	Glu	Arg	Arg	Asp	Asn 455	Tyr	Thr	Lys	Ala	Glu 460	Glu	Ile	Leu	Ser	
Arg 465	Ser	Ile	Val	LYa	Arg 470	Trp	Ala	Asn	Phe	Ala 475	ГЛа	Tyr	Gly	Asn	Pro 480	
Asn	Glu	Thr	Gln	Asn 485	Asn	Ser	Thr	Ser	Trp 490	Pro	Val	Phe	Lys	Ser 495	Thr	
Glu	Gln	Lys	Tyr 500	Leu	Thr	Leu	Asn	Thr 505	Glu	Ser	Thr	Arg	Ile 510	Met	Thr	
Lys	Leu	Arg 515	Ala	Gln	Gln	Сув	Arg 520	Phe	Trp	Thr	Ser	Phe 525	Phe	Pro	Lys	
Val	Leu 530	Glu	Met	Thr	Gly	Asn 535	Ile	Asp	Glu	Ala	Glu 540	Trp	Glu	Trp	ГЛа	
Ala 545	Gly	Phe	His	Arg	Trp 550	Asn	Asn	Tyr	Met	Met 555	Aap	Trp	Lys	Asn	Gln 560	
Phe	Asn	Asp	Tyr	Thr 565	Ser	Lys	Lys	Glu	Ser 570	Суз	Val	Gly	Leu			
<21 <21 <21 <22 <22 <22	0 > SI 1 > LI 2 > T 3 > OI 0 > FI 3 > O' S(0 > SI	EQ II ENGTI YPE: RGAN: EATUI THER equei EQUEI	D NO H: 1: DNA ISM: RE: INF(nCE:	3 125 Art: ORMA' for 1	ific: TION modi:	ial : tru fied	uncat BChl	ced : E co:	14-1 rres]	(A1) pond	995/. ing	4328, zo a	/¥332 .a. 1	2G) r resic	nucleic dues 68	c Acid 3-442
aac	ataga	atc a	aaag	tttt	cc ag	ggcti	tccat	gga	atcaç	gaga	tgt	ggaa	ccc a	aaaca	actgac	60
ctc	agtga	aag a	actg	tttai	ta to	ctaa	atgta	a tg	jatto	ccag	cac	ctaa	acc a	aaaaa	aatgcc	120
act	gtati	tga 1	tatg	gatti	ta to	ggtg	gtggt	t tt	caaa	actg	gaa	catca	atc 1	ttad	catgtt	180
tat ata	gatg	gca a	agtti	atto	ge to	agggi	ttgaa	a aga	agtta	attg	tag	tgte	aat q	gaact	atagg	240
yry tta	ttta	atc a	aaca	gtta	gc t	cttc.	agta	a gy	tcaa	aaaa	ayy	Lage	age (ottto	igtaga	360
aat	ccta	aaa	gtgt	aact	ct c	tttg	gaga:	a agi	ttcc	ggag	cag	cttca	agt 1	cageo	ctgcat	420
ttg	cttt	ctc (ctgg	aagc	ca t'	tcat	tgtt«	c ac	caga	gcca	ttc	cgca	aag 1	zggtt	ccttt	480
aat	gctc	ctt	aaac	ggta	ac at	tctc	tttai	c gaa	ageta	agga	aca	gaac	gtt	gaact	taget	540
aaa	ttga	ctg	gttg	ctcta	ag ag	gaga	atga	g act	zgaa	ataa	tca	agtgi	tct 1	cagaa	aataaa	600
gat	cccca	aag a	aaati	tctt	ct ga	aatga	aagca	a tti	gtt	gtcc	cct	atgg	gac 1	cctt	tgtca	660
gta	aacti	ttg 🤉	gtcc	gacc	gt g	gatg	gtgat	tt:	cctca	actg	aca	gee	aga	catat	tactt	720

50

_

US 9,206,403 B1

_	-1	
-		
~		

-continued

gaac	ttgg	gac a	aattt	caaaa	aa aa	accc	agati	t tt	ggtg	ggtg	tta	ataa	aga 1	gaag	gggaca	a 780
tggt	ttt	ag t	cggt	cggt	gc to	cctg	gctto	c ago	caaaq	gata	aca	atagi	tat (cataa	actaga	a 840
aaag	jaatt	tc a	aggaa	aggti	tt aa	aaaa	tatti	t tt	tccaç	ggag	tga	gtga	gtt 1	ggaa	aaggaa	a 900
tcca	itcct	tt t	tcat	taca	ac ag	gact	gggta	a gat	tgato	caga	gac	ctga	aaa (ctaco	gtgag	g 960
gcct	tggg	gtg a	atgti	gtt	aa aa	gatt	ataat	t tt	catat	tgcc	ctg	cctt	gga q	gttca	accaag	g 1020
aagt	tcto	cag a	aatgo	gggaa	aa ta	aatg	cctt	t tt	ctact	tatt	ttg	aaca	ccg a	atcct	ccaaa	a 1080
ctto	cgto	ggc d	cagaa	atgga	at g	ggag	tgato	g cat	tggct	tatg	aaat	tt				1125
<210 <211 <212 <213 <220 <223)> SI .> LI :> TY :> OF :> OF :> OT ac	EQ II ENGTH YPE: RGANI EATUH THER cid s) NO H: 3' PRT ISM: RE: INFC Beque	4 75 Art: DRMA ence	ific: TION of 1	ial : tr modi:	uncat	ced : BChl	14-1 E	muta	ant	(A19	9s/A:	328/3	7332G)	amino
< 400		- COFT	NCE:			_								_	_	
Asn 1	Ile	Aab	Gln	Ser 5	Phe	Pro	Gly	Phe	His 10	Gly	Ser	Glu	Met	Trp 15	Asn	
Pro	Asn	Thr	Asp 20	Leu	Ser	Glu	Asp	Cys 25	Leu	Tyr	Leu	Asn	Val 30	Trp	Ile	
Pro	Ala	Pro 35	Lys	Pro	Lys	Asn	Ala 40	Thr	Val	Leu	Ile	Trp 45	Ile	Tyr	Gly	
Gly	Gly 50	Phe	Gln	Thr	Gly	Thr 55	Ser	Ser	Leu	His	Val 60	Tyr	Asp	Gly	Lys	
Phe 65	Leu	Ala	Arg	Val	Glu 70	Arg	Val	Ile	Val	Val 75	Ser	Met	Asn	Tyr	Arg 80	
Val	Gly	Ala	Leu	Gly 85	Phe	Leu	Ala	Leu	Pro 90	Gly	Asn	Pro	Glu	Ala 95	Pro	
Gly	Asn	Met	Gly 100	Leu	Phe	Asp	Gln	Gln 105	Leu	Ala	Leu	Gln	Trp 110	Val	Gln	
Lys	Asn	Ile 115	Ala	Ala	Phe	Gly	Gly 120	Asn	Pro	Lys	Ser	Val 125	Thr	Leu	Phe	
Gly	Glu 130	Ser	Ser	Gly	Ala	Ala 135	Ser	Val	Ser	Leu	His 140	Leu	Leu	Ser	Pro	
Gly 145	Ser	His	Ser	Leu	Phe 150	Thr	Arg	Ala	Ile	Leu 155	Gln	Ser	Gly	Ser	Phe 160	
Asn	Ala	Pro	Trp	Ala 165	Val	Thr	Ser	Leu	Tyr 170	Glu	Ala	Arg	Asn	Arg 175	Thr	
Leu	Asn	Leu	Ala 180	ГЛа	Leu	Thr	Gly	Cys 185	Ser	Arg	Glu	Asn	Glu 190	Thr	Glu	
Ile	Ile	Lys 195	Сүз	Leu	Arg	Asn	Lys 200	Asp	Pro	Gln	Glu	Ile 205	Leu	Leu	Asn	
Glu	Ala 210	Phe	Val	Val	Pro	Tyr 215	Gly	Thr	Pro	Leu	Ser 220	Val	Asn	Phe	Gly	
Pro 225	Thr	Val	Asp	Gly	Asp	Phe	Leu	Thr	Asp	Met 225	Pro	Asp	Ile	Leu	Leu 240	
Glu	Leu	Gly	Gln	Phe	∠30	Гла	Thr	Gln	Ile	Leu	Val	Gly	Val	Asn	Lys	
Asp	Glu	Gly	Thr	245 Trp	Phe	Leu	Val	Gly	250 Gly	Ala	Pro	Gly	Phe	255 Ser	Lys	
Asp	Asn	Asp	260 Ser	Ile	Ile	Thr	Ara	265 Lvs	G] 11	Phe	Gln	Glu	270 Glv	Leu	Lvs	
- 18 P	- 1011	275	Der	-16	116		280	-10	JIU	1116	U111	285	σ±γ	Leu	-10	

-continued

Ile Phe Pro Gly Val Ser Glu Phe Gly Lys Glu Ser Ile Leu Phe 290 295 300 His Tyr Thr Asp Trp Val Asp Asp Gln Arg Pro Glu Asn Tyr Arg Glu 305 310 315 320 Ala Leu Gly Asp Val Val Gly Asp Tyr Asn Phe Ile Cys Pro Ala Leu 325 330 335 Glu Phe Thr Lys Lys Phe Ser Glu Trp Gly Asn Asn Ala Phe Phe Tyr 340 345 350 Tyr Phe Glu His Arg Ser Ser Lys Leu Pro Trp Pro Glu Trp Met Gly 355 360 365 Val Met His Gly Tyr Glu Ile 370 <210> SEQ ID NO 5 <211> LENGTH: 966 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: 14-1 mutant (A199S/A328W/Y332G) BChE nucleic acid sequence corresponding to a.a. residues 117-438 <400> SEQUENCE: 5 ggttttcaaa ctggaacatc atctttacat gtttatgatg gcaagtttct ggctcgggtt 60 gaaagagtta ttgtagtgtc aatgaactat agggtgggtg ccctaggatt cttagctttg 120 ccaggaaatc ctgaggctcc agggaacatg ggtttatttg atcaacagtt ggctcttcag 180 tgggttcaaa aaaatatagc agcctttggt ggaaatccta aaagtgtaac tctctttgga 240 gaaagttccg gagcagcttc agttagcctg catttgcttt ctcctggaag ccattcattg 300 ttcaccagag ccattetgca aagtggttce tttaatgete ettgggeggt aacatetett 360 tatgaagcta ggaacagaac gttgaactta gctaaattga ctggttgctc tagagagaat 420 gagactgaaa taatcaagtg tcttagaaat aaagatcccc aagaaattct tctgaatgaa 480 gcatttgttg tcccctatgg gactcctttg tcagtaaact ttggtccgac cgtggatggt 540 gattttctca ctgacatgcc agacatatta cttgaacttg gacaatttaa aaaaacccag 600 660 attttggtgg gtgttaataa agatgaaggg acatggtttt tagtcggtgg tgctcctggc ttcagcaaag ataacaatag tatcataact agaaaagaat ttcaggaagg tttaaaaata 720 ttttttccag gagtgagtga gtttggaaag gaatccatcc tttttcatta cacagactgg 780 gtagatgatc agagacctga aaactaccgt gaggccttgg gtgatgttgt tggggattat 840 aatttcatat gccctgcctt ggagttcacc aagaagttct cagaatgggg aaataatgcc 900 tttttctact attttgaaca ccgatcctcc aaacttccgt ggccagaatg gatgggagtg 960 atgcat 966 <210> SEQ ID NO 6 <211> LENGTH: 322 <212> TYPE: PRT <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: 14-1 mutant (A199S/A328W/Y332G) BChE a.a. residues 117-438 <400> SEQUENCE: 6 Gly Phe Gln Thr Gly Thr Ser Ser Leu His Val Tyr Asp Gly Lys Phe 1 5 10 15 Leu Ala Arg Val Glu Arg Val Ile Val Val Ser Met Asn Tyr Arg Val 20 25 30

Gly Ala Leu Gly Phe Leu Ala Leu Pro Gly Asn Pro Glu Ala Pro Gly 35 40 45

-continued

Asn	Met 50	Gly	Leu	Phe	Asp	Gln 55	Gln	Leu	Ala	Leu	Gln 60	Trp	Val	Gln	Lys	
Asn 65	Ile	Ala	Ala	Phe	Gly 70	Gly	Asn	Pro	Lys	Ser 75	Val	Thr	Leu	Phe	Gly 80	
Glu	Ser	Ser	Gly	Ala 85	Ala	Ser	Val	Ser	Leu 90	His	Leu	Leu	Ser	Pro 95	Gly	
Ser	His	Ser	Leu 100	Phe	Thr	Arg	Ala	Ile 105	Leu	Gln	Ser	Gly	Ser 110	Phe	Asn	
Ala	Pro	Trp 115	Ala	Val	Thr	Ser	Leu 120	Tyr	Glu	Ala	Arg	Asn 125	Arg	Thr	Leu	
Asn	Leu 130	Ala	ГЛа	Leu	Thr	Gly 135	Суз	Ser	Arg	Glu	Asn 140	Glu	Thr	Glu	Ile	
Ile 145	Lys	Cys	Leu	Arg	Asn 150	Lys	Asp	Pro	Gln	Glu 155	Ile	Leu	Leu	Asn	Glu 160	
Ala	Phe	Val	Val	Pro 165	Tyr	Gly	Thr	Pro	Leu 170	Ser	Val	Asn	Phe	Gly 175	Pro	
Thr	Val	Asp	Gly 180	Asp	Phe	Leu	Thr	Asp 185	Met	Pro	Asp	Ile	Leu 190	Leu	Glu	
Leu	Gly	Gln 195	Phe	ГЛа	Lys	Thr	Gln 200	Ile	Leu	Val	Gly	Val 205	Asn	Lys	Asp	
Glu	Gly 210	Thr	Trp	Phe	Leu	Val 215	Gly	Gly	Ala	Pro	Gly 220	Phe	Ser	Lys	Asp	
Asn 225	Asn	Ser	Ile	Ile	Thr 230	Arg	Lys	Glu	Phe	Gln 235	Glu	Gly	Leu	Lys	Ile 240	
Phe	Phe	Pro	Gly	Val 245	Ser	Glu	Phe	Gly	Lys 250	Glu	Ser	Ile	Leu	Phe 255	His	
Tyr	Thr	Asp	Trp 260	Val	Asp	Asp	Gln	Arg 265	Pro	Glu	Asn	Tyr	Arg 270	Glu	Ala	
Leu	Gly	Asp 275	Val	Val	Gly	Asp	Tyr 280	Asn	Phe	Ile	Сүз	Pro 285	Ala	Leu	Glu	
Phe	Thr 290	Lys	ГЛа	Phe	Ser	Glu 295	Trp	Gly	Asn	Asn	Ala 300	Phe	Phe	Tyr	Tyr	
Phe 305	Glu	His	Arg	Ser	Ser 310	Lys	Leu	Pro	Trp	Pro 315	Glu	Trp	Met	Gly	Val 320	
Met	His															
<210 <211 <211 <211 <211 <220 <221	0> SI L> LI 2> T 3> OI 0> FI 3> O ft	EQ II ENGTI YPE: RGANI EATUI THER 111 1	D NO H: 1' DNA ISM: RE: INFO hucle	7 722 Art: ORMA eic	ific: TION acid	ial : 14 sequ	-2 mu ience	utant	: (A:	1995,	/F22'	7A/A:	328W,	/ ¥332	2G) BChE,	
<400)> SI	EQUEI	NCE :	7												
gaaq	gatga	aca 1	tcata	aatt	gc aa	acaaa	agaat	c gga	aaaaq	gtca	gago	ggat	gaa (ttga	acagtt	60
tttę	ggtgg	gca (cggta	aaca	gc ct	ttct	tgga	a att	ceeet	tatg	caca	agee	acc 1	cctt	ggtaga	120
ctto	cgatt	cca a	aaaa	gcca	ca gt	cctct	gaco	c aaq	gtggt	ctg	atat	ttg	gaa 1	geea	acaaaa	180
tato	gcaaa	att (cttg	ctgt	ca ga	aacat	agat	c caa	aagtt	ttc	cag	gett	cca 1	cggat	cagag	240
atgi	ggaa	acc (caaa	cact	ga co	ctcaç	gtgaa	a gao	ctgtt	tat	atci	aaat	tgt a	atgga	attcca	300
gcad	cctaa	aac (caaaa	aaat	ge ca	actgi	atto	g ata	atgga	attt	atg	gtggi	cgg 1	ttt	caaact	360

US 9,206,403 B1

57

-continued

ggaa	acato	cat d	cttta	acate	jt ti	atga	atggo	aag	yttto	tgg	ctcç	gggtt	:ga a	aagag	gttat	t	420
gtag	gtgto	caa t	gaad	ctata	ıg gö	gtggg	gtgcc	cta	aggat	tct	tago	ettte	gee a	aggaa	atco	et	480
gago	getee	cag g	ggaad	atgo	ıg tt	tatt	tgat	caa	acagt	tgg	ctct	tcag	gtg g	ggtto	caaaa	aa	540
aata	atago	cag d	ccttt	ggto	ıg aa	atco	taaa	ı agt	gtaa	actc	tctt	tgga	aga a	aagtt	ccgg	ja	600
gcag	gette	cag t	tago	ctgo	a tt	tget	ttct	cct	ggaa	agcc	atto	catto	gtt (cacca	agago	cc	660
atto	ctgca	aaa g	gtggt	tccg	jc ta	atgo	tcct	tgg	ggggg	gtaa	cato	ctctt	ta	tgaag	gctag	99 99	720
aaca	igaad	egt t	gaad	ettag	jc ta	aatt	gact	ggt	tgct	cta	gaga	agaat	ga g	gacto	yaaat	a	780
atca	agto	gtc t	taga	aata	ia ag	gated	ccaa	u gaa	atto	ettc	tgaa	atgaa	agc a	attt	gttgt	c	840
ccct	atgo	gga d	etect	ttgt	c ag	gtaaa	acttt	ggt	ccga	accg	tgga	atggt	:ga 1	tttt	etcad	et	900
gaca	atgco	cag a	acata	attac	t tç	jaact	tgga	a caa	itta	aaaa	aaad	cccaç	gat 1	tttgg	gtggg	gt	960
gtta	ataa	aag a	atgaa	aggga	ic at	ggtt	ttta	a gto	ggtg	ggtg	ctco	tggo	ctt (cagca	aaga	at	1020
aaca	atag	gta t	ccata	acta	ıg aa	aaga	attt	cag	gaag	ggtt	taaa	aaata	att 1	tttt	cage	ja	1080
gtga	agtga	agt t	tgga	aagg	ja at	ccat	cctt	ttt	catt	aca	caga	actgo	ggt a	agato	gatca	ag	1140
agad	ctga	aaa a	actad	cgte	ja go	geett	gggt	gat	gtte	gttg	ggga	attat	aa 1	tttca	atato	gc	1200
ccto	gcctt	gg a	agtto	cacca	ia ga	agtt	ctca	a gaa	atggg	ggaa	ataa	atgco	ett 1	tttct	acta	at	1260
tttç	gaaca	acc ç	gatco	etcca	ia ad	ettec	gtgg	g cca	igaat	gga	tggg	gagto	gat g	gcate	ggeta	at	1320
gaaa	attga	aat t	tgto	ettte	ıg tt	taco	etete	g gaa	agaa	agag	ataa	attac	cac a	aaaaq	geega	ag	1380
gaaa	attt	ga g	gtaga	atcca	nt aç	gtgaa	acgo	g tgo	gcaa	aatt	ttgo	caaaa	ata 1	tggga	atco	ca	1440
aato	jagad	ctc a	agaad	caata	ıg ca	acaag	getge	g cct	gtct	tca	aaag	gcact	:ga a	acaaa	aata	at	1500
ctaa	acctt	:ga a	ataca	agagt	c aa	acaag	gaata	ato	Jacga	aaac	tacç	gtgct	ca a	acaat	gtco	ja	1560
ttct	ggad	cat d	cattt	tttc	c aa	aagt	cttg	g gaa	atga	acag	gaaa	atatt	:ga 1	tgaag	gcaga	aa	1620
tggg	gagto	gga a	aagca	aggat	t co	cates	getge	j aac	aatt	aca	tgat	ggad	ctg g	gaaaa	atca	aa	1680
ttta	acga	att a	acact	agca	ia ga	aaga	aagt	tgt	gtgg	ggtc	tc						1722
<210 <211 <212 <213 <220 <223)> SE 2> LE 2> TY 3> OF 3> OF 3> OT an	EQ II ENGTH (PE: RGANI EATUH THER MINO) NO H: 57 PRT ISM: RE: INFC acid	8 74 Arti DRMAI 1 sec	fic: TON: quenc	lal 14- ce	·2 mu	ıtant	: (A1	L995,	/F22	7A/A3	328W,	/ ¥332	2G),	full	-
<400)> SE	EQUEI	ICE :	8													
Glu 1	Asp	Asp	Ile	Ile 5	Ile	Ala	Thr	Lys	Asn 10	Gly	Lys	Val	Arg	Gly 15	Met		
Asn	Leu	Thr	Val 20	Phe	Gly	Gly	Thr	Val 25	Thr	Ala	Phe	Leu	Gly 30	Ile	Pro		
Tyr	Ala	Gln 35	Pro	Pro	Leu	Gly	Arg 40	Leu	Arg	Phe	Lys	Lys 45	Pro	Gln	Ser		
Leu	Thr 50	Lys	Trp	Ser	Asp	Ile 55	Trp	Asn	Ala	Thr	Lys 60	Tyr	Ala	Asn	Ser		
Суя 65	Cys	Gln	Asn	Ile	Asp 70	Gln	Ser	Phe	Pro	Gly 75	Phe	His	Gly	Ser	Glu 80		
Met	Trp	Asn	Pro	Asn 85	Thr	Asp	Leu	Ser	Glu 90	Aap	Сүз	Leu	Tyr	Leu 95	Asn		
Val	Trp	Ile	Pro 100	Ala	Pro	Lys	Pro	Lys 105	Asn	Ala	Thr	Val	Leu 110	Ile	Trp		

-continued

Ile	Tyr	Gly 115	Gly	Gly	Phe	Gln	Thr 120	Gly	Thr	Ser	Ser	Leu 125	His	Val	Tyr
Asp	Gly 130	Lys	Phe	Leu	Ala	Arg 135	Val	Glu	Arg	Val	Ile 140	Val	Val	Ser	Met
Asn 145	Tyr	Arg	Val	Gly	Ala 150	Leu	Gly	Phe	Leu	Ala 155	Leu	Pro	Gly	Asn	Pro 160
Glu	Ala	Pro	Gly	Asn 165	Met	Gly	Leu	Phe	Asp 170	Gln	Gln	Leu	Ala	Leu 175	Gln
Trp	Val	Gln	Lys 180	Asn	Ile	Ala	Ala	Phe 185	Gly	Gly	Asn	Pro	Lys 190	Ser	Val
Thr	Leu	Phe 195	Gly	Glu	Ser	Ser	Gly 200	Ala	Ala	Ser	Val	Ser 205	Leu	His	Leu
Leu	Ser 210	Pro	Gly	Ser	His	Ser 215	Leu	Phe	Thr	Arg	Ala 220	Ile	Leu	Gln	Ser
Gly 225	Ser	Ala	Asn	Ala	Pro 230	Trp	Ala	Val	Thr	Ser 235	Leu	Tyr	Glu	Ala	Arg 240
Asn	Arg	Thr	Leu	Asn 245	Leu	Ala	Lys	Leu	Thr 250	Gly	СЛа	Ser	Arg	Glu 255	Asn
Glu	Thr	Glu	Ile 260	Ile	Lys	Суз	Leu	Arg 265	Asn	Lys	Asp	Pro	Gln 270	Glu	Ile
Leu	Leu	Asn 275	Glu	Ala	Phe	Val	Val 280	Pro	Tyr	Gly	Thr	Pro 285	Leu	Ser	Val
Asn	Phe 290	Gly	Pro	Thr	Val	Asp 295	Gly	Asp	Phe	Leu	Thr 300	Asp	Met	Pro	Asp
Ile 305	Leu	Leu	Glu	Leu	Gly 310	Gln	Phe	Lys	Lys	Thr 315	Gln	Ile	Leu	Val	Gly 320
Val	Asn	Lys	Asp	Glu 325	Gly	Thr	Trp	Phe	Leu 330	Val	Gly	Gly	Ala	Pro 335	Gly
Phe	Ser	Lys	Asp 340	Asn	Asn	Ser	Ile	Ile 345	Thr	Arg	Гла	Glu	Phe 350	Gln	Glu
Gly	Leu	Lys 355	Ile	Phe	Phe	Pro	Gly 360	Val	Ser	Glu	Phe	Gly 365	Lys	Glu	Ser
Ile	Leu 370	Phe	His	Tyr	Thr	Asp 375	Trp	Val	Asp	Asp	Gln 380	Arg	Pro	Glu	Asn
Tyr 385	Arg	Glu	Ala	Leu	Gly 390	Asp	Val	Val	Gly	Asp 395	Tyr	Asn	Phe	Ile	Cys 400
Pro	Ala	Leu	Glu	Phe 405	Thr	Lys	Lys	Phe	Ser 410	Glu	Trp	Gly	Asn	Asn 415	Ala
Phe	Phe	Tyr	Tyr 420	Phe	Glu	His	Arg	Ser 425	Ser	Lys	Leu	Pro	Trp 430	Pro	Glu
Trp	Met	Gly 435	Val	Met	His	Gly	Tyr 440	Glu	Ile	Glu	Phe	Val 445	Phe	Gly	Leu
Pro	Leu 450	Glu	Arg	Arg	Asp	Asn 455	Tyr	Thr	Lys	Ala	Glu 460	Glu	Ile	Leu	Ser
Arg 465	Ser	Ile	Val	Lys	Arg 470	Trp	Ala	Asn	Phe	Ala 475	Lys	Tyr	Gly	Asn	Pro 480
Asn	Glu	Thr	Gln	Asn	Asn	Ser	Thr	Ser	Trp	Pro	Val	Phe	Lys	Ser	Thr
Glu	Gln	Lys	Tyr	405 Leu	Thr	Leu	Asn	Thr	Glu	Ser	Thr	Arg	Ile	495 Met	Thr
Lys	Leu	Arg	500 Ala	Gln	Gln	Суз	Arg	505 Phe	Trp	Thr	Ser	Phe	510 Phe	Pro	Lys
Val	Leu	515 G]u	Met	Thr	Glv	Asn	520 Ile	Asp	Glu	Ala	Glu	525 Tro	Glu	Trp	Lvs
					1			P						- + P	-15

530 535 540 Ala Gly Phe His Arg Trp Asn Asn Tyr Met Met Asp Trp Lys Asn Gln 545 550 555 560 Phe Asn Asp Tyr Thr Ser Lys Lys Glu Ser Cys Val Gly Leu 565 570 <210> SEQ ID NO 9 <211> LENGTH: 1125 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: 14-2 mutant (A199/F227A/A328W/Y322G) BChE nucleic acid sequence for a.a. residues 68-442 <400> SEQUENCE: 9 aacatagatc aaagttttcc aggcttccat ggatcagaga tgtggaaccc aaacactgac 60 ctcagtgaag actgtttata tctaaatgta tggattccag cacctaaacc aaaaaatgcc 120 actgtattga tatggattta tggtggtggt tttcaaactg gaacatcatc tttacatgtt 180 tatgatggca agtttctggc tcgggttgaa agagttattg tagtgtcaat gaactatagg 240 gtgggtgccc taggattctt agctttgcca ggaaatcctg aggctccagg gaacatgggt 300 ttatttqatc aacaqttqqc tcttcaqtqq qttcaaaaaa atataqcaqc ctttqqtqqa 360 aatcctaaaa gtgtaactct ctttggagaa agttccggag cagcttcagt tagcctgcat 420 ttqctttctc ctqqaaqcca ttcattqttc accaqaqcca ttctqcaaaq tqqttccqct 480 aatgeteett gggeggtaac atetettat gaagetagga acagaaegtt gaaettaget 540 aaattgactg gttgctctag agagaatgag actgaaataa tcaagtgtct tagaaataaa 600 gatececaag aaattettet gaatgaagea tttgttgtee eetatgggae teetttgtea 660 gtaaactttg gtccgaccgt ggatggtgat tttctcactg acatgccaga catattactt 720 gaacttggac aatttaaaaa aacccagatt ttggtgggtg ttaataaaga tgaagggaca 780 tggtttttag tcggtggtgc tcctggcttc agcaaagata acaatagtat cataactaga 840 aaagaatttc aggaaggttt aaaaatattt tttccaggag tgagtgagtt tggaaaggaa 900 tccatccttt ttcattacac agactgggta gatgatcaga gacctgaaaa ctaccgtgag 960 gccttgggtg atgttgttgg ggattataat ttcatatgcc ctgccttgga gttcaccaag 1020 aagtteteag aatggggaaa taatgeettt ttetaetatt ttgaacaeeg ateeteeaaa 1080 cttccgtggc cagaatggat gggagtgatg catggctatg aaatt 1125 <210> SEQ ID NO 10 <211> LENGTH: 375 <212> TYPE: PRT <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: 14-2 mutant (A199S/F227A/A328W/Y332G) BChE, amino acid sequence for residues 68-442 <400> SEQUENCE: 10 Asn Ile Asp Gln Ser Phe Pro Gly Phe His Gly Ser Glu Met Trp Asn 5 10 15 1 Pro Asn Thr Asp Leu Ser Glu Asp Cys Leu Tyr Leu Asn Val Trp Ile 20 25 30 Pro Ala Pro Lys Pro Lys Asn Ala Thr Val Leu Ile Trp Ile Tyr Gly 35 40 45 Gly Gly Phe Gln Thr Gly Thr Ser Ser Leu His Val Tyr Asp Gly Lys 50 55 60

-continued

Phe 65	Leu	Ala	Arg	Val	Glu 70	Arg	Val	Ile	Val	Val 75	Ser	Met	Asn	Tyr	Arg 80
Val	Gly	Ala	Leu	Gly 85	Phe	Leu	Ala	Leu	Pro 90	Gly	Asn	Pro	Glu	Ala 95	Pro
Gly	Asn	Met	Gly 100	Leu	Phe	Asp	Gln	Gln 105	Leu	Ala	Leu	Gln	Trp 110	Val	Gln
ГЛа	Asn	Ile 115	Ala	Ala	Phe	Gly	Gly 120	Asn	Pro	Lys	Ser	Val 125	Thr	Leu	Phe
Gly	Glu 130	Ser	Ser	Gly	Ala	Ala 135	Ser	Val	Ser	Leu	His 140	Leu	Leu	Ser	Pro
Gly 145	Ser	His	Ser	Leu	Phe 150	Thr	Arg	Ala	Ile	Leu 155	Gln	Ser	Gly	Ser	Ala 160
Asn	Ala	Pro	Trp	Ala 165	Val	Thr	Ser	Leu	Tyr 170	Glu	Ala	Arg	Asn	Arg 175	Thr
Leu	Asn	Leu	Ala 180	Lys	Leu	Thr	Gly	Cys 185	Ser	Arg	Glu	Asn	Glu 190	Thr	Glu
Ile	Ile	Lys 195	Сүз	Leu	Arg	Asn	Lys 200	Asp	Pro	Gln	Glu	Ile 205	Leu	Leu	Asn
Glu	Ala 210	Phe	Val	Val	Pro	Tyr 215	Gly	Thr	Pro	Leu	Ser 220	Val	Asn	Phe	Gly
Pro 225	Thr	Val	Asp	Gly	Asp 230	Phe	Leu	Thr	Asp	Met 235	Pro	Asp	Ile	Leu	Leu 240
Glu	Leu	Gly	Gln	Phe 245	Lys	Lys	Thr	Gln	Ile 250	Leu	Val	Gly	Val	Asn 255	Гла
Asp	Glu	Gly	Thr 260	Trp	Phe	Leu	Val	Gly 265	Gly	Ala	Pro	Gly	Phe 270	Ser	Lys
Asp	Asn	Asn 275	Ser	Ile	Ile	Thr	Arg 280	Lys	Glu	Phe	Gln	Glu 285	Gly	Leu	Lys
Ile	Phe 290	Phe	Pro	Gly	Val	Ser 295	Glu	Phe	Gly	ГÀа	Glu 300	Ser	Ile	Leu	Phe
His 305	Tyr	Thr	Asp	Trp	Val 310	Asp	Asp	Gln	Arg	Pro 315	Glu	Asn	Tyr	Arg	Glu 320
Ala	Leu	Gly	Asp	Val 325	Val	Gly	Asp	Tyr	Asn 330	Phe	Ile	Сүз	Pro	Ala 335	Leu
Glu	Phe	Thr	Lys 340	Lys	Phe	Ser	Glu	Trp 345	Gly	Asn	Asn	Ala	Phe 350	Phe	Tyr
Tyr	Phe	Glu 355	His	Arg	Ser	Ser	Lys 360	Leu	Pro	Trp	Pro	Glu 365	Trp	Met	Gly
Val	Met 370	His	Gly	Tyr	Glu	Ile 375									
<210 <211 <211 <211 <221 <221 <221	0> SI 1> LI 2> T 3> OF 0> FI 3> O 3> O	EQ II ENGTI YPE: RGANI EATUI FHER 1cle:) NO H: 96 DNA ISM: RE: INF(ic ad	11 56 Art: DRMA	ific: TION seque	ial : 14 ence	-2 mu for	ıtanı res:	: (A: idue:	L99S, ≆ 11	/F22′ 7-438	7A/A: 3	328W/	/¥332	2G) BChE
<40)> SI	EQUEI	ICE :	11											
ggti	tttca	aaa (ctgga	aaca	tc af	tctt	cacat	t gtt	tatę	gatg	gcaa	agtti	cct ç	ggct	cgggtt
gaaa	agagt	ta 1	tgta	agtgi	tc a	atga	actat	z agę	ggtgg	ggtg	ccct	cagga	att d	cttaç	getttg
cca	ggaaa	atc (ctga	ggct	cc ag	ggga	acato	g ggt	ttat	ttg	atca	aaca	gtt g	ggct	cttcag
tgg	gttca	aaa a	aaaat	cata	gc ag	geet	tggt	c gga	aaato	ccta	aaaq	gtgta	aac t	ctct	ttgga

US 9,206,403 B1

65

-continued

gaaagttccg	gagcagct	tc agtta	gcctg (catttg	cttt	ctco	ctgga	ag d	ccatt	cattg	300
ttcaccagag	ccattctg	ca aagtg	gttcc 🤅	gctaat	gctc	cttç	gggeg	gt a	aacat	ctctt	360
tatgaagcta	ggaacaga	ac gttga	actta 🤉	gctaaa	ttga	ctg	gttgo	tc t	agag	gagaat	420
gagactgaaa	taatcaag	tg tctta	gaaat a	aaagat	cccc	aaga	aaatt	ct t	cctga	aatgaa	480
gcatttgttg	tcccctat	gg gactc	ctttg 1	tcagta	aact	ttgg	gtccc	jac d	gtgg	gatggt	540
gattttctca	ctgacatg	cc agaca	tatta	cttgaa	cttg	gaca	aattt	aa a	aaaaa	acccag	600
attttggtgg	gtgttaat	aa agatg	aaggg a	acatggi	ttt	tagt	cggt	.gg t	geto	cctggc	660
ttcagcaaag	ataacaat	ag tatca	taact a	agaaaa	gaat	ttca	aggaa	igg t	ttaa	aaaata	720
ttttttccag	gagtgagt	ga gtttg	gaaag q	gaatcca	atcc	ttt	tcat	ta d	cacaç	gactgg	780
gtagatgatc	agagacct	ga aaact	accgt o	gaggeet	ttgg	gtga	atgtt	gt t	9999	gattat	840
aatttcatat	gccctgcc	tt ggagt	tcacc a	aagaagi	ttct	caga	aatgo	idd a	aaata	aatgcc	900
tttttctact	attttgaa	ca ccgat	cctcc a	aaactt	ccgt	ggco	cagaa	itg g	gatgo	ggagtg	960
atgcat											966
<210> SEQ I <211> LENGT <212> TYPE: <213> ORGAN <220> FEATU <223> OTHER 117-4	D NO 12 H: 322 PRT ISM: Art RE: INFORMA 38	ificial TION: 14	-2 (A19	99S/F2:	27A/2	43281	N/Y33	2G)	a.a	residues	
<400> SEQUE	NCE: 12										
Gly Phe Gln 1	Thr Gly 5	Thr Ser	Ser Le	eu His 10	Val	Tyr	Asp	Gly	Lys 15	Phe	
Leu Ala Arg	Val Glu 20	Arg Val	Ile Va 2!	al Val 5	Ser	Met	Asn	Tyr 30	Arg	Val	
Gly Ala Leu 35	Gly Phe	Leu Ala	Leu P: 40	ro Gly	Asn	Pro	Glu 45	Ala	Pro	Gly	
Asn Met Gly 50	Leu Phe	Asp Gln 55	Gln Le	eu Ala	Leu	Gln 60	Trp	Val	Gln	Lys	
Asn Ile Ala 65	Ala Phe	Gly Gly 70	Asn P:	ro Lys	Ser 75	Val	Thr	Leu	Phe	Gly 80	
Glu Ser Ser	Gly Ala 85	Ala Ser	Val Se	er Leu 90	His	Leu	Leu	Ser	Pro 95	Gly	
Ser His Ser	Leu Phe 100	Thr Arg	Ala I 10	le Leu 05	Gln	Ser	Gly	Ser 110	Ala	Asn	
Ala Pro Trp 115	Ala Val	Thr Ser	Leu T <u>y</u> 120	yr Glu	Ala	Arg	Asn 125	Arg	Thr	Leu	
Asn Leu Ala 130	Lys Leu	Thr Gly 135	Cys Se	er Arg	Glu	Asn 140	Glu	Thr	Glu	Ile	
Ile Lys Cys 145	Leu Arg	Asn Lys 150	Asp P:	ro Gln	Glu 155	Ile	Leu	Leu	Asn	Glu 160	
Ala Phe Val	Val Pro 165	Tyr Gly	Thr P:	ro Leu 170	Ser	Val	Asn	Phe	Gly 175	Pro	
Thr Val Asp	Gly Asp 180	Phe Leu	Thr As	sp Met 85	Pro	Asp	Ile	Leu 190	Leu	Glu	
Leu Gly Gln 195	Phe Lys	Lys Thr	Gln I: 200	le Leu	Val	Gly	Val 205	Asn	Lys	Asp	
Glu Gly Thr 210	Trp Phe	Leu Val 215	Gly G	ly Ala	Pro	Gly 220	Phe	Ser	Lys	Asp	

-continued

Asn Asn Ser Ile Ile Thr Arg Lys Glu Phe Gln Glu Gly Leu Lys Ile 225 230 235 240
Phe Phe Pro Gly Val Ser Glu Phe Gly Lys Glu Ser Ile Leu Phe His 245 250 255
Tyr Thr Asp Trp Val Asp Asp Gln Arg Pro Glu Asn Tyr Arg Glu Ala 260 265 270
Leu Gly Asp Val Val Gly Asp Tyr Asn Phe Ile Cys Pro Ala Leu Glu 275 280 285
Phe Thr Lys Lys Phe Ser Glu Trp Gly Asn Asn Ala Phe Phe Tyr Tyr 290 295 300
Phe Glu His Arg Ser Ser Lys Leu Pro Trp Pro Glu Trp Met Gly Val 305 310 315 320
Met His
<210> SEQ ID NO 13 <211> LENGTH: 1722 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: 14-3 mutant (A199S/S287G/A328W/Y332G) BChE nucleic acid sequence
<400> SEQUENCE: 13
gaagatgaca tcataattgc aacaaagaat ggaaaagtca gagggatgaa cttgacagtt 60
tttggtggca cggtaacagc ctttcttgga attccctatg cacagccacc tcttggtaga 120
cttcgattca aaaagccaca gtctctgacc aagtggtctg atatttggaa tgccacaaaa 180
tatgcaaatt cttgctgtca gaacatagat caaagttttc caggcttcca tggatcagag 240
atgtggaacc caaacactga cctcagtgaa gactgtttat atctaaatgt atggattcca 300
gcacctaaac caaaaaatgc cactgtattg atatggattt atggtggtgg ttttcaaact 360
ggaacatcat ctttacatgt ttatgatggc aagtttctgg ctcgggttga aagagttatt 420
gtagtgtcaa tgaactatag ggtgggtgcc ctaggattct tagctttgcc aggaaatcct 480
gaggeteeag ggaacatggg tttatttgat caacagttgg etetteagtg ggtteaaaaa 540
aatatagcag cctttggtgg aaatcctaaa agtgtaactc tctttggaga aagttccgga 600
gcagetteag ttageetgea tttgetttet eetggaagee atteattgtt eaceagagee 660
attetgeaaa gtggtteett taatgeteet tgggeggtaa catetettta tgaagetagg 720
aacagaacgt tgaacttagc taaattgact ggttgctcta gagagaatga gactgaaata 780
atcaagtgtc ttagaaataa agatccccaa gaaattcttc tgaatgaagc atttgttgtc 840
ccctatggga ctcctttggg tgtaaacttt ggtccgaccg tggatggtga ttttctcact 900
gacatgccag acatattact tgaacttgga caatttaaaa aaacccagat tttggtgggt 960
gttaataaag atgaagggac atggttttta gtcggtggtg ctcctggctt cagcaaagat 1020
aacaatagta tcataactag aaaagaattt caggaaggtt taaaaatatt ttttccagga 1080
gtgagtgagt ttggaaagga atccatcctt tttcattaca cagactgggt agatgatcag 1140
agacetgaaa actacegtga ggeettgggt gatgttgttg gggattataa ttteatatge 1200
cctgccttgg agttcaccaa gaagttctca gaatggggaa ataatgcctt tttctactat 1260
tttgaacacc gateeteeaa actteegtgg ceagaatgga tgggagtgat geatggetat 1220
according to the state of the s
yaaaliyaal liytuliyy tilacciciy yaaayaayaayaa alaallacac adaageegag 1380
gaaattttga gtagatccat agtgaaacgg tgggcaaatt ttgcaaaata tgggaatcca 1440

-continued

aato	gagad	etc a	igaad	caata	ag ca	acaaç	getge	g oct	gtct	tca	aaaq	gcact	:ga a	acaaa	aatat	1500	C	
ctaa	acctt	:ga a	ataca	agagt	c aa	acaaç	gaata	ato	gacga	aac	taco	gtgct	ca a	acaat	gtcga	1560	C	
ttct	ggad	at o	attt	ttto	cc aa	aaagt	cttg	g gaa	atga	acag	gaaa	tatt	ga t	gaag	JCAGAA	1620	C	
tggg	gagto	gga a	agca	aggat	t co	cates	getge	g aac	aatt	aca	tgat	ggad	etg g	jaaaa	atcaa	1680	C	
ttta	aacga	itt a	acact	agca	aa ga	aaaga	aagt	tgt	gtgg	ggtc	tc					1722	2	
<210 <211 <212 <213 <220 <223)> SE L> LE 2> TY 3> OF 3> OF 3> OT an	EQ II ENGTH PE: CGANI EATUF THER NINO) NO I: 57 PRT SM: E: INFC acid	14 74 Arti DRMAI	ifici TION: quenc	ial : 14- ce	.3 mu	ıtant	: (A1	.99S/	/5287	/G/A3	328W/	[/] Y332	G) BChE			
<400)> SE	EQUEN	ICE :	14														
Glu 1	Asp	Asp	Ile	Ile 5	Ile	Ala	Thr	Lys	Asn 10	Gly	Lys	Val	Arg	Gly 15	Met			
Asn	Leu	Thr	Val 20	Phe	Gly	Gly	Thr	Val 25	Thr	Ala	Phe	Leu	Gly 30	Ile	Pro			
Tyr	Ala	Gln 35	Pro	Pro	Leu	Gly	Arg 40	Leu	Arg	Phe	Lys	Lys 45	Pro	Gln	Ser			
Leu	Thr 50	Lys	Trp	Ser	Asp	Ile 55	Trp	Asn	Ala	Thr	Lys 60	Tyr	Ala	Asn	Ser			
Cys 65	Cys	Gln	Asn	Ile	Asp 70	Gln	Ser	Phe	Pro	Gly 75	Phe	His	Gly	Ser	Glu 80			
Met	Trp	Asn	Pro	Asn 85	Thr	Asp	Leu	Ser	Glu 90	Asp	Суз	Leu	Tyr	Leu 95	Asn			
Val	Trp	Ile	Pro 100	Ala	Pro	Lys	Pro	Lys 105	Asn	Ala	Thr	Val	Leu 110	Ile	Trp			
Ile	Tyr	Gly 115	Gly	Gly	Phe	Gln	Thr 120	Gly	Thr	Ser	Ser	Leu 125	His	Val	Tyr			
Asp	Gly 130	Lys	Phe	Leu	Ala	Arg 135	Val	Glu	Arg	Val	Ile 140	Val	Val	Ser	Met			
Asn 145	Tyr	Arg	Val	Gly	Ala 150	Leu	Gly	Phe	Leu	Ala 155	Leu	Pro	Gly	Asn	Pro 160			
Glu	Ala	Pro	Gly	Asn 165	Met	Gly	Leu	Phe	Asp 170	Gln	Gln	Leu	Ala	Leu 175	Gln			
Trp	Val	Gln	Lys 180	Asn	Ile	Ala	Ala	Phe 185	Gly	Gly	Asn	Pro	Lys 190	Ser	Val			
Thr	Leu	Phe 195	Gly	Glu	Ser	Ser	Gly 200	Ala	Ala	Ser	Val	Ser 205	Leu	His	Leu			
Leu	Ser 210	Pro	Gly	Ser	His	Ser 215	Leu	Phe	Thr	Arg	Ala 220	Ile	Leu	Gln	Ser			
Gly 225	Ser	Phe	Asn	Ala	Pro 230	Trp	Ala	Val	Thr	Ser 235	Leu	Tyr	Glu	Ala	Arg 240			
Asn	Arg	Thr	Leu	Asn 245	Leu	Ala	Lys	Leu	Thr 250	Gly	Cya	Ser	Arg	Glu 255	Asn			
Glu	Thr	Glu	Ile 260	Ile	Lys	Cys	Leu	Arg 265	Asn	Lys	Asp	Pro	Gln 270	Glu	Ile			
Leu	Leu	Asn 275	Glu	Ala	Phe	Val	Val 280	Pro	Tyr	Gly	Thr	Pro 285	Leu	Gly	Val			
Asn	Phe 290	Gly	Pro	Thr	Val	Asp 295	Gly	Asp	Phe	Leu	Thr	Asp	Met	Pro	Asp			

-continued

Ile 305	Leu	Leu	Glu	Leu	Gly 310	Gln	Phe	Lys	Lys	Thr 315	Gln	Ile	Leu	Val	Gly 320	
Val	Asn	Lys	Asp	Glu 325	Gly	Thr	Trp	Phe	Leu 330	Val	Gly	Gly	Ala	Pro 335	Gly	
Phe	Ser	Lys	Asp 340	Asn	Asn	Ser	Ile	Ile 345	Thr	Arg	Lys	Glu	Phe 350	Gln	Glu	
Gly	Leu	Lys 355	Ile	Phe	Phe	Pro	Gly 360	Val	Ser	Glu	Phe	Gly 365	Lys	Glu	Ser	
Ile	Leu 370	Phe	His	Tyr	Thr	Asp 375	Trp	Val	Asp	Asp	Gln 380	Arg	Pro	Glu	Asn	
Tyr 385	Arg	Glu	Ala	Leu	Gly 390	Asp	Val	Val	Gly	Asp 395	Tyr	Asn	Phe	Ile	Cys 400	
Pro	Ala	Leu	Glu	Phe 405	Thr	Lys	Lys	Phe	Ser 410	Glu	Trp	Gly	Asn	Asn 415	Ala	
Phe	Phe	Tyr	Tyr 420	Phe	Glu	His	Arg	Ser 425	Ser	Lys	Leu	Pro	Trp 430	Pro	Glu	
Trp	Met	Gly 435	Val	Met	His	Gly	Tyr 440	Glu	Ile	Glu	Phe	Val 445	Phe	Gly	Leu	
Pro	Leu 450	Glu	Arg	Arg	Asp	Asn 455	Tyr	Thr	Lys	Ala	Glu 460	Glu	Ile	Leu	Ser	
Arg 465	Ser	Ile	Val	LÀa	Arg 470	Trp	Ala	Asn	Phe	Ala 475	Lys	Tyr	Gly	Asn	Pro 480	
Asn	Glu	Thr	Gln	Asn 485	Asn	Ser	Thr	Ser	Trp 490	Pro	Val	Phe	Lys	Ser 495	Thr	
Glu	Gln	Lys	Tyr 500	Leu	Thr	Leu	Asn	Thr 505	Glu	Ser	Thr	Arg	Ile 510	Met	Thr	
Lys	Leu	Arg 515	Ala	Gln	Gln	Cys	Arg 520	Phe	Trp	Thr	Ser	Phe 525	Phe	Pro	Lys	
Val	Leu 530	Glu	Met	Thr	Gly	Asn 535	Ile	Asp	Glu	Ala	Glu 540	Trp	Glu	Trp	ГЛа	
Ala 545	Gly	Phe	His	Arg	Trp 550	Asn	Asn	Tyr	Met	Met 555	Asp	Trp	Lys	Asn	Gln 560	
Phe	Asn	Asp	Tyr	Thr 565	Ser	Lys	Lys	Glu	Ser 570	Суз	Val	Gly	Leu			
<210 <211 <212 <213 <220 <223	<pre>D> SE L> LE 2> TY 3> OF D> FE 3> OI 3> OI nu </pre>	EQ II ENGTH (PE: RGANI EATUH THER 1Cle: EQUEN	D NO H: 11 DNA ISM: RE: INFC ic ac	15 L25 Art: DRMAT cid s 15	lfici TION: seque	al 14- ence	-3 mu for	ıtant amir	: (A1 10 ac	.995/ zid 1	/S285	7G/A3 lues	328W/ 68-4	′¥332 142	G) BChE	
aaca	ataga	atc a	aaagt	ttto	cc ag	gctt	ccat	gga	atcag	jaga	tgtg	gaad	ccc a	laaca	ictgac	60
ctca	agtga	aag a	actgt	ttat	a to	ctaaa	atgta	a tgo	gatto	cag	caco	ctaaa	acc a	aaaa	atgcc	120
acto	gtatt	cga t	tatg	gatti	a to	gtgg	gtggt	ttt	caaa	actg	gaad	catca	atc t	ttac	atgtt	180
tato	gatgo	gca a	agttt	ctg	ge to	gggt	tgaa	a aga	igtta	attg	tagt	gtca	at g	jaact	atagg	240
gtgg	ggtgo	ecc t	agga	attct	t ag	gcttt	geea	a gga	aato	ctg	aggo	etcca	agg g	jaaca	tgggt	300
ttat	ttga	atc a	aacaç	gttgg	gc to	ettea	agtgg	g gtt	caaa	aaa	atat	agca	agc d	tttg	ıgtgga	360
aato	cctaa	aaa q	gtgta	aacto	ct ct	ttgg	gagaa	a agt	tccc	ıgag	cago	ettea	agt t	ageo	tgcat	420
ttgo	ettto	etc d	etgga	aagco	ca tt	catt	gtto	c acc	agag	jcca	ttct	gcaa	aag t	ggtt	ccttt	480
aato	gctco	ett g	gggcg	ggtaa	ac at	ctct	ttat	: gaa	igcta	ıgga	acaç	gaaco	gtt g	jaact	taget	540

US 9,206,403 B1

-continued

aaat	taoata	attactatoa	agagaatgag	aataaaataa	tapoatatat	+	600
aaau	lgaelg	gilgelelag	agagaatgag	acigaaalaa	leaagigiei	Lagaaalaaa	600
gatc	cccaag	aaattcttct	gaatgaagca	tttgttgtcc	cctatgggac	tcctttgggt	660
gtaa	actttg	gtccgaccgt	ggatggtgat	tttctcactg	acatgccaga	catattactt	720
gaac	ttggac	aatttaaaaa	aacccagatt	ttggtgggtg	ttaataaaga	tgaagggaca	780
tggt	ttttag	tcggtggtgc	tcctggcttc	agcaaagata	acaatagtat	cataactaga	840
aaag	aatttc	aggaaggttt	aaaaatattt	tttccaggag	tgagtgagtt	tggaaaggaa	900
tcca	tccttt	ttcattacac	agactgggta	gatgatcaga	gacctgaaaa	ctaccgtgag	960
gcct	tgggtg	atgttgttgg	ggattataat	ttcatatgcc	ctgccttgga	gttcaccaag	1020
aagt	tctcag	aatggggaaa	taatgccttt	ttctactatt	ttgaacaccg	atcctccaaa	1080
cttc	cgtggc	cagaatggat	gggagtgatg	catggctatg	aaatt		1125

<210> SEQ ID NO 16 <211> LENGTH: 375 <212> TYPE: PRT <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: 14-3 mutant (A199S/S287G/A328W/Y332G) BChE amino acid sequence for residues 68-442 <400> SEQUENCE: 16 Asn Ile Asp Gln Ser Phe Pro Gly Phe His Gly Ser Glu Met Trp Asn Pro Asn Thr Asp Leu Ser Glu Asp Cys Leu Tyr Leu Asn Val Trp Ile Pro Ala Pro Lys Pro Lys Asn Ala Thr Val Leu Ile Trp Ile Tyr Gly Gly Gly Phe Gln Thr Gly Thr Ser Ser Leu His Val Tyr Asp Gly Lys Phe Leu Ala Arg Val Glu Arg Val Ile Val Val Ser Met Asn Tyr Arg Val Gly Ala Leu Gly Phe Leu Ala Leu Pro Gly Asn Pro Glu Ala Pro Gly Asn Met Gly Leu Phe Asp Gln Gln Leu Ala Leu Gln Trp Val Gln Lys Asn Ile Ala Ala Phe Gly Gly Asn Pro Lys Ser Val Thr Leu Phe Gly Glu Ser Ser Gly Ala Ala Ser Val Ser Leu His Leu Leu Ser Pro Gly Ser His Ser Leu Phe Thr Arg Ala Ile Leu Gln Ser Gly Ser Phe 150 155 Asn Ala Pro Trp Ala Val Thr Ser Leu Tyr Glu Ala Arg Asn Arg Thr Leu Asn Leu Ala Lys Leu Thr Gly Cys Ser Arg Glu Asn Glu Thr Glu Ile Ile Lys Cys Leu Arg Asn Lys Asp Pro Gln Glu Ile Leu Leu Asn Glu Ala Phe Val Val Pro Tyr Gly Thr Pro Leu Gly Val Asn Phe Gly Pro Thr Val Asp Gly Asp Phe Leu Thr Asp Met Pro Asp Ile Leu Leu

Glu Leu Gly Gln Phe Lys Lys Thr Gln Ile Leu Val Gly Val Asn Lys

-continued

Asp	Glu	Gly	Thr 260	Trp	Phe	Leu	Val	Gly 265	Gly	Ala	Pro	Gly	Phe 270	Ser	Lys	
Asp	Asn	Asn 275	Ser	Ile	Ile	Thr	Arg 280	Lys	Glu	Phe	Gln	Glu 285	Gly	Leu	Lys	
Ile	Phe 290	Phe	Pro	Gly	Val	Ser 295	Glu	Phe	Gly	Lys	Glu 300	Ser	Ile	Leu	Phe	
His 305	Tyr	Thr	Asp	Trp	Val 310	Asp	Asp	Gln	Arg	Pro 315	Glu	Asn	Tyr	Arg	Glu 320	
Ala	Leu	Gly	Asp	Val 325	Val	Gly	Asp	Tyr	Asn 330	Phe	Ile	Сүз	Pro	Ala 335	Leu	
Glu	Phe	Thr	Lys 340	Lya	Phe	Ser	Glu	Trp 345	Gly	Asn	Asn	Ala	Phe 350	Phe	Tyr	
Tyr	Phe	Glu 355	His	Arg	Ser	Ser	Lys 360	Leu	Pro	Trp	Pro	Glu 365	Trp	Met	Gly	
Val	Met 370	His	Gly	Tyr	Glu	Ile 375										
<210 <211 <212 <213 <220 <223)> SE .> LE :> TY :> OF :> OF :> OI nu	EQ II ENGTH PE: CGANI EATUF THER CLEI) NO H: 96 DNA ISM: RE: INFC ic ac	17 56 Arti DRMAJ 21 s	lfic: TION : seque	ial : 14- ence	-3 mu for	ıtant amir	: (A1 10 ac	.99S/ zid r	/S28 resid	7G/A3 lues	328W/ 117-	[/] Y332 -438	G) BChE	
aatt	tta		taa	acat	c at	ott	acat	att	tato	nata	aca	attt	ot o	aato	agatt	60
9900				acat	.e at		acat	. 900		Jacy	geat			,9000	.999900	100
gaaa	ıgagı	. La l	.ugua	igrgi	.c aa	augaa	ictat	. agg	grgg	,grg	eeet	.agga		clag	Jerre	120
ccag	gaaa	ile c	lgag	gere	c aç	Jggaa	icalg	ggu	LLAL	LLG	alca	acaç	JLLS	gere	licag	180
tggg	jttca	iaa a	aaat	ataç	jc aç	geett	tggt	. gga	iaato	cta	aaaq	gtgta	ac t	ctct	ttgga	240
gaaa	igtto	cg g	gagca	igctt	c ag	gttag	geete	g cat	ttgo	ttt	ctco	tgga	ag c	catt	cattg	300
ttca	ccag	jag d	catt	ctgo	ca aa	agtgg	yttec	: ttt	aato	jctc	cttç	laac	ggt a	acat	ctctt	360
tatg	jaago	ta g	ggaac	agaa	ac gt	tgaa	actt <i>a</i>	ı gct	aaat	tga	ctg	gttgo	etc t	agag	Jagaat	420
gaga	lctga	aa t	aato	aagt	g to	ttag	jaaat	aaa	igato	ccc	aaga	aatt	ct t	ctga	atgaa	480
gcat	ttgt	tg t	ceee	tate	la as	actco	tttg	ggt	gtaa	act	ttgg	gtccc	jac c	gtgg	Jatggt	540
gatt	ttct	ca d	tgad	atgo	cc ag	gacat	atta	u ctt	gaad	ttg	gaca	attt	aa a	aaaa	leccag	600
attt	tggt	ad d	gtgtt	aata	aa ag	gatga	aggo	g aca	tggt	ttt	tagt	cggt	:gg t	gete	ctggc	660
ttca	ıgcaa	ag a	ataac	aata	ng ta	atcat	aact	aga	iaaag	gaat	ttca	nggaa	agg t	ttaa	aaata	720
tttt	ttcc	ag g	gagto	gagto	ya gt	ttgg	gaaag	g gaa	itcca	atcc	ttt	tcat	ta c	cacaç	Jactgg	780
gtag	jatga	atc a	agaga	accto	ja aa	aacta	accgt	gag	gcct	tgg	gtga	atgtt	gt t	adda	jattat	840
aatt	tcat	at g	geeet	gcct	t ge	gagtt	caco	aag	jaagt	tct	caga	atgo	idd e	aata	atgcc	900
tttt	tcta	act a	attt	gaad	ca co	gato	ctcc	: aaa	ctto	cgt	ggco	cagaa	atg g	gatgo	ıgagtg	960
atgo	at															966
<210 <211 <212)> SE .> LE :> TY	EQ II ENGTH (PE :) NO 1: 32 PRT	18 2												

- <212> IIFE: FKI <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: 14-3 mutant (A199S/S287G/A328W/Y332G) BChE amino acid sequence for residues 117-438

<400)> SH	EQUEN	ICE :	18											
Gly 1	Phe	Gln	Thr	Gly 5	Thr	Ser	Ser	Leu	His 10	Val	Tyr	Asp	Gly	Lys 15	Phe
Leu	Ala	Arg	Val 20	Glu	Arg	Val	Ile	Val 25	Val	Ser	Met	Asn	Tyr 30	Arg	Val
Gly	Ala	Leu 35	Gly	Phe	Leu	Ala	Leu 40	Pro	Gly	Asn	Pro	Glu 45	Ala	Pro	Gly
Asn	Met 50	Gly	Leu	Phe	Asp	Gln 55	Gln	Leu	Ala	Leu	Gln 60	Trp	Val	Gln	Lys
Asn 65	Ile	Ala	Ala	Phe	Gly 70	Gly	Asn	Pro	Lys	Ser 75	Val	Thr	Leu	Phe	Gly 80
Glu	Ser	Ser	Gly	Ala 85	Ala	Ser	Val	Ser	Leu 90	His	Leu	Leu	Ser	Pro 95	Gly
Ser	His	Ser	Leu 100	Phe	Thr	Arg	Ala	Ile 105	Leu	Gln	Ser	Gly	Ser 110	Phe	Asn
Ala	Pro	Trp 115	Ala	Val	Thr	Ser	Leu 120	Tyr	Glu	Ala	Arg	Asn 125	Arg	Thr	Leu
Asn	Leu 130	Ala	Lys	Leu	Thr	Gly 135	Cys	Ser	Arg	Glu	Asn 140	Glu	Thr	Glu	Ile
Ile 145	Lys	Сүз	Leu	Arg	Asn 150	Lys	Asp	Pro	Gln	Glu 155	Ile	Leu	Leu	Asn	Glu 160
Ala	Phe	Val	Val	Pro 165	Tyr	Gly	Thr	Pro	Leu 170	Gly	Val	Asn	Phe	Gly 175	Pro
Thr	Val	Asp	Gly 180	Aap	Phe	Leu	Thr	Asp 185	Met	Pro	Aap	Ile	Leu 190	Leu	Glu
Leu	Gly	Gln 195	Phe	LYa	Lys	Thr	Gln 200	Ile	Leu	Val	Gly	Val 205	Asn	Lys	Asp
Glu	Gly 210	Thr	Trp	Phe	Leu	Val 215	Gly	Gly	Ala	Pro	Gly 220	Phe	Ser	Lys	Asp
Asn 225	Asn	Ser	Ile	Ile	Thr 230	Arg	Lys	Glu	Phe	Gln 235	Glu	Gly	Leu	Lys	Ile 240
Phe	Phe	Pro	Gly	Val 245	Ser	Glu	Phe	Gly	Lys 250	Glu	Ser	Ile	Leu	Phe 255	His
Tyr	Thr	Asp	Trp 260	Val	Asp	Asp	Gln	Arg 265	Pro	Glu	Asn	Tyr	Arg 270	Glu	Ala
Leu	Gly	Asp 275	Val	Val	Gly	Asp	Tyr 280	Asn	Phe	Ile	Суз	Pro 285	Ala	Leu	Glu
Phe	Thr 290	Lys	Lya	Phe	Ser	Glu 295	Trp	Gly	Asn	Asn	Ala 300	Phe	Phe	Tyr	Tyr
Phe 305	Glu	His	Arg	Ser	Ser 310	Lys	Leu	Pro	Trp	Pro 315	Glu	Trp	Met	Gly	Val 320
Met	His														
<210 <211 <212 <213 <220 <223	0> SH L> LH 2> TY 3> OH 0> FH 3> OY B(EQ II ENGTH (PE: RGANI EATUF THER ChE r) NO H: 17 DNA SM: RE: INFO nucle	19 722 Arti DRMAJ	ific: FION	ial : 12- sequ	-7 mu ience	itant	: (A1	1995,	/F22	7A/S2	287G/	/A328	3W/Y332G
<400)> SI	EQUEN	ICE :	19											
gaag	gatga	aca t	cata	atto	gc aa	acaaa	agaat	gga	aaaq	gtca	gago	ggato	gaa c	ttga	acagtt

60

120

tttggtggca cggtaacagc ctttcttgga attccctatg cacagccacc tcttggtaga

US 9,206,403 B1

79

-continued

tatgcaaat cttgctgta gaactaga caagttte cagsttee aggateaga 240 atgragaace caacaatag cottgatga gactgttat attaaatgt atggstee 300 gaactaae caacaatge cottgatga agsttetge atggsgtg stateaaet 400 gaactaae gaacatag ggggggge caggatte taggatte aggaatea 400 gaagteeag ggaacagg ttaterga caacgteg cottgaga aggteeag 600 gaagteeag ggaacagg ttaterga caacgteg cottagga gaagteeg 600 gaagteeag ggaacagg ttaterga caacgteg cottagga gaagteeg 700 aacagaeg cottgggg aacteeta aggtee totggage at acteeta cgaagteeg 700 aacagaegt tageetge tategeeea teggaget tetgagaate 900 gaacageeag aggteeag tageetge tagegetee teggageatg acteeta 200 gaacageag tegeteege tategeeea teggaget teggagaatg gaegaata accagegt tageetge tategeeag aggtegge cotoggetga categetge 900 gacageeag actattee tyaacteg agaateete teggaggga 1100 gaacageag actattee tyaacteg acagees tagetggg attegee 1000 geggeteag actattee tagetgee aggegge 1000 geggetgag actaetee tageteea agaagette aggaaggg taacatee 1100 gaacageag actaetee tageagaatg acgeggeg atgegge atgegtg attegee 1100 aacaatage teggaagga atgegge gegeggaagg tagetggg agtegg atgege 1100 gaacageag actaetee tageagaagg tgeggeaat 1100 agaetgeeag actaetee tageagaagg tgeggeata 1100 agaetgeeag actaetee tageagaagg tgeggeata 1100 agaetgeeag actaetee tageagaagg tgeggeaat 1100 agaetgeag agaeteeag gaegteeag tgeggeaat 1100 agaetgeag ateseetge geeetgg geetgeg tageagaag tageage 1200 gaaatgeat tegeaaga tegegeeg tgggeaat ttgeaaata 1200 gaaatgeat tegeaagg caagetee agaegaag tagegeaa tageagaa 1200 ctaacetga atesegtg gaaatgeg tegeaage tageacteg acaasate 1200 gaaatgea tegeaagg caagetee agaegaag tagegegeaa tagegeaa 1200 gaaatgea tegeteea agaagat tegeggege tegeaaga tageagaa 1200 ctaacetga atesege agaagete tegesgeae tagegeed acaasate 1200 ctaacetga atesege agaagete tegetegge tegeaage 1200 ctaacetga atesege agaagete tegetegge tegeaage gaagaatese acaagetga 1200 ctaacetga atesege agaagetee tegeaaga tagesgeaa tagegeaace 1200 ctaacetga atesege agaagetee agaagaat tegesgeae tagesteeag 1200 ctaacetga atesege agaagetee tegesgeaeeg tegesgeee
adgtgggaace caacactgs ectedgga gaetgttt ateteaatg atggsttee 300 geaeteaae caacactgs ectedggag agtteteg etegggtgg titteeaaet 400 geaeteag gaacatag ggggggege etaggatet atggtggg gggggaetee 430 gaggeteag ggaacatggg titattgat caacagtgg etteggagae agtteteg 900 geaggteteg taggeteege tasgeteet etgggggga eatetett ggggggae actetett ggaggaege attggtgeg 400 accataggae teettggg tgaatet ggtegete ggatggeg etggggae attgetege 100 geagtetag taggetge taatgeteet ggtegete ggatggaege attgetege 100 geagtetag taggetge taaggeteet ggtegete gaaggeage gatggaege 400 accataggae teettggg tgaatett ggtegee taggaetet ggtegege taggaetee 100 geagtetag taggetge taaggetee tggtegete taggaege 100 geagtegga eteettggg tgtaattg ggtegete taggaaege 100 geagtegga eteettggg tgtaattg ggteggege teggaege 100 geagtegga eteettggg tgtaatett ggteggege teggatggaege 100 geagtegga eteettggg tgtaatett ggteggege teggaggaege 100 geagtegga teggaege atggetge 100 geagtegga eteettggg tgtaaett ggtegggege teggaggaege 100 geagtegga eteettggg tgtaaett ggteggege teggaege 100 geagtegga teggaege atggetge 100 geagtegga eteettgg eggetggg getegggege teggaege 100 geagtegga teggaege aggggaege atggtgege 100 geagtegga teggaege aggggaege atggetgege 100 geagtegga teggaege agggggaege atggggaege 100 geagtegga teggaege aggggaege atggeggaege 100 geagtegga atgeaggga atggetggg geteggggaege atggeggaege 1100 geagtegga gatgaege ggaegegga gggggaage gagaegegae 1120 cetgeeteg ageaegeg geaegegg eggaaegeg tgggaggaege agaageege 1120 cetgeeteg ataegegg eedeege eedeege asgeeteg aaggeege atggeggaege aagaegege 1120 geagtgaege agaegegg eedeege eedeege aaggeege aaggeegeg atggeggaegeege aaggeegeg 1120 geagtegga atggegeege aaggeegeg eedeege aaggeege agaegegeg atggeggeege aaggeegeg atggeggeege aaggeegeg agaegegge agaegegeg 1120 cetaectga ataegege eedeegee asgeege aaggeege aaggeegeg atggeegee aaggeegeg aaggeegeg aaggeegeg aaggeegeg aaggeege aaggeege aaggeegeg aaggeegege aaggeegeg aaggeegeg aaggee
geacataad caaaaaa aa da aa da ya aa da ya
gqaacatcat otttacatgt titatgatge aagtttotig otegggttga asgagttatt 420 gtagtgtcat tgaactatag ggtgggtgee ctaggattet tagetttege aggaateet 480 gaagttega tgaactatag ggtgggtgee ctaggattet tagetttege aggattee agaa 540 aattatagea otttagetgg aateettaa agtgtaace tettatggag aagtteegg 600 geagtteaa tgaectge tatgettee titggetgea acteettett tgaagetagg 720 aacagaacgt tgaectge tatgeteet uggtegetea cateettett ugaagtagg actgaata 740 ceceataggg oteettiggg tgaaactet uggtegeetea gaagaatag agattgaag attgaagt 940 geagteegg acatatteet tgaactteg ggtegeetea gaagaatag actgegggt 960 gtagtaggg acteettegg tgaaagtt ageggggg acteetteg agaagatag 960 gtagtaggg acteettegg agattet ageggggg agattette 900 gaactagaa gtagaggga actattet tgaacttg geeggggg agatgatteg 1620 aacataga tetacatag aaagaatt caggaaggg atgetggg atgetged tittecagaa 1600 gtagatgagt ttggaaagga atcateett titteataa cagactggg agatgateg 1200 cettgaacac agatteetee gaaggagaa ataatgeet titteetaa 1200 cettgaacac agatteetee gaaggagaa daaageet 1200 gaaatteg gaagaate ageteete gaagaaga daaatace taggacegaa 1200 gaaatteg gaagaate ageteete gaagaaga taggaagaat 1200 gaaatteg gaagaate cacaagaata gaegaagaag agaaatataca aaagacega 1200
giagigicai tigaactatag giiggigigic ciaggatit taqottigc agaaatcoi 480 gaggotcag gaacatggi titattigat caacagiig cicticagig giicaaaaa 540 aatatagaag cictigging aatootaa agigaactoi tottiggaga agitcogaa 660 attoigoaaa giigticogo taagotcoi tiggoogaa catoottia tigaaqotaggi 720 aacagaacji tigaactag tagotogo taggotgic ciggotgat catoottia tigaaqotaggi 720 aacagaacji tigaactag agatoccaa gaaatoot gigaggatag gaigagaa 730 accaatgot tigaactag agatoccaa gaatoot tiggoogaag attigitgi 840 coctatigga cictitiggi tigaactii gicogacog tigaatgaaga titigitgi 940 gicaattaa agatoccaa gaattot tigaogagati tigaagaaatgi 1020 aacaatagi toaactag aaagaatt caggaggit taaaatat titiccaggi 1080 gicagdigat tigaacata gatocotot titoataa cagacaggi agatgatagi 1100 aqacatgaa attacega goottiggi gidagdit titigaaga attagot 1100 coctgootiga agitacaca gaagtotca gaatgaga atagotta 1120 coctgootiga agitacaca agatocotog gagaggi giggaggat gootgagat 1200 coctgootiga agitacaca gaagtotca gaatgagaa atagotat 1200 coctgootiga agitacaca gaagtotca gaatgagaga tagagatagi 1200 coctgootiga agitacaca gaagtotca gaatgagaga tagagatagi 1200 coctgootiga agitacaca agatocot gigacagat gagagatagi catigoo gaaattag tigtoota agaagaacgi coggaagga gigaggat gootgagat 1200 coctgootiga agitacaca agatocot gigacaatga gaagaatag acaacoo saaataga cocaagagat cacaagtig cotgotaa acaagoo gaaattag tigtoota agaacaatgi cacaagaga tatagoo tiggaadtag tigtoota agaagaatgi cotgigo caaaatga acaaacata tigtoo ciaacotiga aacaagagt cacaagagat agagaaatag gaaatatga tigaagaagaa 1620 tiggaagtaga aagaagaat cactoocig gaacaatga gaaatatga tigaagaagaa 1620 tiggaagtaga aagaaggat catagotig aaagaagatgi cagaagatga gaaattag tigaagaagaa 1620 tiggaagtaga aagaaggat catagotig aaagaagat tigtiggigot to 1722 <200 Stop IN No 20 <200 Stop IN No 20 <200 25 An Incou Tir Val Phe Oly Oly Tir Val Tha An Phe Luu Oly Ile Pro 20 20 20 20 20 20 20 20 20 20
<pre>gaggctccag ggaacatggg tttattgat caacagtgg ctcttaag ggttcaaaa 540 aatatagcag cctttggtgg aatcctaaa agtgtactc tctttggaga agttccaga 600 gcagcttag ttagctga tttgcttt ctggaggca ataattgt caccagagce 660 attctgcaaa gtggttccg taatgtcct tgggcggtaa catctttt tgaagctagg 720 aacagaacgt tgaactaa agatcccaa gaattct tgaatgaag attgtgt 940 ccctatgggg ctcctttggg tgtaaacttg ggtggtctg ggagggg attgtggg 940 gttaacaag atgaagaga atggtttta ggtcggacgg ggagggg attgttccaag 100 gtgaagaggat tcatactg aaagaatt cagaacgg ggagggg attgttccaag 100 gtgaagaggat tagaacaa gaactct dagaagag atagttccagaa 1140 agacctgaa actaccgtg ggcttggg gatgtgtg gggggt gatgatata ttctcaatg 1200 cctgccttgg agtcaccaa gaagttca ggaaggag atagtgct tttcaatg 1200 cctgccttgg agtcaccaa gaagttca ggaagggag atagtgct tttctact 1260 tttgaacac gatccacca actccgtgg ccgaacgga ggagggg gatgagat 1320 gaaatgaat tgtcttgg ttacccag gaaggtcg gaagggag ataatgcc 1320 gaaatgaat tgtcttgg ttacccag gaaggag ccgggagg gaagagaa gaagacga 1440 aatgagact agaacaaag cacaagctg cggaaggag ataatgcc 1320 gaaatgaa ataaggaagat cacatggg ccggaaggag ataatgcc 1320 gaaatgaa agaagaat cacaggaag tgggaagtga gaagaaga 1440 aatgagact agaacaaag cacaagctg cggaaggag ataatgac aaagacca 1600 tttgaacac gaacaacag cacaagctg gaacgaacg gaaaattga tggaggag 162 ttgagagga agaagaag cacatgcgg aacaattac tagtggaacg aaaataga 1620 tuggagagg aagaagaa gaagaaga gaagaaga tggtgggt tc 1722 cloo SRO ID NO 20 clio Lother 574 clio SRO ID NO 20 clio Lother 574 clio Lother 574 clio Lother 574 clio Lother 72 clio SRO ID NO 20 clio Lother 72 clio Lother 72 clio SRO ID NO 20 clio L</pre>
aatatagaag cotttygtyg aatootaa agtytaato totttygaga agttoogga 600 geogottoog ttagootga tttgottot ootggaagaa attatut cacagagee 600 attotgaaa gtygtoogo taatgotoo tggaoggaa catototta tgaagaaga 700 aacagaacgi tgaactago taaatgaat ggtogotoo gagaagaaga gaotgaaata 700 attaagga otoottoggg tgaaattat ggtoogoo tggatggtga tttotoact 900 geoatgoong acatatact tgaactggg cattggttg googoo tggatggtga tttotoact 900 getaataag atgaaggaa tggtttta gtooggaggt cacagatgga ttggtggg 960 gttaataag atgaaggaa tggtttta gtooggaggt cacagatgga 1020 aacaatagta tataactag aaagaatt caggaaggt taaaatat tttocagaa 1020 agaactgoga acattaat tgaacggg aggtggg gootgog 100 gtgaaggag ttggaaggaa atcoatcot tttotataa cagaacggg agatgaa 1140 agaactgaa acaacggta ggoottggg gatgtgtg gggagtata tttocaga 1140 agaactgaa acaacgga ggoottggg cagatggag tggaggag gaaggaa 1320 gaattigaa gtagacaa actoogtg goottggg cagaagga gaatataa ttocatago 1320 gaattigaa ttgtottigg tttacoctag gaaggagga taataca aaagoogga 1380 gaattiga ttgtottigg ttacoctag atgoggoagaa taggaatat tggaaataa 1500 ctaacotga atacaggta aggagatg cocagaatgg tggagatga gaagaata 1500 ctaacotga atacagga agaagaag tggagaa taggagaa caaattag 1500 ttotggagatga acacaggta acaaggtg coctgotta aaagaact taggaaataa 1620 tggaggaga agacagaga agaagaaga tggtggga to 2 372 210> SEO ID NO 20 211> LEMMFNI SY1 212> OFFF PRT 213> OFFF PRT 213> OFFFF PRT 214> Calmor Marine Sy1 214> Calmor Marine Sy1 215> OFFFF PRT 216> Calmor Marine Sy1 216> Calmor Marine Sy1 217> Calmor Su2UNCE: 20 Clu App App Ile Ile Ile Ala Thr Lyo App Oly Lyo Val App Oly Mat 150 216> Calmor Marine Sy1 216> Calmor Marine Sy1 217 Ala Clin Pro Pro Leu Gly Arg Leu Arg Phe Lyo Lyo Pro Gln Ser 250 250 Crine Ty0 Ty Ser App Ile Typ Arn Ala Thr Lyo Tyr Ala Aen Ser 50 Cyo Cyo Glin Aan Ile App Oln Ser Phe Pro Gly Phe His Gly Ser Glu
<pre>gcacttcag ttagcctgca tttgetttet octggaagee atteattgtt caccagagee 660 attetgoaaa gtggtteege taatgeteet tgggeggtaa catetetta tgaagetagg 720 accagaecgt tgaaettage taattget ggtggetet gaagaatag gaetgaaata 780 atteagtgte ttagaattaa agateceea gaaattette tgaagage attegttge 840 coctatggga eteettigg tgtaaactt ggteggegg tgggaggga ttttgeteggg 960 gtaataaag atgaaggae atggtttta gteggtggt otcetgget cacaaagat 1020 aacaatgta teataetag aaaagaatt eaggaaggt taaaattat ttteeaga 1080 gtgaaggag ttggaaagga ateeteett ttteattae cagaetggt agatgae 1140 agaecegaa actaeegtg ggeettggg tgatgtgt gggggat ataateet ttteeaga 1200 cotgoettgg agtteeeea gaegteet gaagggegga ataatgeet ttteeata 1200 cotgoettgg agtteeeea gaegteegg eeggaaggg ataataeee aaageeegg 1380 gaaattgea ttgetettgg tttaceeegg tgggaaga taggaetee 1220 gaaatgaat eagaeaatag cacaagetg eeggeaaat teggaatega 1440 aatgagaet eagaeaatg cacaagetg eeggeaaat teggeggaa 1620 tteggaaet agaeaaatg cacaagetg eeggeaaat teggtgeet acaaageeaga 1620 tteggaaet agaeeaatg cacaagetg geettggg eegteet aaeeagteg gaaaatae 1680 tttaacgat accatgee aacaagetg geettgegte te</pre>
attctgcaaa gtggttccgt taagtctct tgggoggta catctttt tgaagtag 920 accagaacgt tgaacttag taaattgac ggtggtgctca gagagaag gactgaaata 780 atcaagtgte ttagaactaa agaccacaa gaacttet tgaaggag attggtgg ttttetcaet 900 gacatgccag acatattaet tgaacttgg caattaaa aaaccagat tttggtggg 940 gttaataaag atgaaggaa atggttttta gtoggtggtg ctcctgget cagcaagaat 1020 aacaatagta tcatactag aaagaatt caggaaggt taaaatatt ttteccaga 1080 gtgagegag ttggaaagga atcateet ttteataa aaaccaggt gagagaagg 1140 agaceegaa actaceega ggeettggg gaetgtggg ggatgtag tgatgaeg 1140 agaceegaa actaceega ggeettgge cagaatgga tgagagat 1200 ceteereega ggeettegg eegaagge atggggga ataateet tteereega 1200 ceteereega ggeettegg eegaagga teggagga ataateee aaageega 1300 gaaatteg gtagaecaa gaagteete gaaaggag ataataca aaageeega 1300 gaaatteg gtagaecaa agtgaagg eegagg ggegaagga tgagagatag 1300 gaaatteg gtagaecaa agtgaaegg tgggaaat ttegaaaat tgggaatea 1500 ctaaceteg ateceeaa gaegteeg eeggeae taggegatga gaagaaca 1600 tteggaagteg ataacaag cacageeg eeggeae taggegee gaaaattag 1500 tteggaagtega aageaggat eegegege taggegaa taggegeegaa 1620 teggaagtgga aageaggat eeaeggaa teggeete 1722 <100 SEO ED NO 20 <100 SEO EN ENFENT <10 SEO ENFENTE <10 SEO EN ENFENT <10 SEO ENFENTE <10 SEO ENFENTE
aacagaacgt tgaactage taactgeet ggetgeete ggagaatg gaetgaata 780 atcaagtgee ttagaaata agateeeea gaaatteet egaatgaage attggtgee 940 gaetgeeag acatataet tgaactgge caattaaa aaaceeagat tteggggg 960 gttaataaag atgaaggae atggtttta gteggtggt eteetgget eagaagat 1020 aacaatagta teataeeag aaaagaatt eagaaggt taaaaatat tteeeagaa 1080 gtgagtgag tteggaaagga acceeteet tteeatae eagaeegge agatgaeeag 1140 agaeedgaa aetaeegga ggeettggg gaegtgtgg gggatataa tteeataet 1220 ceegeetgg agteeaeaa gaagteee gaatgggga ataatgeet tteeaaat 1240 ttegaacaee gaeeeeaa aeteeegg geeetggg gaegtgeg gggagtag deaggega 1200 cetgeetegg agteeaeaa gaagteee gaaggagga ataatgeet tteetaetae 1200 cetgeetegg agteeaeaa gaagteee gaaggagga gaggagga deagteee aaageeegg 1380 gaaatteg gtagaeea agtegaaeegg tgggaaat ttgeaaaat tegegaaeaa 1200 cetaeeetgg agteeaeaa gaagteeteg gaaggaaga ataatgeete aaageeegg 1380 gaaatteg gtagaeeaa geaeggeg eetgege eetgeeaaat tegegaaeaaata 1500 cetaaceteg aaacaatag eacaageeg geeetgeg eetgeeaa tegeggeeaaa tegeggaaeaateaa 1600 tteggaaet eatteeetee gaaagaagaa tegeggaae taegtgeeea aacaageega 1620 teggagatgga aageaggat eeeaggeg gaaatatae tegaggaaeaaataa 1680 tteaggaae eatteee gaaagaagaa tegeggaeetee 1722 <2100 SEO ED NO 20 <2110 SEO ED NO 20 <2110 SEO ED NO 20 <2110 SEO ED NO 20 <2111 SEO ENFITS 77 <2120 SEO ED NO 20 <2120 SEO EN EN EN <2120 SEO EN EN EN <
atcaagtgtc ttagaaata agatcccca gaaattctt tgaatgaag attgttgte 840 coctatggga ctotttggg tgtaaactt ggtogacga tggttggg tgtttctcact 900 gacatgocag acatatact tgaactgga caattaaa aacocagat tttggtggg 960 gttaataaag atgaaggga atggtttt gtoggggg tocotggct cagaaagat 1020 aacaatagta toataactag aaaagaatt caggaaggt taaaatat ttttccagga 1080 gtgagtggat tggaaagga atccatect tttoattac cagactggg aggtgatag 1140 agacctgaaa actacogtga ggecttggg gatgttgt gggattata ttcatatg 1200 cotgecttgg agttcaccaa gaagtetca gaatgggga ataatgectt tttoatat 1260 tttgaacaco gatoctocaa actocgtg coagaatgg tgggagtgat goaggegat 1320 gaaattgaa ttgtcttgg ttacccag gaaggaag ataatgect tttoataat 1500 ctagaattga ttgtcatca ggaaacgg tgggaaat ttgcaaaata tgggaatcag 1500 ttotggaact agaacaatag cacaaggetg coctggatag aaatatga tggaagaga ataagagact agaacaatag cacaaggetg gaagtataa ttogagaacga 1620 ttotggaact cattttto aaagtcttg gaaatgaag gaaatatga tgaagcaga 1722 <210> SEQ ID NO 20 <211> LENGTH: 574 <212> VTPE: PRT <212> VTPE: PRT <222> VTPE: PRT <222> VTPE: PRT <223> OTHENNENTION: 12-7 mutant (A1995/F227A/S287G/A328W/Y332U) BCHE amino acid sequence <200> SEQUENCE: 20 Gu Aap Asp Ile Ile Ala Thr Lys Asn Cly Lys Val Arg Cly Met 15 Aon Leu Thr Val Phe Gly Gly Thr Val Thr Ala Phe Leu Gly Ile Pro 20 Ty Ala Clh Pro Pro Leu Gly Arg Leu Arg Phe Lys Lys Pro Clh Ser 50 Cy Cys Ch Da An Ile App Glh Ser Phe Pro Gly Phe His Gly Ser Glu
ccctatggga ctcctttggg tgtaaacttt ggtccgacog tggatggtg ttttctcact 900 gacatgccag acatatact tgaacttgga caatttaaa aacccagat tttggtgggg 960 gtaataaag atgaagggac atggtttta gtcggtggt ctcctggct cagcaagat 1020 aacaatagta tcatacatag aaaagaatt caggaaggt taaaaatat ttttccagga 1080 gtgagtgag ttggaagga atcatcct tttcataca cagactggg agatgatcag 1140 agacctgaaa actaccgtga ggccttggg gatgtgtg gggattata tttcatatgc 1200 cctgccttgg agtcaccaa gaagtcca gaagtgcg cagaatgga tgggaggat gcatggctat 1320 gaaattgaat ttgtcttgg tttacctcg gaagaggag ataatacca aaaagccgga 1300 gaaattgaat tggcatcat agtgaacag tggggaatat tggaaacta agtggaatca 1440 aatgagact agaacaatag cacaagtgg cctgtctca aaagcactga acaaagaca 1500 ctaaccttga atacagagt cacaagatg ggaatata tggagaaca 1620 ttggaagtga aagcaggat ccatagctg gaaatagaag gaaatatga tgaagacga 1620 ctggagagtga aagcaggat ccatagctg gaagtgg ctggggatgat gaagacga 1620 ctggaagtga aagcaggat ccatagctg gaaagaag tggtggg ctggggcat 1722 ctlaaccttga atacagaag agaagaag tggtggg gaatgtgg gaagtcggaa 1620 ctggaagtga aagcaggat ccatagcag gaagatgacg gaaagatga 1620 cttaacctgaca gaagaagat tggtggggt cc 1722 ctlaacctgaca gaagaag tggcagaag 1620 ctlaa
gacatgccag acatatact tgaacttgg caatttaaa aaacccagat tttggtggtg 960 gttaataaag atgaagggac atggtttta gtcggtggt ctcctggctt cagcaagat 1020 aacaatagta tcatacatag aaaagaatt caggaaggt taaaatatt ttttccagga 1040 ggagtgagt ttggaaagga atccatcott tttcataca cagactgggt agtggtat g 1200 cctgcottgg agtccacaa gaagttca gaatgggg agtgggagtata tttcatatag 1200 cctgcottgg agtcaccaa gaagttcag gacggggag ataatgccat tttctactat 1200 gaaattgga ttggtdg ttaccacaa gaagtcag gaggggggag ataatgccat agggaaca 1320 gaaattgg gtagatcaa agtggaagg tgggcaaat ttgcaaaata tggggacta 1440 aatgagact agaacaatag cacaagcgg cctgtctta aaagcactgg accaaaaatat 1500 ctaaggat catacagag cacaagtgg cctgtctaa aaagcactgg accaaaatt 1500 ctaagagata accatgcag gaagat ccatcgctg gaaagaac tacgtgcca acaagtgcag 1620 tttggaact gataccaagag agaagat ccatcgctg gaacaataca tgatggactg gaaaaataca 1620 ttggaagtgga aagcaggat ccatcgctg gaacaataca tgatggactg gaaaaataga 1620 ctloo SEQ ID NO 20 1722 c210> SEQ ID NO 20 1722 c210> SEQ IDN N21 25 c220> EAUREINE 10 c220> EAUREINE 10 c220> EAUREINE 10 c210> SEQUENCE: 20 10
gtaataaag atgaaggga atggtttta gtoggtggg ctoctggott cagaaaga aacaatagta toataactag aaaagaatt cagaaggtt taaaaatat tttoccagga gtgagtgag ttggaagga atootoott ttootatao cagactggg agatgatoon gtgagtgag ttggaagga atootoott ttootatao cagactggg agatgatoon agacotgaaa actaocgtg ggoottggg gatgttgt ggggattata ttootatoo cotgoottg agtocacaa gaagtotca gatgggga ataatgoott ttootatat 1200 cotgoottg agtocacaa gaagtotca gatgggga ataatgoott ttootata gaaattgat ttgtottigg ttaccot gaagagag ataatgoot ttootata gaaattga ttgtottigg ttaccot gaagagag ataataca aaaagcoga gaaattga gtagatcoa agtgaacgg coggootta aagoaatat tggaacaa atagagact agaacaatg cacaaggtg cotgootta aaagacatga cacaatgo ctaacottga atacagagt cacaaggtg cotgootta aaagacatga cacaatgo ttgggagtgga agcaggat ccatagotg gaataatac tagtggoot a caaatgo ttgggagtgga agcaggat ccatagotg gaataatac tagtggoot a caaatgo ttaacgat accatgoa gaagaaagt tgtggggot to 1722
aacaatagta tataacatag aaaagaattt caggaaggtt taaaatatt ttttccagga 1080 gtgagtgagt ttggaaagga atcatcatt tttattaa cagactggg agatgataa aqacctgaa actaccgtg ggccttggg gatgtgtg ggggatataa tttatatag cctgccttgg agtcaccaa gaagtotca gaatggggga ataatgcctt tttctattat gaaattgaa ttgctttgg ttacccag gagggggaa ataatgcctt tttctatat gaaattgaa ttgctttgg ttaccctg gaaagaagg tggggagga gaatgggaggat g gaaattga gtagatccat agtgaacgg tgggcaaat ttgcaaaata tgggaatca atagagact agaacaatg cacaagatg ccgtcttca aaagcacga acaaagaa foo ctacactga atacagagt aacaagaata atgacgaac tacgtgcta acaatgcga ttgggagtgga agcaggatt ccatcgctgg aacaataga tagtaggacgaa ttgggagtgga agcaggatt ccatcgctgg aacaataca tggtggacaa ttgggagtgga agcaggatt ccatcgctgg aacaataca tggtggacaa ttgggagtgga agcaggatt ccatcgctgg aacaataca tggtggacgaa ttgaggagtgga agcaggatt ccatcgctgg aacaataca tggtggacgaa ttgagstgga agcaggatt ccatcgctgg aacaataca tggtggacgaa ttaacgatt acatagcaa gaagaagat tgtgtgggt t club SEQ ID NO 20 club Apg Apg Ile Ile Ile Ala Thr Lys Asn Gly Lys Val Arg Gly Met 1 5 Asn Leu Thr Val Phe Gly Gly Thr Val Thr Ala Phe Leu Gly Ile Pro 20 Tyr Ala Gln Pro Pro Leu Gly Arg Leu Arg Phe Lys Lys Pro Gln Ser 400 - SEQUENCE: 20 Glu Asp Asp Ile Ile The Ala Thr Lys Asn Gly Lys Val Arg Gly Met 1 5 Asn Leu Thr Val Phe Gly Arg Leu Arg Phe Lys Lys Pro Gln Ser 400 - SEQUENCE: 20 Gry Ala Gln Pro Pro Leu Gly Arg Leu SP He Lys Lys Pro Gln Ser 50 Cys Cys Gln Asn Ile Apg Gln Ser Phe Pro Gly Phe His Gly Ser Glu
ggaggtggag ttggaaagga atcateett ttteattaea cagaetgggt agtgatea 1140 agaeetgaa aetaeegga ggeettggg gatgtgtg gggattaa ttteatage 1200 cetgeetgg agteeeea aeteeggg eeagaatgga tgggaggag geatggeta 1320 gaaattgaat ttgtettgg tttaeeteg gaaagaagag ataattaeae aaaageegg 1380 gaaattgaa gtagateet agtgaaaegg tgggeaaatt tgeaaaata tgggaatee 1440 aatgagaete agaacaatag eacaagetgg eetgetea aaageeetga acaaaatat 1500 etaeeetga ateeggag aageetgg eetgetee aaageaetga eeaaaatat 1500 etaeeetga ataeagagte aacaagaeta atgeagaae taegtgetea eeaaatat 1500 tteggaagtgga aageaggat eeategteg gaaatgeag gaaatatga tgagaeega 1620 tgggagtgga aageaggat ceategetg gaaatgeag gaaatatga tgagaeega 1620 tgggagtgga aageaggat eeategetg gaaatgeag gaaatatga tgagaeega 1620 tteaeetta eeategeag gaaagaagat tggggggt te 1722 <210> SEQ ID NO 20 <211> LENOTH: 574 <212> TYPE: PRT <212> OF EATURE: <223> OF HER INNORMATION: 12-7 mutant (Al99S/F227A/S287G/A328W/Y332G) BChE amino acid sequence <400> SEQUENCE: 20 Glu Asp Asp Ile Ile Ile Ala Thr Lys Asm Gly Lys Val Arg Gly Met 1 5 10 15 Asm Leu Thr Val Phe Gly Gly Thr Val Thr Ala Phe Leu Gly Ile Pro 20 30 Tyr Ala Gln Pro Fro Leu Gly Arg Leu Arg Phe Lys Lys Pro Gln Ser 5 400 45 Leu Thr Lys Trp Ser Asp Ile Trp Asm Ala Thr Lys Tyr Ala Asm Ser 50 Cys Cys Gln Asm Ile Asp Gln Ser Phe Pro Gly Phe His Gly Ser Glu
agacctgaa actaccgtga ggoottggg gatgttgt ggggattata tttcatatg 1200 cotgcottgg agttcaccaa gaagttota gaaggggaa ataatgoott tttctatat 1260 tttgaacacc gatcotccaa acttcogtgg ocagaatgga tgggagtgat goatggotat 1320 gaaattgaa ttgtotttgg tttaccotg gaaagaagag ataattacac aaaagoogga 1380 gaaattga gtagatcat agtgaacgg tgggcaaat ttgcaaaat tgggaatca 1440 aatgagact agaacaatag cacaagotgg octgtotta aaagoactga acaaaatat 1500 ctaaccttga atacagagt aacaagaata atgacgaaac tacgtgota acaaagata 1500 ctaaccttga atacagagt cacaagottg gaatgacag gaaatatga tgaagcagaa 1620 ttgggagtgga aagcaggat ccatcgotgg aacaataca tggtggct gaaaaatcaa 1680 tttacggat acaatagcaa gaaagaaagt tgtgtgggt tc 1722 <210> SEQ ID N0 20 <211> LENOTH: 574 <212> TVF: PRT <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: 12-7 mutant (A1995/F227A/S237G/A328W/Y332G) ECHE amino acid sequence <400> SEQUENCE: 20 Glu Asp Asp IIe IIe IIe Ala Thr Lys Asn Gly Lys Val Arg Gly Met 1 0 15 Asm Leu Thr Val Phe Gly Gly Thr Val Thr Ala Phe Leu Gly IIe Pro 20 Tyr Ala Gln Pro Pro Leu Gly Arg Leu Arg Phe Lys Lys Pro Gln Ser 35 Asy Ley Trp Ser Asp IIe Trp Asn Ala Thr Lys Tyr Ala Asn Ser 50 Cys Cys Gln Asn IIe Asp Gln Ser Phe Pro Gly Phe His Gly Ser Glu
cctgccttgg agttcacca gaagttctca gaaggggaa ataatgcctt tttctactat 1260 tttgaacacc gatcctccaa acttccgtgg ccagaatgga tgggagtgat gcatggctat 1320 gaaatttga ttgtctttgg tttacctctg gaaagaaga ataattacac aaaagccgga 1380 gaaatttga gtagatccat agtgaaacgg tgggcaaatt ttgcaaaata tgggaacca 1440 aatgagact agaacaatag cacaagctgg cctgtcttca aaagcactga acaaaaatt 1500 ctaaccttga atacagagt aacaatgac agaaagaag ataattaca cacaatgtcga 1620 tgggagtgga aagcaggatt ccatcgctgg aacaattaca tgatggactg gaaaaacaa 1680 tttaacgatt accatagcaa gaaagaagt tgtgtgggt tc 1722 c210> SEO ID NO 20 1722 c211> LENGTH: 574 1230 c220> FEATURE: 223 c400> SEQUENCE: 20 Glu Asp Asp Ite Ite Ite Ala Thr Lys Asn Gly Lys Val Arg Gly Met 1 1 10 15 Asn Leu Thr Val Phe Gly Gly Thr Val Thr Ala Phe Leu Gly Ite Pro 20 20 Tyr Ala Gln Pro Pro Leu Gly Arg Leu Arg Phe Lys Lys Pro Gln Ser 40 45 Leu Thr Lys Trp Ser Asp Ite Trp Asn Ala Thr Lys Tyr Ala Asn Ser 50 60 Cys Cys Gln Asn Ite Asp Gln Ser Phe Pro Gly Phe His Gly Ser Glu 5
tttgaacacc gatcttcaa acttcogtg ccagaatgga tgggagtgat gcatggctat 1320 gaaattgaa ttgttttgg tttaccttg gaaagaagag ataattacac aaagccaga 1380 gaaatttga gtagacca agtgaaacgg tgggcaaatt ttgcaaaata tgggaatca 1440 aatgagact agaacaatag cacaagctgg cctgtcttca aaagcactga acaaaatat 1500 ctaaccttga atacagagt aacaagata atgacgaac tacgtgctca acaatgtega 1560 ttctggacat catttttcc aaagtctg gaaatgacag gaaatatga tgagagcagaa 1620 tgggagtgga aagcaggatt ccatcgctgg aacaattaca tgatggactg gaaaaatcaa 1680 ttaacgatt acaatagcag gaaagaagt tgtgtgggte te 1722 <210> SEQ ID NO 20 <211> SEQ ID NO 20 <212> TYPE: PRT <213> ORGNISM: Artificial <220> FPATURE: <223> OTHER INFORMATION: 12-7 mutant (A1995/F227A/S287G/A328W/Y332S) BChE amino acid sequence <2400> SEQUENCE: 20 Glu Asp Asp Ite Itle Itle Ata Thr Lys Asn Gly Lys Val Arg Gly Met 1 5 Asn Leu Thr Val Phe Gly Gly Thr Val Thr Ala Phe Leu Gly Itle Pro 20 Tyr Ala Gln Pro Pro Leu Gly Arg Leu Arg Phe Lys Lys Pro Gln Ser 35 Asn Leu Thr Var Phe Gly Gly Thr Val Thr Ala Phe Leu Gly Itle Pro 20 Tyr Ala Gln Pro Pro Leu Gly Arg Leu Arg Phe Lys Lys Pro Gln Ser 35 Leu Thr Lys Trp Ser Asp Ite Trp Asn Ala Thr Lys Tyr Ala Asn Ser 50 Cys Cys Gln Asn Ite Asp Gln Ser Phe Pro Gly Phe His Gly Ser Glu
<pre>gaattgaat ttgctttgg ttacctcg gaagaagaag ataattacac aaaagcoga 1380 gaaatttga gtagatccat agtgaacog tgggcaatt ttgcaaaata tgggaacca 1440 aatgagact agaacaatag cacaagctgg cctgtcttca aaagcactga acaaaaata 1500 ctaaccttga atacaagagt aacaagaata atgacgaaa tacgtggtca acaatgtcag 1620 ttctggacat catttttcc aaaagtctg gaaatgacag gaaatattga tgaagcagaa 1620 tgggagtgga aagcaggatt ccatcgctgg aacaattaca tgatggactg gaaaaatcaa 1680 tttaacgatt acactagcaa gaaagaaagt tgtgtgggtc tc 1722 </pre>
<pre>gaattttga gtagatccat agtgaacgg tgggcaatt ttgcaaata tggggatcca atgggactc agaacaatg cacaagctg cctgtctta aaagcactg acaaaatat tctggacat catttttcc aaagtcttg gaatgacag gaatattga tgagacgagaa tactgggagtgga aagcaggatt ccatcgctgg aacaattaca tgatggactg gaaaaatca tgggggtgga aagcaggatt ccatcgctgg aacaattaca tgatggactg gaaaaatca ttaacgatt acactagcaa gaagaaagt tgtgtgggtc tc ttaacgatt acactagcaa gaagaaagt tgtgtgggtc tc t210> SEQ ID N0 20 <211> LENGTH: 574 <212> TYPE: PR 213> ORGANISM: Artificial <220> FEATURE: <233> OTHER INFORMATION: 12-7 mutant (A1995/F227A/S287G/A328W/Y332G) BChE amino acid sequence <400> SEQUENCE: 20 Glu Asp Asp IIe IIe IIe Ala Thr Lys Asn Gly Lys Val Arg Gly Met 1 5 Asn Leu Thr Val Phe Gly Gly Thr Val Thr Ala Phe Leu Gly IIe Pro 20 Tyr Ala Gln Pro Pro Leu Gly Arg Leu Arg Phe Lys Lys Pro Gln Ser 35 Leu Thr Lys Trp Ser Asp IIe Trp Asn Ala Thr Lys Tyr Ala Asn Ser 50 Cys Cys Gln Asn IIe Asp Gln Ser Phe Pro Gly Phe His Gly Ser Glu</pre>
aatgagacte agaacaatag cacaagetgg eetgtettea aaageaetga acaaaaata 1500 ctaacettga atacagagte aacaagaata atgaegaaa taegtggetea acaatgtega 1560 ttetggacat eattittee aaaagtettg gaaatgaeag gaaatattga tgaageagaa 1620 tgggagtgga aageaggatt eeategetgg aacaattaea tgatggaetg gaaaaateaa 1680 tttaacgatt acaetageaa gaaagaagt tgtgtgggte te 1722 <210> SEQ ID NO 20 <211> LENOTH: 574 <212> TYPE: PPT <212> ORGANISM: Artificial <220> FEATURE: <220> FEATURE: <220> SEQUENCE: 20 Glu Asp Asp II e II e II e Ala Thr Lys Asn Gly Lys Val Arg Gly Met 1 5 10 15 Asn Leu Thr Val Phe Gly Gly Thr Val Thr Ala Phe Leu Gly II e Pro 20 25 30 Tyr Ala Gln Pro Pro Leu Gly Arg Leu Arg Phe Lys Lys Pro Gln Ser 40 40 45 Leu Thr Lys Trp Ser Asp II e Trp Asn Ala Thr Lys Tyr Ala Asn Ser 50 Cys Cys Gln Asn II e Asp Gln Ser Phe Pro Gly Phe His Gly Ser Glu
ctaaccttga atacagagte aacaagaata atgacgaac taegtgetea acaatgtega 1560 ttetggacat eatttttee aaaagtettg gaaatgacag gaaatattga tgaagcagaa 1620 tgggagtgga aageaggatt eeategetgg aacaattae tgatggaetg gaaaataea 1680 tttaacgatt acactageaa gaaagaaagt tgtgtgggte te 1722 <210 > SEQ ID NO 20 <211 > LENGTH: 574 <212 > TYPE: PRT <213 > ORGANISM: Artificial <220 > FEATURE: <223 > OTHER INFORMATION: 12-7 mutant (A1995/F227A/S287G/A328W/Y332G) BChE amino acid sequence <400 > SEQUENCE: 20 Glu Asp Asp Ile Ile Ile Ala Thr Lys Asn Gly Lys Val Arg Gly Met 1 5 5 10 10 25 Asn Leu Thr Val Phe Gly Gly Thr Val Thr Ala Phe Leu Gly Ile Pro 20 7yr Ala Gln Pro Pro Leu Gly Arg Leu Arg Phe Lys Lys Pro Gln Ser 40 40 45 Leu Thr Lys Trp Ser Asp Ile Trp Asn Ala Thr Lys Tyr Ala Asn Ser 50 Cys Cys Gln Asn Ile Asp Gln Ser Phe Pro Gly Phe His Gly Ser Glu
ttctggaat atttttcc aaaagtctg gaaatgacag gaatattga tgaagcagaa 1620 tgggagtgga aagcaggatt ccatcgctgg aacaattaca tgatggactg gaaaaatcaa 1680 tttaacgatt acactagcaa gaaagaaagt tgtgtgggtc tc 1722 <210 > SEQ ID NO 20 <211 > LENGTH: 574 <212 > TYPE: PRT <213 > ORGANISM: Artificial <220 > FEATURE: <223 > OTHER INFORMATION: 12-7 mutant (A1995/F227A/S287G/A328W/Y332G) EChE amino acid sequence <400 > SEQUENCE: 20 Glu Asp Asp Ile Ile Ile Ala Thr Lys Asn Gly Lys Val Arg Gly Met 1 5 Asn Leu Thr Val Phe Gly Gly Thr Val Thr Ala Phe Leu Gly Ile Pro 20 25 40 Tyr Ala Gln Pro Pro Leu Gly Arg Leu Arg Phe Lys Lys Pro Gln Ser 35 40 40 Leu Thr Lys Trp Ser Asp Ile Trp Asn Ala Thr Lys Tyr Ala Asn Ser 50 Cys Cys Gln Asn Ile App Gln Ser Phe Pro Gly Phe His Gly Ser Glu
tgggagtgga aagcaggatt ccatcgctgg aacaattaca tgatggactg gaaaatcaa 1680 tttaacgatt acactagcaa gaaagaaagt tgtgtgggtc tc 1722 <210 > SEQ ID NO 20 <211 > LENGTH: 574 <212 > TYPE: PRT <213 > ORGANISM: Artificial <220 > FEATURE: <223 > OTHER INFORMATION: 12-7 mutant (A1995/F227A/S287G/A328W/Y332G) BChE amino acid sequence <400 > SEQUENCE: 20 Glu Asp Asp Ile Ile Ile Ala Thr Lys Asn Gly Lys Val Arg Gly Met 1 5 10 15 Asn Leu Thr Val Phe Gly Gly Thr Val Thr Ala Phe Leu Gly Ile Pro 20 25 Cyr Ala Gln Pro Pro Leu Gly Arg Leu Arg Phe Lys Lys Pro Gln Ser 30 Tyr Ala Gln Pro Pro Leu Gly Arg Leu Arg Phe Lys Lys Pro Gln Ser 50 Cys Cys Gln Asn Ile Asp Gln Ser Phe Pro Gly Phe His Gly Ser Glu
<pre>tttaacgatt acactagcaa gaaagaaagt tgtgtgggt tc 1722 </pre>
<pre><210> SEQ ID NO 20 <211> LENGTH: 574 <212> TYPE: PRT <213> ORGANISM: Artificial <220> FEATURE: <222> OTHER INFORMATION: 12-7 mutant (A199S/F227A/S287G/A328W/Y332G) BChE amino acid sequence <400> SEQUENCE: 20 Glu Asp Asp Ile Ile Ile Ala Thr Lys Asn Gly Lys Val Arg Gly Met 1 5 Asn Leu Thr Val Phe Gly Gly Thr Val Thr Ala Phe Leu Gly Ile Pro 20 25 70 25 70 90 25 70 90 25 Tyr Ala Gln Pro Pro Leu Gly Arg Leu Arg Phe Lys Lys Pro Gln Ser 30 Tyr Ala Gln Pro Pro Leu Gly Arg Leu Arg Phe Lys Lys Pro Gln Ser 50 25 70 70 55 70 70 70 70 70 70 70 70 70 70 70 70 70</pre>
<pre><400> SEQUENCE: 20</pre> Glu Asp Asp Ile Ile Ile Ala Thr Lys Asn Gly Lys Val Arg Gly Met 1 f1 Asn Leu Thr Val Phe Gly Gly Gly Thr Val Thr Ala Phe Leu Gly Ile Pro Tyr Ala Gln Pro Pro Leu Gly Arg Leu Arg Phe Lys $\frac{1}{50}$ Pro Gln Ser Leu Thr So Try Ser Asp Ile Try Ser Asp Ile Try Ala Gly Ala Thr Lys Tyr Ala Asn Ser Cys Cys Gln Asn Ile Asp Gln Ser Phe Pro Gly Phe His Gly Ser Glu
Asp Asp I I I Asp I </td
AsnLeuThrValPheGlyGlyGlyThrValThrAlaPheLeuGlyIleProTyrAlaGlyProProGlyGlyFroGlyLucAgProLysLysProGlnSerLeuThrSoTrySerAspGlyTrySerAspGlyTrySerAspSerSerCysCysGlnAsnIleAspGlnSerProGlyProGlySerGlu
TyrAlaGlnProProLeuGlyArgPneLysLysLysProGlnSerLeuThrLysTyrSerAsgThrTrgAsgAlaThrLysTyrAlaAsgSerLysTyrSerSerSerSerSerSerSerSerSerSerSerSerCysCysGlnAsgIleAsgGlnSerPheProGlyPheHisGlySerGlu
Leu Thr Lys Trp Ser Asp IIe Trp Asn Ala Thr Lys Tyr Ala Asn Ser 50 Cys Cys Gln Asn Ile Asp Gln Ser Phe Pro Gly Phe His Gly Ser Glu
Cys Cys Gln Asn Ile Asp Gln Ser Phe Pro Gly Phe His Gly Ser Glu
cys cys din Ash fie Ash din Set Fne Fro diy Fne His diy Set diu
65 70 75 80

-continued

Met	Trp	Asn	Pro	Asn 85	Thr	Asp	Leu	Ser	Glu 90	Asp	Суз	Leu	Tyr	Leu 95	Asn
Val	Trp	Ile	Pro 100	Ala	Pro	Lys	Pro	Lys 105	Asn	Ala	Thr	Val	Leu 110	Ile	Trp
Ile	Tyr	Gly 115	Gly	Gly	Phe	Gln	Thr 120	Gly	Thr	Ser	Ser	Leu 125	His	Val	Tyr
Asp	Gly 130	Lys	Phe	Leu	Ala	Arg 135	Val	Glu	Arg	Val	Ile 140	Val	Val	Ser	Met
Asn 145	Tyr	Arg	Val	Gly	Ala 150	Leu	Gly	Phe	Leu	Ala 155	Leu	Pro	Gly	Asn	Pro 160
Glu	Ala	Pro	Gly	Asn 165	Met	Gly	Leu	Phe	Asp 170	Gln	Gln	Leu	Ala	Leu 175	Gln
Trp	Val	Gln	Lys 180	Asn	Ile	Ala	Ala	Phe 185	Gly	Gly	Asn	Pro	Lys 190	Ser	Val
Thr	Leu	Phe 195	Gly	Glu	Ser	Ser	Gly 200	Ala	Ala	Ser	Val	Ser 205	Leu	His	Leu
Leu	Ser 210	Pro	Gly	Ser	His	Ser 215	Leu	Phe	Thr	Arg	Ala 220	Ile	Leu	Gln	Ser
Gly 225	Ser	Ala	Asn	Ala	Pro 230	Trp	Ala	Val	Thr	Ser 235	Leu	Tyr	Glu	Ala	Arg 240
Asn	Arg	Thr	Leu	Asn 245	Leu	Ala	Lys	Leu	Thr 250	Gly	Суз	Ser	Arg	Glu 255	Asn
Glu	Thr	Glu	Ile 260	Ile	Lys	Суз	Leu	Arg 265	Asn	Lys	Asp	Pro	Gln 270	Glu	Ile
Leu	Leu	Asn 275	Glu	Ala	Phe	Val	Val 280	Pro	Tyr	Gly	Thr	Pro 285	Leu	Gly	Val
Asn	Phe 290	Gly	Pro	Thr	Val	Asp 295	Gly	Asp	Phe	Leu	Thr 300	Asp	Met	Pro	Asp
Ile 305	Leu	Leu	Glu	Leu	Gly 310	Gln	Phe	Lys	Lys	Thr 315	Gln	Ile	Leu	Val	Gly 320
Val	Asn	Lys	Asp	Glu 325	Gly	Thr	Trp	Phe	Leu 330	Val	Gly	Gly	Ala	Pro 335	Gly
Phe	Ser	Lys	Asp 340	Asn	Asn	Ser	Ile	Ile 345	Thr	Arg	Lys	Glu	Phe 350	Gln	Glu
Gly	Leu	Lys 355	Ile	Phe	Phe	Pro	Gly 360	Val	Ser	Glu	Phe	Gly 365	Lys	Glu	Ser
Ile	Leu 370	Phe	His	Tyr	Thr	Asp 375	Trp	Val	Aab	Asp	Gln 380	Arg	Pro	Glu	Asn
Tyr 385	Arg	Glu	Ala	Leu	Gly 390	Asp	Val	Val	Gly	Asp 395	Tyr	Asn	Phe	Ile	Суз 400
Pro	Ala	Leu	Glu	Phe 405	Thr	Lys	Lys	Phe	Ser 410	Glu	Trp	Gly	Asn	Asn 415	Ala
Phe	Phe	Tyr	Tyr 420	Phe	Glu	His	Arg	Ser 425	Ser	Lys	Leu	Pro	Trp 430	Pro	Glu
Trp	Met	Gly 435	Val	Met	His	Gly	Tyr 440	Glu	Ile	Glu	Phe	Val 445	Phe	Gly	Leu
Pro	Leu 450	Glu	Arg	Arg	Asp	Asn 455	Tyr	Thr	Lys	Ala	Glu 460	Glu	Ile	Leu	Ser
Arg 465	Ser	Ile	Val	Lys	Arg 470	Trp	Ala	Asn	Phe	Ala 475	Lys	Tyr	Gly	Asn	Pro 480
Asn	Glu	Thr	Gln	Asn 485	Asn	Ser	Thr	Ser	Trp 490	Pro	Val	Phe	Lys	Ser 495	Thr

-continued

Glu Gln Lys Tyr Leu Thr Leu Asn Thr Glu Ser Thr Arg Ile Met Thr 500 505 510 Lys Leu Arg Ala Gln Gln Cys Arg Phe Trp Thr Ser Phe Phe Pro Lys 515 520 525 Val Leu Glu Met Thr Gly Asn Ile Asp Glu Ala Glu Trp Glu Trp Lys 530 535 540 Ala Gly Phe His Arg Trp Asn Asn Tyr Met Met Asp Trp Lys Asn Gln 545 550 555 560 Phe Asn Asp Tyr Thr Ser Lys Lys Glu Ser Cys Val Gly Leu 565 570 <210> SEQ ID NO 21 <211> LENGTH: 1125 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: 12-7 mutant (A199S/F227A/S287G/A328W/Y332G) BChE nucleic acid sequence for amino acid residues 68-442 <400> SEQUENCE: 21 aacatagatc aaagttttcc aggcttccat ggatcagaga tgtggaaccc aaacactgac 60 ctcagtgaag actgtttata tctaaatgta tggattccag cacctaaacc aaaaaatgcc 120 actgtattga tatggattta tggtggtggt tttcaaactg gaacatcatc tttacatgtt 180 tatgatggca agtttctggc tcgggttgaa agagttattg tagtgtcaat gaactatagg 240 gtgggtgccc taggattctt agctttgcca ggaaatcctg aggctccagg gaacatgggt 300 ttatttgatc aacagttggc tcttcagtgg gttcaaaaaa atatagcagc ctttggtgga 360 aatcctaaaa gtgtaactct ctttggagaa agttccggag cagcttcagt tagcctgcat 420 ttgctttctc ctggaagcca ttcattgttc accagagcca ttctgcaaag tggttccgct 480 aatgeteett gggeggtaac atetettat gaagetagga acagaaegtt gaaettaget 540 aaattgactg gttgctctag agagaatgag actgaaataa tcaagtgtct tagaaataaa 600 gatececaag aaattettet gaatgaagea tttgttgtee eetatgggae teetttgggt 660 gtaaactttg gtccgaccgt ggatggtgat tttctcactg acatgccaga catattactt 720 gaacttggac aatttaaaaa aacccagatt ttggtgggtg ttaataaaga tgaagggaca 780 tggtttttag tcggtggtgc tcctggcttc agcaaagata acaatagtat cataactaga 840 aaagaatttc aggaaggttt aaaaatattt tttccaggag tgagtgagtt tggaaaggaa 900 tccatccttt ttcattacac agactgggta gatgatcaga gacctgaaaa ctaccgtgag 960 gccttgggtg atgttgttgg ggattataat ttcatatgcc ctgccttgga gttcaccaag 1020 aagtteteag aatggggaaa taatgeettt ttetaetatt ttgaacaeeg ateeteeaaa 1080 cttccgtggc cagaatggat gggagtgatg catggctatg aaatt 1125 <210> SEQ ID NO 22 <211> LENGTH: 375 <212> TYPE: PRT <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: 12-7 mutant (A199S/F227A/S287G/A328W/Y332G) BChE amino acid sequence for residues 68-442 <400> SEOUENCE: 22 Asn Ile Asp Gln Ser Phe Pro Gly Phe His Gly Ser Glu Met Trp Asn 5 10 15 1 Pro Asn Thr Asp Leu Ser Glu Asp Cys Leu Tyr Leu Asn Val Trp Ile

			20					25					30		
Pro .	Ala	Pro 35	Lys	Pro	Гүз	Asn	Ala 40	Thr	Val	Leu	Ile	Trp 45	Ile	Tyr	Gly
Gly	Gly 50	Phe	Gln	Thr	Gly	Thr 55	Ser	Ser	Leu	His	Val 60	Tyr	Asp	Gly	Lys
Phe 65	Leu	Ala	Arg	Val	Glu 70	Arg	Val	Ile	Val	Val 75	Ser	Met	Asn	Tyr	Arg 80
Val	Gly	Ala	Leu	Gly 85	Phe	Leu	Ala	Leu	Pro 90	Gly	Asn	Pro	Glu	Ala 95	Pro
Gly	Asn	Met	Gly 100	Leu	Phe	Asp	Gln	Gln 105	Leu	Ala	Leu	Gln	Trp 110	Val	Gln
Lys .	Asn	Ile 115	Ala	Ala	Phe	Gly	Gly 120	Asn	Pro	LÀa	Ser	Val 125	Thr	Leu	Phe
Gly	Glu 130	Ser	Ser	Gly	Ala	Ala 135	Ser	Val	Ser	Leu	His 140	Leu	Leu	Ser	Pro
Gly 145	Ser	His	Ser	Leu	Phe 150	Thr	Arg	Ala	Ile	Leu 155	Gln	Ser	Gly	Ser	Ala 160
Asn .	Ala	Pro	Trp	Ala 165	Val	Thr	Ser	Leu	Tyr 170	Glu	Ala	Arg	Asn	Arg 175	Thr
Leu	Asn	Leu	Ala 180	Lys	Leu	Thr	Gly	Cys 185	Ser	Arg	Glu	Asn	Glu 190	Thr	Glu
Ile	Ile	Lys 195	Сүв	Leu	Arg	Asn	Lys 200	Asp	Pro	Gln	Glu	Ile 205	Leu	Leu	Asn
Glu	Ala 210	Phe	Val	Val	Pro	Tyr 215	Gly	Thr	Pro	Leu	Gly 220	Val	Asn	Phe	Gly
Pro 225	Thr	Val	Asp	Gly	Asp 230	Phe	Leu	Thr	Asp	Met 235	Pro	Asp	Ile	Leu	Leu 240
Glu	Leu	Gly	Gln	Phe 245	Lys	Lys	Thr	Gln	Ile 250	Leu	Val	Gly	Val	Asn 255	Lys
Asp	Glu	Gly	Thr 260	Trp	Phe	Leu	Val	Gly 265	Gly	Ala	Pro	Gly	Phe 270	Ser	Lys
Asp	Asn	Asn 275	Ser	Ile	Ile	Thr	Arg 280	Lys	Glu	Phe	Gln	Glu 285	Gly	Leu	Гла
Ile	Phe 290	Phe	Pro	Gly	Val	Ser 295	Glu	Phe	Gly	Lys	Glu 300	Ser	Ile	Leu	Phe
His 305	Tyr	Thr	Asp	Trp	Val 310	Asp	Asp	Gln	Arg	Pro 315	Glu	Asn	Tyr	Arg	Glu 320
Ala	Leu	Gly	Asp	Val 325	Val	Gly	Asp	Tyr	Asn 330	Phe	Ile	Сүз	Pro	Ala 335	Leu
Glu	Phe	Thr	Lys 340	ГЛа	Phe	Ser	Glu	Trp 345	Gly	Asn	Asn	Ala	Phe 350	Phe	Tyr
Tyr	Phe	Glu 355	His	Arg	Ser	Ser	Lys 360	Leu	Pro	Trp	Pro	Glu 365	Trp	Met	Gly
Val	Met 370	His	Gly	Tyr	Glu	Ile 375									
<210 <211 <212 <213 <220 <223	> SE > LE > T > OF > FE > O BC > SE	EQ II ENGTH PE: CGANI EATUH THER THER THE r) NO H: 90 DNA [SM: RE: INF(hucle JCE:	23 66 Art: DRMA eic a 23	ific: TION acid	ial : 12 sequ	-7 mu lence	utani e fo:	: (A: ram:	1995 ino a	/F22 acid	7A/S2 res:	287G, idues	/A328 ≆ 11′	3W/Y3 7-438

US 9,206,403 B1

87

-continued

ggttttcaaa ctggaacatc atctttacat gtttatgatg gcaagtttct ggctcgggtt 60
gaaagagtta ttgtagtgtc aatgaactat agggtgggtg ccctaggatt cttagctttg 120
ccaggaaatc ctgaggctcc agggaacatg ggtttatttg atcaacagtt ggctcttcag 180
tgggttcaaa aaaatatagc agcctttggt ggaaatccta aaagtgtaac tctctttgga 240
gaaagttccg gagcagcttc agttagcctg catttgcttt ctcctggaag ccattcattg 300
ttcaccagag ccattctgca aagtggttcc gctaatgctc cttgggcggt aacatctctt 360
tatgaagcta ggaacagaac gttgaactta gctaaattga ctggttgctc tagagagaat 420
gagactgaaa taatcaagtg tcttagaaat aaagatcccc aagaaattct tctgaatgaa 480
gcatttgttg tcccctatgg gactcctttg ggtgtaaact ttggtccgac cgtggatggt 540
gattttctca ctgacatgcc agacatatta cttgaacttg gacaatttaa aaaaacccag 600
attttggtgg gtgttaataa agatgaaggg acatggtttt tagtcggtgg tgctcctggc 660
ttcagcaaag ataacaatag tatcataact agaaaagaat ttcaggaagg tttaaaaata 720
ttttttccag gagtgagtga gtttggaaag gaatccatcc tttttcatta cacagactgg 780
gtagatgatc agagacctga aaactaccgt gaggccttgg gtgatgttgt tggggattat 840
aatttcatat gccctgcctt ggagttcacc aagaagttct cagaatgggg aaataatgcc 900
tttttctact attttgaaca ccgatcctcc aaacttccgt ggccagaatg gatgggagtg 960
atgcat 966
<pre><213> ORGANISM: Artificial <220> FEATURE: <220> FEATURE: <223> OTHER INFORMATION: 12-7 mutant (A199S/F227A/S287G/A328W/Y332G) BChE amino acid sequence for residues 117-438</pre>
<400> SEQUENCE: 24
Gly Phe Gln Thr Gly Thr Ser Ser Leu His Val Tyr Asp Gly Lys Phe 1 5 10 15
Leu Ala Arg Val Glu Arg Val Ile Val Val Ser Met Asn Tyr Arg Val 20 25 30
Gly Ala Leu Gly Phe Leu Ala Leu Pro Gly Asn Pro Glu Ala Pro Gly
Asn Met Gly Leu Phe Asp Gln Gln Leu Ala Leu Gln Trp Val Gln Lys
50 55 60
Ash ile Ala Ala Phe Giy Giy Ash Pro Lys Ser Val Thr Leu Phe Giy 65 70 75 80
Glu Ser Ser Gly Ala Ala Ser Val Ser Leu His Leu Leu Ser Pro Gly 85 90 95
Ser His Ser Leu Phe Thr Arg Ala Ile Leu Gln Ser Gly Ser Ala Asn 100 105 110
Ala Pro Trp Ala Val Thr Ser Leu Tyr Glu Ala Arg Asn Arg Thr Leu 115 120 125
Asn Leu Ala Lys Leu Thr Gly Cys Ser Arg Glu Asn Glu Thr Glu Ile 130 135 140
Ile Lys Cys Leu Arg Asn Lys Asp Pro Gln Glu Ile Leu Leu Asn Glu
145 150 155 160
Ala Phe Val Val Pro Tyr Gly Thr Pro Leu Gly Val Asn Phe Gly Pro 165 170 175
Thr Val Asp Gly Asp Phe Leu Thr Asp Met Pro Asp Ile Leu Leu Glu

o	n
- O	У

continued

180 185 190	_
Leu Gly Gln Phe Lys Lys Thr Gln Ile Leu Val Gly Val Asn Lys Asp 195 200 205	
Glu Gly Thr Trp Phe Leu Val Gly Gly Ala Pro Gly Phe Ser Lys Asp 210 215 220	
Asn Asn Ser Ile Ile Thr Arg Lys Glu Phe Gln Glu Gly Leu Lys Ile 225 230 235 240	
Phe Phe Pro Gly Val Ser Glu Phe Gly Lys Glu Ser Ile Leu Phe His 245 250 255	
Tyr Thr Asp Trp Val Asp Asp Gln Arg Pro Glu Asn Tyr Arg Glu Ala	
Leu Gly Asp Val Val Gly Asp Tyr Asn Phe Ile Cys Pro Ala Leu Glu	
Phe Thr Lys Lys Phe Ser Glu Trp Gly Asn Asn Ala Phe Phe Tyr Tyr	
290 295 300 Phe Glu His Arg Ser Ser Lys Leu Pro Trp Pro Glu Trp Met Gly Val	
305 310 315 320 Met His	
<210> SEQ ID NO 25 <211> LENGTH: 1722 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: 12-4 mutant (A199S/F227A/S287G/A328W/E441D) BChe nucleic acid sequence	
<400> SEQUENCE: 25	
gaagatgaca tcataattgc aacaaagaat ggaaaagtca gagggatgaa cttgacagtt tttggtggca cggtaacagc ctttcttgga attccctatg cacagccacc tcttggtaga	60 120
cttcgattca aaaagccaca gtctctgacc aagtggtctg atatttggaa tgccacaaaa	180
tatgcaaatt cttgctgtca gaacatagat caaagttttc caggcttcca tggatcagag	240
atgtggaacc caaacactga cctcagtgaa gactgtttat atctaaatgt atggattcca	300
gcacctaaac caaaaaatgc cactgtattg atatggattt atggtggtgg ttttcaaact	360
ggaacatcat ctttacatgt ttatgatggc aagtttctgg ctcgggttga aagagttatt	420
gtagtgtcaa tgaactatag ggtgggtgcc ctaggattct tagctttgcc aggaaatcct	480
gaggeteeag ggaacatggg tttatttgat caacagttgg etetteagtg ggtteaaaaa	540
aatatagcag cetttggtgg aaateetaaa agtgtaaete tetttggaga aagtteegga	600
gcagetteag ttageetgea tttgetttet eetggaagee atteattgtt eaceagagee	660
attetgeaaa gtggtteege taatgeteet tgggeggtaa catetettta tgaagetagg	720
aacagaacgt tgaacttagc taaattgact ggttgctcta gagagaatga gactgaaata	780
atcaagtgtc ttagaaataa agatccccaa gaaattcttc tgaatgaagc atttgttgtc	840
ccctatggga ctcctttggg tgtaaacttt ggtccgaccg tggatggtga ttttctcact	900
gacatgccag acatattact tgaacttgga caatttaaaa aaacccagat tttggtgggt	960
gttaataaag atgaagggac atggttttta gtctatggtg ctcctggctt cagcaaagat	1020
aacaatagta tcataactag aaaagaattt caggaaggtt taaaaatatt ttttccagga	1080
gtgagtgagt ttggaaagga atccatcctt tttcattaca cagactgggt agatgatcag	1140
agacctgaaa actaccgtga ggccttgggt gatgttgttg gggattataa tttcatatgc	1200

US 9,206,403 B1

91

cctgccttgg agttcaccaa gaagttctca gaatggggaa ataatgcctt tttctactat

-continued

92

tttgaacacc gatcctccaa acttccgtgg ccagaatgga tgggagtgat gcatggctat	1320													
gacattgaat ttgtctttgg tttacctctg gaaagaagag ataattacac aaaagccgag	1380													
gaaattttga gtagatccat agtgaaacgg tgggcaaatt ttgcaaaata tgggaatcca	1440													
aatgagactc agaacaatag cacaagctgg cctgtcttca aaagcactga acaaaaatat	1500													
ctaaccttga atacagagtc aacaagaata atgacgaaac tacgtgctca acaatgtcga	1560													
ttctggacat cattttttcc aaaagtcttg gaaatgacag gaaatattga tgaagcagaa	1620													
tgggagtgga aagcaggatt ccatcgctgg aacaattaca tgatggactg gaaaaatcaa	1680													
tttaacgatt acactagcaa gaaagaaagt tgtgtgggtc tc	1722													
<pre>210> SEQ ID NO 26 211> LENGTH: 574 212> TYPE: PRT 213> ORGANISM: Artificial 220> FEATURE: 220> FEATURE: 223> OTHER INFORMATION: 12-4 mutant (A199S/F227A/S287G/A328W/E441D) BChe amino acid sequence 2400> SEQUENCE: 26</pre>														
<400> SEQUENCE: 26														
1 5 10 15														
Asn Leu Thr Val Phe Gly Gly Thr Val Thr Ala Phe Leu Gly Ile Pro 20 25 30														
Tyr Ala Gln Pro Pro Leu Gly Arg Leu Arg Phe Lys Lys Pro Gln Ser 35 40 45														
Leu Thr Lys Trp Ser Asp Ile Trp Asn Ala Thr Lys Tyr Ala Asn Ser 50 55 60														
Cys Cys Gln Asn Ile Asp Gln Ser Phe Pro Gly Phe His Gly Ser Glu 65 70 75 80														
Met Trp Asn Pro Asn Thr Asp Leu Ser Glu Asp Cys Leu Tyr Leu Asn 85 90 95														
Val Trp Ile Pro Ala Pro Lys Pro Lys Asn Ala Thr Val Leu Ile Trp														
Ile Tyr Gly Gly Gly Phe Gln Thr Gly Thr Ser Ser Leu His Val Tyr														
115 120 125 Asp Gly Lys Phe Leu Ala Arg Val Glu Arg Val Ile Val Val Ser Met														
130 135 140														
Asn Tyr Arg Val Gly Ala Leu Gly Phe Leu Ala Leu Pro Gly Asn Pro 145 150 155 160														
Glu Ala Pro Gly Asn Met Gly Leu Phe Asp Gln Gln Leu Ala Leu Gln 165 170 175														
Trp Val Gln Lys Asn Ile Ala Ala Phe Gly Gly Asn Pro Lys Ser Val 180 185 190														
Thr Leu Phe Gly Glu Ser Ser Gly Ala Ala Ser Val Ser Leu His Leu 195 200 205														
Leu Ser Pro Gly Ser His Ser Leu Phe Thr Arg Ala Ile Leu Gln Ser 210 215 220														
Gly Ser Ala Asn Ala Pro Trp Ala Val Thr Ser Leu Tyr Glu Ala Arg														
Asn Arg Thr Leu Asn Leu Ala Lys Leu Thr Gly Cys Ser Arg Glu Asn														
245 250 255 Glu Thr Glu Ile Ile Lys Cys Leu Ard Asn Lys Asn Pro Gln Glu Ile														
260 265 270														

-continued

L	eu	Leu	Asn 275	Glu	Ala	Phe	Val	Val 280	Pro	Tyr	Gly	Thr	Pro 285	Leu	Gly	Val	
A	sn	Phe 290	Gly	Pro	Thr	Val	Asp 295	Gly	Asp	Phe	Leu	Thr 300	Asp	Met	Pro	Asp	
I 3	le 05	Leu	Leu	Glu	Leu	Gly 310	Gln	Phe	Lys	Lys	Thr 315	Gln	Ile	Leu	Val	Gly 320	
v	al	Asn	Lys	Asp	Glu 325	Gly	Thr	Trp	Phe	Leu 330	Val	Tyr	Gly	Ala	Pro 335	Gly	
P	he	Ser	Lys	Asp 340	Asn	Asn	Ser	Ile	Ile 345	Thr	Arg	Lys	Glu	Phe 350	Gln	Glu	
G	ly	Leu	Lys 355	Ile	Phe	Phe	Pro	Gly 360	Val	Ser	Glu	Phe	Gly 365	Lys	Glu	Ser	
I	le	Leu 370	Phe	His	Tyr	Thr	Asp 375	Trp	Val	Asp	Asp	Gln 380	Arg	Pro	Glu	Asn	
Т 3	yr 85	Arg	Glu	Ala	Leu	Gly 390	Asp	Val	Val	Gly	Asp 395	Tyr	Asn	Phe	Ile	Сув 400	
P	ro	Ala	Leu	Glu	Phe 405	Thr	Гла	ГЛа	Phe	Ser 410	Glu	Trp	Gly	Asn	Asn 415	Ala	
P	he	Phe	Tyr	Tyr 420	Phe	Glu	His	Arg	Ser 425	Ser	Lys	Leu	Pro	Trp 430	Pro	Glu	
T	rp	Met	Gly 435	Val	Met	His	Gly	Tyr 440	Asp	Ile	Glu	Phe	Val 445	Phe	Gly	Leu	
P	ro	Leu 450	Glu	Arg	Arg	Asp	Asn 455	Tyr	Thr	Lys	Ala	Glu 460	Glu	Ile	Leu	Ser	
A: 4	rg 65	Ser	Ile	Val	Lys	Arg 470	Trp	Ala	Asn	Phe	Ala 475	Lys	Tyr	Gly	Asn	Pro 480	
A	sn	Glu	Thr	Gln	Asn 485	Asn	Ser	Thr	Ser	Trp 490	Pro	Val	Phe	Lys	Ser 495	Thr	
G	lu	Gln	Lys	Tyr 500	Leu	Thr	Leu	Asn	Thr 505	Glu	Ser	Thr	Arg	Ile 510	Met	Thr	
\mathbf{L}_{j}	уs	Leu	Arg 515	Ala	Gln	Gln	Суз	Arg 520	Phe	Trp	Thr	Ser	Phe 525	Phe	Pro	Lys	
v	al	Leu 530	Glu	Met	Thr	Gly	Asn 535	Ile	Asp	Glu	Ala	Glu 540	Trp	Glu	Trp	Гла	
A 5	la 45	Gly	Phe	His	Arg	Trp 550	Asn	Asn	Tyr	Met	Met 555	Asp	Trp	Lys	Asn	Gln 560	
P	he	Asn	Asp	Tyr	Thr 565	Ser	Lys	Lys	Glu	Ser 570	Суз	Val	Gly	Leu			
	210 211 212 213 220 223)> SI 2> LI 2> TY 3> OF 0> FF 3> OT BC 0)> SI	EQ II ENGTH (PE: RGAN) EATUH CHER CHE 1 EQUEN	D NO H: 1: DNA ISM: RE: INF(nucle NCE:	27 125 Art: DRMA ⊇ic a 27	ific: TION acid	ial : 12 sequ	-4 mu lence	utant e foi	: (A: r am:	1995, ino a	/F22' acid	7A/S: res:	287G, idue:	/A328 3 68-	3W/E441D -442)
a	aca	ataga	atc a	aaagi	ttt	cc aç	ggcti	tccat	c gga	atcaç	gaga	tgt	ggaa	ccc a	aaaca	actgac	6
C.	tca	igtga	aag a	actgi	ttai	ta to	ctaa	atgta	a tgo	gatto	ccag	caco	ctaa	acc a	aaaaa	aatgcc	12
a	ctg	gtatt	:ga t	tatg	gatti	ta to	ggtg	gtggt	t tt	caaa	actg	gaa	catca	atc 1	ttad	catgtt	18
t	ato	gatgo	gca a	agtti	cctg	gc to	cgggi	ttgaa	a aga	agtta	attg	tagi	gtca	aat q	gaact	tatagg	24

US 9,206,403 B1

95

-continued

gtg	ggtgo	ccc t	tagga	attct	t aq	gctti	gcca	u gga	aaato	cctg	aggo	ctcca	agg g	gaaca	atggg	t 300
ttat	ttga	atc a	aacaç	gttgg	ge to	cttca	agtgg	g gtt	caaa	aaaa	atai	cagea	age d	ctttç	ggtgg	a 360
aato	cctaa	aaa g	gtgta	aacto	ct ct	ttg	gagaa	ı agt	tccg	ggag	cago	cttca	agt t	cageo	ctgca	t 420
ttgo	ettto	ctc d	ctgga	aagco	ca ti	ccatt	gtto	acc	agag	gcca	ttci	cgcaa	aag t	ggtt	cege	t 480
aato	gctco	ctt ç	gggcg	ggtaa	ac at	cctct	ttat	gaa	ageta	agga	acaç	gaaco	gtt ç	gaact	tage	t 540
aaat	tgad	ctg g	gttgo	eteta	ag aq	gagaa	atgag	g act	gaaa	ataa	tcaa	agtgt	cct t	cagaa	aataa	a 600
gato	cccca	aag a	aaatt	cctto	ct ga	aatga	aagca	ttt	gttg	gtcc	ccta	atggg	gac t	ccctt	tggg	t 660
gtaa	aactt	ttg g	gtcc	gacco	gt g	gatgo	gtgat	ttt	cctca	actg	acat	cgeea	aga d	catat	tact	t 720
gaad	cttgg	gac a	aatti	caaaa	aa aa	accca	agatt	tt	ggtgg	ggtg	ttaa	ataaa	aga t	gaag	ggac	a 780
tggt	tttt	tag t	tctat	ggt	gc to	cctg	gette	ago	caaaq	gata	acaa	atagt	at o	cataa	actag	a 840
aaaq	gaatt	ttc a	aggaa	aggtt	t aa	aaaat	attt	ttt	ccaç	ggag	tga	gtgag	gtt t	cggaa	aagga	a 900
tcca	atcct	ttt t	tcat	taca	ac aç	gacto	gggta	ı gat	gato	caga	gaco	ctgaa	aaa d	ctaco	gtga	g 960
gcct	tggg	gtg a	atgti	gtt	aa aa	gatta	ataat	tto	catat	gcc	ctgo	cctt	gga g	gttca	accaa	g 1020
aagt	tete	cag a	aatgo	gggaa	aa ta	aatgo	ccttt	tto	ctact	att	ttga	aacad	ccg a	atcct	ccaa	a 1080
ctto	ccgt	ggc (cagaa	atgga	at go	ggagt	gate	g cat	gget	atg	acat	t				1125
<213 <213 <213 <220 <223	<pre><210> SEQ ID NO 28 <211> LENGTH: 375 <212> TYPE: PRT <213> ORGANISM: Artificial <220> FEATURE: <220> OTHER INFORMATION: 12-4 mutant (A1995/F227A/S287G/A328W/E441D) BChE amino acid sequence for residues 68-442</pre>															
	<400> SEQUENCE: 28															
<400)> SH	EQUEI	NCE :	28												
<400 Asn 1)> SH Ile	EQUEI Asp	NCE: Gln	28 Ser 5	Phe	Pro	Gly	Phe	His 10	Gly	Ser	Glu	Met	Trp 15	Asn	
<400 Asn 1 Pro)> SH Ile Asn	EQUEI Asp Thr	NCE: Gln Asp 20	28 Ser 5 Leu	Phe Ser	Pro Glu	Gly Asp	Phe Cys 25	His 10 Leu	Gly Tyr	Ser Leu	Glu Asn	Met Val 30	Trp 15 Trp	Asn Ile	
<400 Asn 1 Pro Pro	D> SI Ile Asn Ala	EQUEN Asp Thr Pro 35	NCE : Gln Asp 20 Lys	28 Ser 5 Leu Pro	Phe Ser Lys	Pro Glu Asn	Gly Asp Ala 40	Phe Cys 25 Thr	His 10 Leu Val	Gly Tyr Leu	Ser Leu Ile	Glu Asn Trp 45	Met Val 30 Ile	Trp 15 Trp Tyr	Asn Ile Gly	
<400 Asn 1 Pro Pro Gly	D> SI Ile Asn Ala Gly 50	Asp Thr Pro 35 Phe	NCE: Gln Asp 20 Lys Gln	28 Ser 5 Leu Pro Thr	Phe Ser Lys Gly	Pro Glu Asn Thr 55	Gly Asp Ala 40 Ser	Phe Cys 25 Thr Ser	His 10 Leu Val Leu	Gly Tyr Leu His	Ser Leu Ile Val 60	Glu Asn Trp 45 Tyr	Met Val 30 Ile Asp	Trp 15 Trp Tyr Gly	Asn Ile Gly Lys	
<400 Asn 1 Pro Pro Gly Phe 65	D> SH Ile Asn Ala Gly 50 Leu	Asp Thr Pro 35 Phe Ala	NCE: Gln Asp 20 Lys Gln Arg	28 Ser 5 Leu Pro Thr Val	Phe Ser Lys Gly Glu 70	Pro Glu Asn Thr 55 Arg	Gly Asp Ala 40 Ser Val	Phe Cys 25 Thr Ser Ile	His 10 Leu Val Leu Val	Gly Tyr Leu His Val 75	Ser Leu Ile Val 60 Ser	Glu Asn Trp 45 Tyr Met	Met Val 30 Ile Asp Asn	Trp 15 Trp Tyr Gly Tyr	Asn Ile Gly Lys Arg 80	
<400 Asn 1 Pro Gly Phe 65 Val)> SH Ile Asn Ala Gly 50 Leu Gly	EQUE Asp Thr Pro 35 Phe Ala Ala	NCE: Gln Asp 20 Lys Gln Arg Leu	28 Ser 5 Leu Pro Thr Val Gly 85	Phe Ser Lys Gly Glu 70 Phe	Pro Glu Asn Thr 55 Arg Leu	Gly Asp Ala 40 Ser Val Ala	Phe Cys 25 Thr Ser Ile Leu	His 10 Leu Val Leu Val Pro 90	Gly Tyr Leu His Val 75 Gly	Ser Leu Ile Val 60 Ser Asn	Glu Asn Trp 45 Tyr Met Pro	Met Val 30 Ile Asp Asn Glu	Trp 15 Trp Tyr Gly Tyr Ala 95	Asn Ile Gly Lys Arg 80 Pro	
<400 Asn 1 Pro Gly Phe 65 Val Gly	<pre>D> SF Ile Asn Ala Gly 50 Leu Gly Asn</pre>	EQUEN Asp Thr Pro 35 Phe Ala Ala Met	NCE: Gln Asp 20 Lys Gln Arg Leu Cly 100	28 Ser 5 Leu Pro Thr Val Gly 85 Leu	Phe Ser Lys Gly Glu 70 Phe	Pro Glu Asn Thr 55 Arg Leu Asp	Gly Asp Ala 40 Ser Val Ala Gln	Phe Cys 25 Thr Ser Ile Leu Gln 105	His 10 Leu Val Leu Val Pro 90 Leu	Gly Tyr Leu His Val 75 Gly Ala	Ser Leu Ile Val 60 Ser Asn Leu	Glu Asn Trp 45 Tyr Met Pro Gln	Met Val 30 Ile Asp Asn Glu Trp 110	Trp 15 Trp Tyr Gly Tyr Ala 95 Val	Asn Ile Gly Lys Arg 80 Pro Gln	
<400 Asn 1 Pro Gly Phe 65 Val Gly Lys	<pre>D> SF Ile Asn Ala Gly Leu Gly Asn Asn</pre>	EQUER Asp Thr Pro 35 Phe Ala Ala Met Ile 115	NCE: Gln Asp 20 Lys Gln Arg Leu Gly 100 Ala	28 Ser 5 Leu Pro Thr Val Gly 85 Leu Ala	Phe Ser Lys Gly Glu 70 Phe Phe	Pro Glu Asn Thr 55 Arg Leu Asp Gly	Gly Asp Ala 40 Ser Val Ala Gln Gly 120	Phe Cys 25 Thr Ser Ile Leu Gln 105 Asn	His 10 Leu Val Leu Val Pro 90 Leu Pro	Gly Tyr Leu His Val 75 Gly Ala	Ser Leu Ile Val 60 Ser Asn Leu Ser	Glu Asn Trp 45 Tyr Met Pro Gln Val 125	Met Val 30 Ile Asp Asn Glu Trp 110 Thr	Trp 15 Trp Tyr Gly Tyr Ala 95 Val Leu	Asn Ile Gly Lys Arg 80 Pro Gln Phe	
<400 Asn 1 Pro Gly Phe 65 Val Gly Lys Gly	<pre>D> SF Ile Asn Ala Gly Clux Gly Asn Asn Glu 130</pre>	Asp Thr Pro 35 Phe Ala Ala Met Ile 115 Ser	NCE: Gln Asp 20 Lys Gln Arg Leu Gly 100 Ala Ser	28 Ser 5 Leu Pro Thr Val Gly 8 Leu Ala Gly	Phe Ser Lys Gly Glu 70 Phe Phe Ala	Pro Glu Asn Thr 55 Arg Leu Asp Gly Ala 135	Gly Asp Ala 40 Ser Val Ala Gln Gly 120 Ser	Phe Cys 25 Thr Ser Ile Leu Gln 105 Asn Val	His 10 Leu Val Leu Val Pro 90 Leu Pro Ser	Gly Tyr Leu His Gly Ala Lys Leu	Ser Leu Ile Val 60 Ser Asn Leu Ser His 140	Glu Asn Trp 45 Tyr Met Pro Gln Val 125 Leu	Met Val 30 Asp Asn Glu Trp 110 Thr Leu	Trp 15 Trp Gly Tyr Ala 95 Val Leu Ser	Asn Ile Gly Lys Arg 80 Pro Gln Phe Pro	
<400 Asn Pro Gly Phe 65 Val Gly Gly 145	<pre>D> SF Ile Asn Ala Gly 50 Leu Gly Asn Glu Asn Glu 130 Ser</pre>	EQUER Asp Thr Pro 35 Phe Ala Ala Ala Ile 115 Ser His	NCE: Gln Asp 20 Lys Gln Arg Leu Cly 100 Ala Ser Ser	28 Ser 5 Leu Pro Thr Val Gly 85 Leu Ala Gly Leu	Phe Ser Lys Gly Glu 70 Phe Phe Ala Phe 150	Pro Glu Asn Thr 55 Arg Leu Asp Gly Ala 135 Thr	Gly Asp Ala 40 Ser Val Ala Gln 120 Ser Arg	Phe Cys 25 Thr Ser Ile Leu Gln 105 Asn Val Ala	His 10 Leu Val Leu Val Pro 90 Leu Pro Ser Ile	Gly Tyr Leu His Val Gly Ala Lys Leu Leu	Ser Leu Ile Val 60 Ser Asn Leu Ser His 140 Gln	Glu Asn Trp 45 Tyr Met Pro Gln Val 125 Leu Ser	Met Val 30 Ile Asp Glu Trp 110 Thr Leu Gly	Trp 15 Trp Tyr Gly Tyr Ala 95 Val Leu Ser Ser	Asn Ile Gly Lys Arg 80 Pro Gln Phe Pro Ala	
<400 Asn 1 Pro Gly Phe 65 Val Gly Lys Gly 145 Asn	D> SF Ile Asn Ala Gly 50 Leu Gly Asn Glu 130 Ser Ala	Asp Thr Pro 35 Phe Ala Ala Ala Met Ile 115 Ser His Pro	NCE: Gln Asp 20 Lys Gln Arg Leu Gly 100 Ala Ser Ser Trp	28 Ser 5 Leu Pro Thr Val Gly Leu Ala 165	Phe Ser Lys Gly Glu 70 Phe Phe Ala Phe 150 Val	Pro Glu Asn Thr 55 Arg Leu Asp Gly Ala 135 Thr Thr	Gly Asp Ala 40 Ser Val Ala Gln Gly 120 Ser Arg Ser	Phe Cys 25 Thr Ser Leu Gln 105 Asn Val Ala Leu	His 10 Leu Val Leu Val Pro Ser Ile Tyr 170	Gly Tyr Leu His Gly Ala Lys Leu Leu Leu S5 Glu	Ser Leu Ile Val 60 Ser Asn Leu Ser His 140 Gln Ala	Glu Asn Trp 45 Tyr Met Pro Gln Ual 125 Leu Ser Arg	Met Val 30 Asp Asn Glu Trp 110 Thr Leu Gly Asn	Trp 15 Trp Gly Tyr Ala 95 Val Leu Ser Ser Arg 175	Asn Ile Gly Lys Rag Bo Pro Gln Phe Pro Ala 160 Thr	

-continued

Ile	Ile	Lys 195	Суз	Leu	Arg	Asn	Lys 200	Asp	Pro	Gln	Glu	Ile 205	Leu	Leu	Asn		
Glu	Ala 210	Phe	Val	Val	Pro	Tyr 215	Gly	Thr	Pro	Leu	Gly 220	Val	Asn	Phe	Gly		
Pro 225	Thr	Val	Asp	Gly	Asp 230	Phe	Leu	Thr	Asp	Met 235	Pro	Asp	Ile	Leu	Leu 240		
Glu	Leu	Gly	Gln	Phe 245	Lys	Lys	Thr	Gln	Ile 250	Leu	Val	Gly	Val	Asn 255	Lys		
Asp	Glu	Gly	Thr 260	Trp	Phe	Leu	Val	Tyr 265	Gly	Ala	Pro	Gly	Phe 270	Ser	Lys		
Asp	Asn	Asn 275	Ser	Ile	Ile	Thr	Arg 280	Lys	Glu	Phe	Gln	Glu 285	Gly	Leu	Lys		
Ile	Phe 290	Phe	Pro	Gly	Val	Ser 295	Glu	Phe	Gly	Гуз	Glu 300	Ser	Ile	Leu	Phe		
His 305	Tyr	Thr	Asp	Trp	Val 310	Asp	Asp	Gln	Arg	Pro 315	Glu	Asn	Tyr	Arg	Glu 320		
Ala	Leu	Gly	Asp	Val 325	Val	Gly	Aab	Tyr	Asn 330	Phe	Ile	Сүз	Pro	Ala 335	Leu		
Glu	Phe	Thr	Lys 340	Lys	Phe	Ser	Glu	Trp 345	Gly	Asn	Asn	Ala	Phe 350	Phe	Tyr		
Tyr	Phe	Glu 355	His	Arg	Ser	Ser	Lys 360	Leu	Pro	Trp	Pro	Glu 365	Trp	Met	Gly		
Val	Met 370	His	Gly	Tyr	Asp	Ile 375											
<21. <212 <212 <221 <220 <222	L> LF 2> T 3> OF 0> FF 3> O BC 0> SF	ENGTI YPE : RGANI EATUI THER CHE 1 EQUEI	H: 9 DNA ISM: RE: INF(nucle NCE:	75 Art: DRMA ∋ic a 29	ific: TION acid	ial : 12- sequ	-4 mu lence	itant e foi	: (Al r ami	L99S, ino a	/F22' acid	7A/S2 res:	287G, idue:	/A328 s 11'	3W/E44 7-441	1D)	
ggti	ttca	aaa (ctgga	aacat	cc at	ctt	cacat	: gtt	tate	gatg	gcaa	agtti	cct q	ggcto	cgggtt		60
gaaa	agagt	ta 1	ttgta	agtgi	cc aa	atgaa	actat	ago	ggtgg	ggtg	ccct	cagga	att «	cttaq	gctttg		120
cca	ggaaa	atc o	ctga	ggct	cc aq	gggaa	acato	g ggt	ttat	ttg	atca	aacaq	gtt 🤉	ggcto	cttcag		180
tgg	gttca	aaa a	aaaat	zataç	gc aq	geett	tggt	gga	aato	cta	aaaq	gtgta	aac 1	cctct	ttgga		240
gaa	agtto	ccg g	gagca	agcti	cc aq	gttaq	geetç	g cat	ttgo	ttt	ctco	ctgga	aag (ccati	cattg		300
ttca	accaç	gag (ccati	cctgo	ca aa	agtgo	gttco	c gct	caato	gctc	ctt	aaacé	ggt a	aacat	cctctt		360
tate	gaago	cta 🤉	ggaa	cagaa	ac gt	tgaa	actta	a gct	aaat	tga	ctg	gttgo	ctc 1	caga	gagaat		420
gaga	actga	aaa 1	taat	caagt	tg to	cttaç	gaaat	aaa	agato	ccc	aaga	aaati	cct 1	cctga	aatgaa		480
gcat	ttgt	tg 1	tece	ctato	aa a	actco	etttç	g ggt	gtaa	aact	ttg	gtcc	gac d	cgtg	gatggt		540
gati	ttct	cca	ctga	catgo	cc aq	gacat	tatta	a cti	gaad	cttg	gaca	aatti	caa a	aaaaa	acccag		600
atti	tggt	ag s	gtgti	taata	aa aq	gatga	aaggo	g aca	atggt	ttt	tagi	cctat	agg t	gato	cctggc		660
ttca	agcaa	aag a	ataa	caata	ag ta	atcat	caact	aga	aaaq	gaat	ttca	aggaa	agg 1	tta	aaaata		720
ttt	ttc	cag g	gagt	gagto	ga gt	ttg	gaaaq	g gaa	atcca	atcc	ttti	tcat	ta 🤇	cacaç	gactgg		780
gta	gatga	atc a	agaga	acct	ga aa	aacta	accgt	c gag	ggcct	tgg	gtga	atgti	gt 1	ggg	gattat		840
aati	tcat	tat o	geeet	cgcct	t g	gagti	caco	c aag	gaagt	tct	caga	aatgo	ggg a	aaata	aatgcc		900
ttt	tcta	act a	attt	zgaa	ca co	gato	cctco	c aaa	actto	cgt	ggco	cagaa	atg q	gatgo	ggagtg		960

-continued

atgcatggct atgac

<210> SEQ ID NO 30 <211> LENGTH: 325 <212> TYPE: PRT <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: 12-4 mutant (A199S/F227A/S287G/A328W/E441D) BChE amino acid sequence for residues 117-441 <400> SEQUENCE: 30 Gly Phe Gln Thr Gly Thr Ser Ser Leu His Val Tyr Asp Gly Lys Phe Leu Ala Arg Val Glu Arg Val Ile Val Val Ser Met Asn Tyr Arg Val Gly Ala Leu Gly Phe Leu Ala Leu Pro Gly Asn Pro Glu Ala Pro Gly Asn Met Gly Leu Phe Asp Gln Gln Leu Ala Leu Gln Trp Val Gln Lys Asn Ile Ala Ala Phe Gly Gly Asn Pro Lys Ser Val Thr Leu Phe Gly Glu Ser Ser Gly Ala Ala Ser Val Ser Leu His Leu Leu Ser Pro Gly Ser His Ser Leu Phe Thr Arg Ala Ile Leu Gln Ser Gly Ser Ala Asn Ala Pro Trp Ala Val Thr Ser Leu Tyr Glu Ala Arg Asn Arg Thr Leu Asn Leu Ala Lys Leu Thr Gly Cys Ser Arg Glu Asn Glu Thr Glu Ile Ile Lys Cys Leu Arg Asn Lys Asp Pro Gln Glu Ile Leu Leu Asn Glu Ala Phe Val Val Pro Tyr Gly Thr Pro Leu Gly Val Asn Phe Gly Pro Thr Val Asp Gly Asp Phe Leu Thr Asp Met Pro Asp Ile Leu Leu Glu Leu Gly Gln Phe Lys Lys Thr Gln Ile Leu Val Gly Val Asn Lys Asp Glu Gly Thr Trp Phe Leu Val Tyr Gly Ala Pro Gly Phe Ser Lys Asp Asn Asn Ser Ile Ile Thr Arg Lys Glu Phe Gln Glu Gly Leu Lys Ile Phe Phe Pro Gly Val Ser Glu Phe Gly Lys Glu Ser Ile Leu Phe His Tyr Thr Asp Trp Val Asp Asp Gln Arg Pro Glu Asn Tyr Arg Glu Ala Leu Gly Asp Val Val Gly Asp Tyr Asn Phe Ile Cys Pro Ala Leu Glu Phe Thr Lys Lys Phe Ser Glu Trp Gly Asn Asn Ala Phe Phe Tyr Tyr Phe Glu His Arg Ser Ser Lys Leu Pro Trp Pro Glu Trp Met Gly Val Met His Gly Tyr Asp

1. A method for generating butyrylcholinesterase mutants, said method comprising:

- generating an initial structure of the transition state structure for the rate determining step of the cocaine hydrolysis catalyzed by a possible butyrylcholinesterase mutant;
- performing a sufficiently long time molecular dynamics simulation on the transition state structure in water to have a stable molecular dynamic trajectory;
- analyzing the molecular dynamic trajectory and estimating the hydrogen binding energies between the carbonyl oxygen of the (–)-cocaine benzoyl ester and the oxyanion hole of the possible butyrylcholinesterase mutant;
- if the hydrogen binding energies between the carbonyl 15 oxygen of the (–)-cocaine benzoyl ester and the possible butyrylcholinesterase mutant, in the transition state, are stronger than the hydrogen binding energies between the carbonyl oxygen of the (–)-cocaine benzoyl ester and wild type butyrylcholinesterase: 20
 - calculating the hydrogen binding energies,
 - evaluating the energy barrier, and
 - generating butyrylcholinesterase mutant.

2. The method of claim **1**, wherein said generating an initial structure of the transition state structure is based on reaction ²⁵ coordinate calculations for the wild type butyrylcholinest-erase.

3. The method of claim **1**, wherein said generating butyrylcholinesterase mutant comprising:

performing site directed mutagenesis on a nucleic acid ₃₀ sequence encoding wild type butyrylcholinesterase, to generate the mutant butyrylcholinesterase nucleic acid sequence;

expressing a protein encoded by mutant nucleic acid sequence to produce mutant butyrylcholinesterase, and performing a catalytic activity assay on the mutant butyrylcholinesterase.

4. The method of claim 1, wherein said hybrid quantum mechanical/molecular mechanical geometry optimization, calculating the hydrogen binding energies, and evaluating the energy barrier are conducted only if the hydrogen binding energies between the carbonyl oxygen of the (-)-cocaine benzoyl ester and the possible butyrylcholinesterase mutant, in the transition state, are stronger than known butyrylcholinesterase mutants against (-)-cocaine.

5. The method of claim 1, further comprising determining the rate limiting step in the hydrolysis of (-)-cocaine by the possible butyrylcholinesterase mutant by conducting the molecular dynamic simulations and quantum mechanical/molecular mechanical calculations relating to the transition states for other reaction steps between (-)-cocaine by the possible butyrylcholinesterase mutant, and calculating respective energy barriers, thereby establishing which of the reaction steps is rate determining one.

6. The method of claim **1**, wherein if the hydrogen binding energies between the carbonyl oxygen of the (–)-cocaine benzoyl ester and the possible butyrylcholinesterase mutant, in the transition state, are stronger than the hydrogen binding energies between the carbonyl oxygen of the (–)-cocaine benzoyl ester and wild type butyrylcholinesterase further performing hybrid quantum mechanical/molecular mechanical geometry optimization to refine the molecular dynamics-simulated structure prior to calculating the hydrogen binding energies.

* * * * *